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Abstract 
 
Objectives: To perform a case note review to describe unusual clinical 
manifestations of NF2 within the patient cohort. To describe quality of life 
(QOL) in individuals with Neurofibromatosis 2 (NF2) using qualitative and 
quantitative measures. To develop a reliable, validated disease-specific 
score to measure QOL in NF2.  
Design:   A case note review of 61 patients with NF2 was performed to 
identify trends or novel findings. The novel finding of hypertension in the 
cohort was investigated using a retrospective cohort study. The causes of 
epilepsy in NF2 were explored using imaging and histological findings. 
Qualitative interviews and a focus group session generated items for a pilot 
questionnaire.  This was tested and refined. The final version (NFTI-QOL) 
was validated with two generic QOL questionnaires and the use of two 
control groups.  
Results: Trends in cause of death and surgical intervention were described. 
In the hypertension study, 50 patients with NF2 were matched against 45 
controls.  Mean systolic and diastolic blood pressure (BP) was significantly 
higher in the NF2 group than the control group (p=0.003). Imaging of 5 
individuals with epilepsy and NF2 was reviewed and cortical lesions were 
identified in all cases. NF2 impacts QOL in a number of areas, and these are 
described using framework analysis and quantitative measures.  An 8-point 
disease-specific QOL score for NF2 patients was developed with good 
internal reliability. It correlated strongly with clinician rated disease severity in 
 4 
 
NF2, with stronger correlation than the Short-form 36 (SF-36) in this regard, 
and was validated against both SF-36 and EuroQOL.  
Conclusions: The primary aim of this project was to produce a disease-
specific QOL score for NF2 and this has been achieved. There was a novel 
finding of hypertension in NF2, and if this is confirmed with a prospective 
study, it may lead to changes in assessment and management. 
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1.1 Summary 
 
Neurofibromatosis 2 (NF2) is a rare, autosomal dominant, tumour suppressor 
disorder, with an incidence of approximately 1 in 25,000 - 33,000. NF2 is 
characterised by bilateral vestibular schwannomas (BVS) and schwannomas 
of other cranial, spinal and peripheral nerves. Cranial and spinal 
meningiomas, ependymomas and NF2 neuropathy also form part of the 
diagnostic criteria.  
 
In adults, the initial symptom is usually unilateral or bilateral hearing loss, 
which may be associated with tinnitus and vertigo. Facial palsy may arise 
from tumour infiltration or compression, mononeuropathy or trauma following 
surgical excision of a vestibular schwannoma. Ophthalmic and peripheral 
nerve abnormalities may be the presenting features in children with NF2. 
 
Controversy exists in the management of NF2, with regard to timing and 
completeness of excision of vestibular schwannomas; the role of hearing-
preservation surgery; the indication for ‘sleeper’ auditory brainstem implant 
and the place of radiotherapy in the management of NF2 tumours. NF2 is a 
distressing disease and often has a negative impact on quality of life. 
 
Advances in the molecular biology of NF2 have led to the identification of 
potential targets for medical therapies and the commencement of clinical 
trials. Current outcome measures include tumour size, hearing loss and 
quality of life As NF2 is such a rare condition, published outcomes are often 
small series, and meta-analysis of several studies may be required to 
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demonstrate real differences in treatment groups. There has previously been 
little data published on quality of life in NF2 and no consensus as to which 
method should be employed to measure quality of life in NF2. 
 
1.2 Historical aspects of NF2 
a. First published description of NF2 
 
The first published description of NF2 was in the Edinburgh Medical and 
Surgical Journal in 1822. James Wishart was a Scottish surgeon and 
President of the Royal College of Surgeons of Edinburgh, and he described 
the case of Michael Blair, a twenty-two year old baker, who presented with a 
two year history of progressive bilateral hearing loss (Wishart, 1822). 
 
The patient’s father also reported that his son was noted to have right visual 
loss at the age of four months, had a ‘peculiarly shaped head, being 
considerably longer than natural’ and a tendency to fall over. Perhaps due to 
his balance problems, Michael Blair sustained two significant occupational 
head injuries. The first at the age of thirteen was sustained whilst apprentice 
to a gardener, when he was delivered a ‘violent blow’ on his head with a 
pitchfork to the left of the union of coronal and sagittal sutures.  
 
The second occurred at the age of nineteen when he fell over on the street 
whilst carrying a basket of bread on his head, striking his occiput. Tumours 
were apparent at both sites of trauma within a short period of time of the 
injury, appearing to protrude from the cranial sutures, the occipital growth 
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being extremely tender. Mr Blair was offered a diagnostic biopsy of his 
occipital tumour, but declined.  
Six months later the patient represented with worsening symptoms.  His 
occipital tumour had increased in size, his hearing and vision had been 
completely lost and he was suffering from painful seizures, preceded by 
olfactory aura. Following consultation with his colleague, Mr Wishart made 
the decision to biopsy one of the lesions. The patient was sat on a chair and 
the smaller tumour was explored with an incision over the lesion. It was found 
to originate from the cranial cavity, protruding through a bony defect in the 
cranium, covered by an intact layer of dura. The dura was pierced and no 
further action was taken: the wound was dressed but not closed.  
 
Post-operatively Mr Blair developed significant vomiting and hypotension. 
Three days later, the tumour ‘fungated’ through the dura and continued to 
grow, by 10 days post-operatively there was also drainage of ‘clear serum’ 
and a significant improvement in symptoms – the vomiting settled, his 
hearing and vision improved. It is likely that his worsening symptoms pre-
operatively were due to increased intracranial pressure and the dural 
puncture allowed decompression of the cranial cavity, hence the clinical 
improvement. 
 
Unfortunately he began to discharge pus from the incision and became 
systematically unwell two weeks post-operatively, with pain and rigors and 
died. A post-mortem was performed and revealed a thickened and irregular 
cranium; multiple tumours attached to the dura; enlarged lateral ventricles; 
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and multiple cranial nerve tumours, particularly affecting the 5th and 7th. The 
‘general tendency to the formation on tumours seemed to proceed also down 
the medulla spinalis’. 
 
b. Demarcation of NF2 from NF1 
 
It is likely that the first published description of Neurofibromatosis 1 (NF1) 
was in 1761, when a St Thomas’ Hospital physician provided an account of a 
man of about thirty years, who ‘had been accustomed during the greater part 
of his life to a constant succession of wens that shot out in several places on 
his head, trunks, arms and legs: which indisposition he inherited from his 
father’ (Akenside, 1768). 
 
Sixty years after Wishart’s description of NF2, von Recklinghausen published 
his seminal review entitled ‘On Multiple Cutaneous Fibroma and their 
Relationship to Multiple Neuromas’ (von Recklinghausen, 1882) which 
included a literature review, reports of two new cases and concluded that 
neuromas and cutaneous fibromas were related structurally. Following this 
article, the eponymous name for NF1 became ‘von Recklinghausen’ disease.  
 
Initially, NF1 and NF2 were treated as separate entities. In 1903, Henneberg 
and Koch described ‘central neurofibromatosis’, with tumours of the eighth 
cranial nerves bilaterally, but no cutaneous lesions, (Henneberg and Koch, 
1903) and differentiated it from the more common von Recklinghausen 
‘peripheral neurofibromatosis’. However this correct assumption that the 
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conditions were distinct was sent awry by the publication of Harvey Cushing’s 
paper which concluded that ‘when the acoustic tumours are bilateral they are 
very apt to be merely a local expression of a more widespread process of the 
von Recklinghausen type’ (Cushing, 1917). Following this, NF1 and NF2 
were widely regarded as associated conditions. 
 
c. Genetic Inheritance of NF2 
 
In the early 1900s, many authors postulated that ‘central neurofibromatosis’ 
was an inherited condition, but the most detailed description was by Gardner 
and Frazier in 1930 (Gardner and Frazier, 1930) when they described the 
condition in 38 family members spread over five generations. They found that 
half of the family members at risk developed the condition and proposed that 
it was of autosomal dominant inheritance. Gardner’s index family appeared to 
have a mild clinical course which led to the description of milder cases as 
having Gardner type NF2, with more severe cases having Wishart type NF2. 
 
d. NF1 as a separate entity to NF2  
 
The fact that neurofibromatosis 1 and 2 are two unrelated conditions was 
proven when the diseases were mapped to different chromosomes. NF1 
maps to chromosome 17 and NF2 to chromosome 22. NF2 is inherited in an 
autosomal dominant manner; however 50% of cases arise from de novo 
mutations.  
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The defective gene causing NF2 was first localised to chromosome 22 in 
1987 (Rouleau et al., 1987). Restriction fragment length polymorphisms 
(RFLPs) were used to show that loss of alleles on chromosome 22 was 
frequent both in unilateral vestibular schwannomas (UVS) and bilateral 
vestibular schwannomas in NF2. Genetic linkage analysis established that 
the defect was on the long arm of chromosome 22, in the immediate vicinity 
of D22S1 (Rouleau et al., 1987). The combined use of family studies and 
tumour deletion mapping narrowed the location of the NF2 gene to within the 
q12 band of chromosome 22 (Wolff et al., 1992, Rouleau et al., 1990). 
 
1.3  Diagnosis of NF2 
 
A diagnosis of NF2 may be made on clinical and radiological findings, or 
more increasingly by the identification of an abnormality of the NF2 gene on 
chromosome 22. In order to facilitate the accurate diagnosis of NF2 prior to, 
or in the absence of genetic markers of the disease, a number of clinical 
diagnostic criteria have been developed.   
 
a. Clinical Diagnostic Criteria for NF2 
 
A total of five sets of clinical diagnostic criteria for NF2 have been proposed. 
Three main sets have been devised; the first was devised by expert 
consensus (National Institute for Health - NIH), and was revised at a later 
date.  The second (Manchester criteria) was a revision of the NIH criteria, 
taking into account the results of a large population study of NF2, the original 
was published in 1992 (Evans et al., 1992a), and the revised criteria 
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published in 1999, 2002 and 2012 (Evans et al., 1999c, Evans et al., 2012, 
Baser et al., 2002b). The third set was produced by an expert committee 
(National Neurofibromatosis Foundation Clinical Care Advisory Board) 
following review of the literature (Gutmann et al., 1997a). 
 
All sets of criteria diagnosed NF2 in the presence of bilateral vestibular 
schwannomas and in people with a first-degree relative with NF2 plus either 
a vestibular schwannoma at less than 30 years or at least two other 
characteristic disease features of NF2. The most commonly used criteria in 
now the revised Manchester criteria (see below) and its most recent form 
may be found below. A further revision has been made, (Evans et al., 2012) 
the basic content has not changed, but there have been changes to format 
and wording: 
 
Bilateral vestibular schwannoma of family history of NF2 plus 
1) UVS or 
2) Any two of: meningioma, glioma, neurofibroma, schwannoma, and 
posterior subcapsular opacities 
Or 
Multiple meningioma (two or more) plus UVS or any two of: glioma, 
neurofibroma, schwannoma and cataract. 
 
Table 1. Revised Manchester criteria for diagnosis of NF2 (Evans et al., 2012). 
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The authors also state that ‘individuals who meet Manchester criteria for NF2 
or who have evidence of a germline or mosaic NF2 mutation on molecular 
testing should be considered to be affected by NF2’ (Evans et al., 2012). 
   
The diagnostic efficacy of each set was evaluated in 2002, with reference to 
people that do not have bilateral vestibular schwannomas but who do have 
other signs of NF2 (Baser et al., 2002b). This study concluded that none of 
the existing sets of criteria was satisfactory in certain patient groups, and that 
a single, revised set of diagnostic criteria be devised to replace all the 
existing sets of criteria. It was thought that the addition of mononeuropathy 
and molecular data would improve the sensitivity. Specificity was not 
assessed but the paper states that there is considerable evidence that 
specificity is high (approaching 99%) and similar for each set of diagnostic 
criteria (Baser et al., 2002b). 
 
b. Differential Diagnosis for NF2 
i. Neurofibromatosis type 1 
 
Neurofibromatosis 1 (NF1) is a clinically and genetically different disease 
from NF2, but there are a few overlapping clinical features that may 
occasionally cause confusion with NF2. NF1 is more common than NF2, with 
a birth incidence of 1 in 2500-3500 and a prevalence of 1 in 4000-5000 
(Evans et al., 2010). It is an autosomal dominant condition, affecting the gene 
on chromosome 17q11.2. The protein product, neurofibromin, acts as a 
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tumour suppressor, and patients with NF1 have a tendency to develop 
benign and malignant tumours (Ferner, 2010). 
The diagnostic criteria for NF1 are based on the presence of at least two of 
the following features: 
• A first degree relative with NF1 
• Six or more café au lait patches (may be present at birth or, if not, appear 
in the first few years of life) 
• Axillary or groin freckling 
• Two or more neurofibromas or one plexiform neurofibroma 
• Lisch nodules (in iris) 
• Optic pathway glioma 
• Bony dysplasia of sphenoid wing 
• Pseudoarthrosis of the long bones 
Table 2 Diagnostic criteria for NF1 from NIH Consensus Development 
Conference (National Institutes of Health Consensus Development Committee, 
1988). 
 
ii. Schwannomatosis  
 
Schwannomatosis has been described as the third major form of 
neurofibromatosis (MacCollin et al., 2005). In the past there has been 
speculation that schwannomatosis was an attenuated form of NF2, as there 
is an overlap in their presentation and phenotype. However clinical and 
genetic studies have shown that they are distinct conditions (MacCollin et al., 
2003). 
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Molecular analysis at the NF2 locus in schwannomatosis-derived tumours did 
reveal a number of alterations, however there was no evidence of NF2 
mutations in normal tissue, or of shared germline NF2 locus alterations in the 
families studied (MacCollin et al., 2003). An inactivating germline mutation in 
exon 1 of the tumour suppressor gene SMARCB1 (INI1) has been reported in 
patients with schwannomatosis. It is located on chromosome 22, close to the 
NF2 gene (Hulsebos et al., 2007). 
 
Schwannomatosis is characterised by the presence of multiple 
schwannomas, in the absence of vestibular tumours. Pain does appear to be 
the most significant feature of schwannomatosis (MacCollin et al., 2005). It is 
difficult to accurately predict the incidence and prevalence of 
schwannomatosis; however a Finnish study estimated the annual incidence 
of newly diagnosed cases as 1 in 1,700,000 (Antinheimo et al., 2000). 
Schwannomatosis is rarely familial, and when familial occurrence occurs, 
incomplete penetrance is common (Jacoby et al., 1997, Evans et al., 1997). 
 
Diagnostic criteria for schwannomatosis have been developed and revised 
(MacCollin et al., 2005, Baser et al., 2006) and the most current criteria are 
below. An initial diagnosis of schwannomatosis may be re-classified to that of 
NF2 if vestibular tumours develop. 
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All patients with definite or possible schwannomatosis must not fulfil 
any of the existing sets of diagnostic criteria for NF2, and have no 
evidence of vestibular schwannoma on high-quality MRI scan, no first-
degree relative with NF2 and no known constitutional NF2 mutation.  
1. Definite Schwannomatosis 
A. Age older than 30 years and two or more non-intradermal schwannomas, 
at least one with histological confirmation, or 
B. One pathologically confirmed schwannoma plus a first degree relative who 
meets the above criteria. 
2. Possible Schwannomatosis 
A. Age younger than 30 years and two or more non-intradermal 
schwannomas, at least one with histological confirmation, or 
B. Age older than 45 years and two or more non-intradermal schwannomas, 
at least one with histological confirmation, or 
C. Radiographic evidence of a schwannoma and first degree relative meeting 
the criteria for definite schwannomatosis. 
3. Segmental Schwannomatosis 
Meets criteria for either definite or possible schwannomatosis but limited to 
one limb, or five or fewer contiguous segments of the spine. 
 
Table 3. Diagnostic criteria for schwannomatosis (Baser et al., 2006).  
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iii. Other schwannoma syndromes 
 
The Carney complex is a rare autosomal dominant condition characterised 
by melanotic schwannomas, spotty skin pigmentation, endocrine tumours, 
myxomas and endocrine tumours. There has been one report of a family of 
seven, who were affected by a new syndrome of multiple deep 
schwannomas, multiple nevi and multiple leiomyomas. The schwannomas 
and leiomyomas only manifest in adulthood and transmission appears to be 
autosomal dominant (Gorlin and Koutlas, 1998). 
 
iv. Sporadic non-vestibular schwannomas 
 
These tumours may occur in all age groups; however peak incidence is 
between the third and sixth decades. The most common sites for the 
development of sporadic schwannomas are the head and neck, and the 
flexor surfaces of the extremities (Schiethauer et al., 1999). There is no 
significant difference between the incidence in males and females, and it is 
unrelated to racial background. Sporadic schwannomas affect sensory roots 
more commonly than motor roots or sympathetic nerves (MacCollin et al., 
2005). 
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1.4  NF2 Epidemiology 
 
The most recent and detailed epidemiological data for NF2 are provided by 
the North West Regional family genetic register. The register covers a 
population of 4.1 million based around Manchester in the North West of 
England. In their most recent report, (Evans et al., 2010) data from the last 
five decades are presented, with data from the highest incidence decade 
(1974-1983) shown below:  
Birth incidence: 1 in 33,206 
Prevalence 1 in 56,161 
De novo proportion: 56%  
Mosaicism: 17% 
Median age at diagnosis (de novo): 23 years (range 4-48) 
Median age at diagnosis (familial): 20 years (range 3-39) 
 
1.5  NF2 Genetics 
 
NF2 is inherited in an autosomal dominant manner; however more than 50% 
of cases arise from de novo mutations (Evans et al., 2010). 
 
a. The  NF2 gene 
 
The defective gene causing NF2 was first localised to chromosome 22 in 
1987 (Rouleau et al., 1987). Restriction fragment length polymorphisms 
 30 
 
(RFLPs) were used to show that loss of alleles on chromosome 22 was 
frequent both in unilateral vestibular schwannomas and bilateral vestibular 
schwannomas in NF2. Genetic linkage analysis established that the defect 
was on the long arm of chromosome 22, in the immediate vicinity of D22S1 
(Rouleau et al., 1987). The combined use of family studies and tumour 
deletion mapping narrowed the location of the NF2 gene to within the q12 
band of chromosome 22 (Rouleau et al., 1990, Wolff et al., 1992). 
 
b. The NF2 gene product 
 
Merlin (moesin-ezrin-radixin like protein), also known as schwannomin, is a 
66-69kDa protein encoded by the NF2 gene (Rouleau et al., 1993, Trofatter 
et al., 1993). It contains 16 exons and 595 amino acids (Gutmann, 1997). 
Sequence alignment has demonstrated that merlin is homologous to the 
ezrin/radixin/moesin (ERM) protein family (Gutmann et al., 1999). 
 
The ERM proteins are thought to function as general cross-linkers between 
actin based cytoskeletons and plasma membranes (Arpin et al., 1994). Merlin 
appears to have additional properties to those of the ERM proteins. In 
addition to functions of cellular remodelling and formation of membrane 
microvilli and ruffles, merlin has also been shown to suppress the growth of 
cells in vitro and in vivo (Gutmann et al., 1999). 
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c. Tumourigenesis in NF2 
 
Schwannomas and meningiomas from individuals with NF2 have 
demonstrated inactivating mutations in both NF2 alleles (Rouleau et al., 
1993, Trofatter et al., 1993). 
It has also been found that the NF2 gene is implicated in the development of 
sporadic schwannomas and meningiomas without NF2. Significantly reduced 
or absent expression of merlin, using protein-specific antibodies has been 
found in sporadic meningiomas, ependymomas and schwannomas 
(Gutmann et al., 1997b). 
 
d. Genotype/phenotype correlation 
 
Historically, NF2 has been sub-grouped by the severity of its symptoms, 
initially into the Gardner (mild) and Wishart (severe) subtypes. In 1995, a 
genotype-phenotype was first described and this has been further confirmed 
and clarified (Merel et al., 1995, Selvanathan et al., 2010). 
 
There are a variety of mutations that may affect the NF2 gene, resulting in 
the condition NF2. Mutations can cause a loss of protein, reduced protein 
function, or a gain of protein function (abnormal allele leading to truncated 
protein product). Mutations leading to the production of a truncated protein, 
such as nonsense or frameshift mutations, tend to be linked to more severe 
disease than those caused by large deletions, missense mutations and in-
frame deletions (Evans et al., 1998a). 
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A study comparing clinical presentation of mutations resulting in truncated 
protein versus loss of protein expression revealed that those with protein 
truncation had a significantly: younger age of diagnosis; higher 
prevalence/proportion of meningiomas, spinal tumours and other cranial 
nerve schwannomas (not VS). They presented earlier with VS and had a 
higher mean number of cutaneous lesions. Symptom-wise, those with 
truncating mutations had a younger age of onset of: hearing loss; tinnitus; 
paraesthesiae; wasting; weakness and headaches (Selvanathan et al., 
2010). 
 
e. Mosaicism 
 
More than 50% of people with NF2 have no family history of the disease and 
have developed the mutation in a de novo manner. De novo mutations may 
occur at either the pre-zygotic or post-zygotic stage. Pre-zygotic mutations 
occur in the germline cells of either of the parents. Post-zygotic mutations 
can occur in any cell after fertilisation and cell division. If it occurs in the post-
zygotic stage, mosaicism may develop.  
 
Mosaicism means that the affected individual will have mixed cell populations 
with and without mutation. Leukocytes are often unaffected, or only a 
proportion are affected, (Kluwe and Mautner, 1998) so the mutation cannot 
be detected during blood tests for the NF2 mutation, only in tumour cells. The 
timing of the development of the post-zygotic mutation will affect the number 
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of cells affected and thus the severity of the disease. The individual may 
develop severe, mild or incomplete disease phenotypes depending on the 
type of tissue affected, particularly that of neural crest origin. 
 
Mosaicism is likely to lead to milder phenotypes, as a result of a reduced 
population of mutation-bearing cells. Mosaicism may explain the 
phenomenon of the index case in a family having relatively mild disease, but 
children who inherit the mutation have typical phenotypes.  If the mutation is 
present in the germ-line cells, there is a 50% chance of the child inheriting 
the disorder in an autosomal dominant manner, and developing the disease 
in a typical, non-mosaic fashion.  
 
A presumed diagnosis of mosaicism may be made from when patients 
appear to have limited tumour formation within a specific anatomical area, or 
do not fulfil the criteria for a diagnosis of NF2 but do have many clinical 
characteristics. Mosaicism may also be diagnosed when no mutation of the 
NF2 gene is discovered in blood DNA. Using exon scanning techniques, 
mutations have been discovered in up to 66% of all affected subjects (Parry 
et al., 1994). It may be that current technology fails to detect certain 
mutations, such as large deletions, promoter and intronic mutations and 
locus heterogeneity may play a role (Kluwe et al., 2003). However, it has 
been proposed that somatic mosaicism may account for a high proportion of 
these cases (Kluwe and Mautner, 1998, Evans et al., 1998b). 
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f. Screening for NF2 in the ‘at-risk’ individual 
 
Individuals are ‘at-risk’ of NF2 when they have a parent with features of NF2 
or when they have some of the clinical features of the disease, but fall short 
of the Manchester criteria for diagnosis (Evans et al., 2012). It is advised that 
these individuals undergo screening until their residual risk is less than 1%.  
 
Genetic analysis is often performed, but a mutation-negative blood test does 
not rule out NF2. This is due to the relatively high proportion of mosaicism 
within individuals with no family history of the disease – around 40% of those 
who do fill the criteria for ‘classical NF2’ will not have an identifiable mutation 
within their blood (Evans et al., 2012). It is therefore important to have further 
ways of screening those individuals whose presenting features could 
represent mosaic NF2 but may just be a chance association.  
 
Screening of individuals at risk of NF2 can be divided into three groups, 
those at high-risk (≥20%), moderate risk (1-19%) and those with a parental 
family history of NF2. The risk of NF2 in an individual has been predicted by 
using genetic testing of over 1000 individuals through the Manchester NF2-
testing service and tables of risk are available in the publication (Evans et al., 
2012). 
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i. High risk individuals (Group A, ≥20% risk of NF2) 
 
Examples include:  
Isolated unilateral vestibular schwannoma (UVS) in person <20 years old 
Isolated cranial meningioma in person <20 years old 
Childhood isolated schwannoma at another site 
*Childhood typical retinal hamartoma 
Individuals fulfilling two Manchester criteria <50yrs, with additional criterion of 
childhood mononeuropathy. 
Table 4 High risk individuals (Evans et al., 2012, Evans et al., 1999b, Evans et al., 
2007, Evans et al., 2008). 
 
This group should undergo mutation testing for NF2 in blood and tumour (if 
available), as there is at least a 5% chance of finding a mutation in blood 
(Evans 2012).  
 
If blood mutation testing is negative, these high risk individuals should 
undergo audiological assessment, imaging (brain and spine MRI), ophthalmic 
examination and cutaneous examination at presentation and again at 18-20 
years of age. They should also undergo cranial MRI at age 25, 35 and 45 
years (or 5, 10 and 20 years after first assessment). If no further features of 
NF2 are found they should be discharged (risk of NF2 will now be <1%). The 
exception is those within the group that have childhood typical retinal 
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hamartoma. If mutation testing is negative in these patients, a normal cranial 
and spinal MRI at age 18 years will be enough to reduce their risk to <1% 
and they can be discharged at this point. 
 
ii. Moderate risk individuals (Group B, 1-19% risk of NF2) 
Examples include: 
UVS aged 20-30years 
Individuals fulfilling two Manchester criteria at >50 years of age. 
Table 5. Moderate risk individuals (Evans et al., 2012, Evans et al., 1999b).  
 
Blood mutation analysis should be offered but only has a <5% chance of 
proving positive as most cases in this group are likely due to mosaicism. 
Cranial and spinal MRI, ophthalmic and cutaneous examination should be 
performed at presentation. If no further features of NF2 are found, then 
cranial MRI should be performed at 5, 10 and 20 years after first assessment. 
If these are normal then the risk is <1% and the individual may be discharged 
(Evans et al., 2012). 
 
ii. Positive family history in parent 
 
If a child has a parent with NF2, then they should be presumed to have a 
50% risk of NF2 and screening can begin with ophthalmological assessment 
for cataracts soon after birth. If the previous two generations are affected 
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then the risk will be 50%. If the mutation has previously been identified within 
the family then mutation testing of blood DNA will provide an accurate 
answer as to whether the child has developed the disease. If, however, the 
affected parent was a de novo case and blood mutation testing in the child is 
negative, the risk of NF2 may be substantially less than 50% (Evans et al., 
2012). 
 
A table of risk of NF2 pre- and post-genetic testing in this scenario is 
available, and may be as low as 1.25% (Evans et al., 2012). In these cases, 
screening should commence with cranial and spinal MRI at the age of 10 
years and continue until the risk of disease if <1%. Between 10 and 20 years, 
scans are performed every two years and over the age of 20 years, every 3-5 
years. The risk of NF2 falls with negative screening and may fall below 1% at 
15 years (if parent has mosaic disease and MRI at 15yrs is normal), 25 years 
or rarely 40 years if NF2 is multi-generational but no mutation has been 
identified.  If at this point, there is no evidence of NF2, the individual can be 
discharged from further assessment. 
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1.6  Natural history and cause of death in NF2 
a. Tumour growth 
 
A study has assessed patterns of intra-cranial tumour growth in 17 patients 
with NF2 with a mean follow-up of 9.5 years (range 4-20.7 years) (Dirks et 
al., 2012). Overall, 59.2% displayed a saltatory growth pattern (alternating 
periods of growth and quiescence), 29.6% of tumours exhibited linear growth 
and 11.2% showed exponential growth. A younger age at the onset of NF2-
related symptoms (p=0.01) and female sex (p=0.05) were associated with an 
increased growth rate in meningiomas (Dirks et al., 2012). 
 
b. Life expectancy 
 
In one study of the natural history of NF2, predictors of survival rate following 
diagnosis were: 5 year survival - 85%, 10 year survival - 67% and 20 year 
survival - 38% (Otsuka et al., 2003). The United Kingdom NF2 registry study 
(Baser et al., 2002a) found that of their study group of 368 people, 74 had 
died during follow-up (20%). In an earlier study of 150 patients, mean age at 
death in 40 cases was 36.25 years. Mean actuarial survival from diagnosis 
was 15 years. Over 40% would be expected to have died by 50 years and all 
cases by 70 years (Evans et al., 1992a). 
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c. Predictors of mortality 
 
A large study using data from the United Kingdom NF2 registry found four 
covariates that predicted the risk of mortality in NF2. These were: age at 
diagnosis; presence of intracranial meningiomas; type of NF2 mutation and 
type of treatment centre (specialist versus non-specialist) (Baser et al., 
2002a). Kaplan-Meier survival curves are below (Figs 1-4). Relative risk of 
mortality increased 1.13 fold per year decrease in age of diagnosis, 
increased 2.51 fold in the presence of meningiomas and decreased by 0.34 
fold when patients were treated in a specialist NF2 centre. The risk of 
mortality in those with NF2 missense mutations was very low compared to 
those with other types of mutations (Baser et al., 2002a). 
 
Figure 1. Kaplan-Meier survival curve (log-rank test): age at diagnosis (p<0.0001) 
(Baser et al., 2002a). 
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Figure 2. Kaplan-Meier survival curve (log-rank test): intracranial meningiomas 
(Baser et al., 2002a).  
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Figure 3. Kaplan-Meier survival curve (log-rank test): type of constitutional NF2 
mutation (p=0.002) (Baser et al., 2002a). 
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Figure 4. Kaplan-Meier survival curve (log-rank test): type of treatment centre 
(p=0.0001) (Baser et al., 2002a). 
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d. Cause of death 
 
There are few reports of the cause of death in NF2. In the UK NF2 registry 
study (Baser et al., 2002a) the causes of 74 deaths during follow-up were 
reported, and are summarised below: 
Cause of death % (n) 
‘Tumour burden’ 68.9 (51) 
Post-operative 
complications 
18.9 (14) 
Malignancy associated 
with NF2-related tumour 
4.0 (3) 
Traffic accident 2.7 (2) 
Suicide 2.7 (2) 
Fall 1.4 (1) 
Myocardial infarction 1.4 (1) 
 
Table 6. Cause of death in NF2 (Baser et al., 2002a). 
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1.7 Clinical manifestations of NF2 
 
The clinical manifestations of NF2 have been described in four major studies 
and their findings are summarised below: adapted from (Evans, 2009). 
Characteristic Study 
Kanter et 
al. (1980) 
Evans et al. 
(1992a) 
Parry et 
al. (1994) 
Mautner et 
al. (1996) 
Number of cases 73 120 63 48 
Sporadic cases 0 45 17 44 
Mean age onset 
(years) 
20 (n=59) 22 20 17 
Intracranial 
meningiomas % 
18 45 49 58 
Spinal tumours % n/a 26 67 90 
Skin tumours % 32 (n=73) 68 (n=100) 67 64 
Café-au lait 
macules % 
42 (n=31) 43 (n=100) 47 n/a 
Cataract % n/a 38 (n=90) 81 62 
Intracranial 
astrocytoma % 
n/a 4.1 1.6 n/a 
Ependymoma % n/a 2.5 3.2 6 
Optic sheath 
meningioma % 
n/a 4.1 4.8 8  
 
 
Table 7. Clinical manifestations of NF2 (Evans, 2009). 
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A large clinical study (n=100) found that the first presenting symptom was: 
hearing loss in 44%; weakness or wasting in 12%; tinnitus in 10%; balance 
disturbance in 8%; seizure in 8%;  pain in 4%; dysthaesia in 2% and visual 
loss in 1%. Eleven percent were asymptomatic at diagnosis and were 
detected through screening with a positive family history (Evans et al., 
1992a). 
 
a. Vestibular schwannoma 
 
Bilateral vestibular schwannomas (VS) are the main hallmark of 
neurofibromatosis 2, and the majority of individuals with NF2 will develop 
them within the course of their life. VS tend to present with symptoms related 
to the compression of the vestibular and cochlear nerves at the internal 
auditory meatus (IAM) and cerebellopontine angle (CPA). These include 
hearing loss, tinnitus and vertigo. VS can also cause compression of the 
facial nerve, leading to facial palsy, and trigeminal nerve, leading to facial 
dysthaesia and paraesthesia. Large tumours may also cause cerebellar and 
brainstem compression, impair drainage of cerebrospinal fluid (CSF) at the 
fourth ventricle, leading to non-communicating hydrocephalus and compress 
the lower cranial nerves leading to bulbar signs. 
 
i. Hearing loss 
 
Hearing loss is the presenting symptom of NF2 of 60% of patients and is 
most often due to bilateral vestibular schwannomas. The loss of sensory 
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perception is an extremely emotive feature of disease and many with NF2 
face the likelihood of complete hearing loss. The nature of hearing loss in 
NF2 can be extremely variable and difficult to predict, it is not related to the 
size of the tumour and may gradually worsen, suddenly be lost and even 
worsen and then improve. Hearing loss in NF2 is functionally very significant 
and may be used as a trigger for intervention and an end-point in clinical 
trials. Patients with NF2 may also experience tinnitus and vertigo, which is 
discussed further in this section. 
 
Natural history of hearing loss in NF2 
 
A large study of the natural history of hearing loss following diagnosis of NF2 
showed that if an individual had measurable hearing, they were unlikely to 
experience any worsening over the short-term (7 months to 2 years) following 
diagnosis. Many were diagnosed with NF2 before they had noticeable 
hearing loss, patients who were diagnosed at a younger age and had a 
positive family history for NF2 had better hearing at diagnosis. They also 
found that the rate and size of change is unlikely to be similar in both ears, 
even when untreated (Masuda et al., 2004). A significant decline in hearing 
occurred over long-term follow-up.  
 
Mechanisms of hearing loss in NF2 
 
It was initially presumed that hearing loss in NF2 was as a direct result of 
compression and stretching of the cochlear nerve by a vestibular 
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schwannoma. However a number of features of NF2-related hearing loss 
have questioned this explanation. The severity of hearing loss does not 
appear to be related to the size of the tumour, and may continue to progress 
during periods of tumour stability (Fisher et al., 2009). The onset of hearing 
loss is not predictable and may deteriorate gradually, or in a stepwise 
fashion, may suddenly be lost and can remit. Hearing loss may even predate 
radiological diagnosis of a vestibular schwannoma and the pattern of hearing 
loss in one ear will not predict that in the contra-lateral ear  (Masuda et al., 
2004). 
 
A prospective natural history study of one hundred individuals with NF2 
attempted to gain further insight into mechanisms of hearing loss in NF2 
(Asthagiri et al., 2012). They found that although the presence of hearing loss 
was correlated with larger vestibular schwannoma volumes, there were also 
a large proportion of ears with hearing loss that had small tumour volumes 
(47% of ears with hearing loss had tumour size of <0.5 cm3). They had 
hypothesised that alternative or additional mechanisms of hearing loss in 
NF2 may include: intralabyrinthine haemorrhage; endolymphatic hydrops; 
disruption of cochlear vascular supply and/or alteration in the biochemistry 
within the inner ear fluids. Inner ear MR imaging was performed, with FLAIR 
sequences to assess for the presence of elevated proteins within the 
labyrinth.  
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In this study, raised intralabyrinthine protein was found in 94% of ears with 
hearing loss and in 70% of normal hearing ears with an ipsilateral vestibular 
schwannoma (Asthagiri et al., 2012). The five normal hearing ears assessed 
in the absence of a vestibular schwannoma did not show any evidence of 
raised intralabyrinthine protein. The cochlear aperture appeared to be 
blocked by the vestibular schwannoma in 96% of the ears with raised protein 
and only in 14% of ears without raised protein. The authors therefore 
postulate that blockage of the cochlear aperture may underlay elevation of 
intralabyrinthine protein, possibly contributed to by: disruption of the blood-
CSF-labyrinthine barrier by permeable tumour vessels (Yamazaki et al., 
2009); impaired clearance by tumour compression or involvement of the 
cochlear nerve disrupting axonal transport; and/or increased protein 
production or deposition.  
 
It is thought that increased protein may cause biochemical degradation of the 
cochlea, a study of the proteome within perilymph of ears with a vestibular 
schwannoma (non-NF2) using mass-spectrometry revealed fifteen potential 
protein bio-markers – some of which had known roles in hearing and 
deafness (Lysaght et al., 2011). 
 
Assessment of hearing loss 
 
Hearing loss in NF2 has conventionally been assessed with detection of 
sound (pure tone thresholds) and speech discrimination. The pure tone 
audiogram (PTA) is generally performed by a trained audiologist within a 
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sound booth and assesses levels of sound detection over a range of 
frequencies. The pure tone average is often used and can be calculated by 
taking the average in decibels of the thresholds for pure tones at 500, 1000 
and 2000Hz. Additional measurements at 4kHz allow further differentiation 
around thresholds indicative of speech discrimination. 
 
Speech audiometry is a more practical assessment of useful hearing, as it 
assesses the ability to hear and repeat standardised lists of words at different 
decibel levels. Various thresholds can be produced from this test, including 
speech-recognition threshold (SRT)  - the minimum intensity at which 50% of 
disyllable words are correctly identified, and the maximum speech 
discrimination score (SDS), the percentage of single syllable words correctly 
identified at 40dB above the SRT. The American Association of 
Otolayngology hearing outcomes scale is a composite of the pure tone 
average and speech discrimination score, and has been used widely as an 
outcome following hearing preservation surgery for vestibular schwannoma 
(Committee on Hearing and Equilibrium, 1995). However the insensitivity 
within grade D – grouping all hearing ears with maximum SDS or less than 
50dB together – means that it is likely to miss clinically relevant changes in 
hearing in NF2 patients with a single hearing ear, and do should not be used 
as a standardised endpoint in NF2 trials. Instead, maximum word recognition 
score has been endorsed as the preferred primary endpoint (Plotkin et al., 
2013). 
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More detailed techniques have been used for assessment when implantation 
with a cochlear or auditory brainstem implant is considered. These include 
oto-acoustic emissions (OAE), auditory brainstem response (ABR), 
promontory stimulation and cochlear nerve action potential (CNAP). 
Management of hearing loss in NF2 
 
Hearing aids may be helpful in the early stages, but are often less effective in 
NF2-associated hearing loss. If there is reasonable hearing in one ear, and 
no hearing in the other, then a Contralateral Routing of Sound (CROS) or 
bone-anchored hearing aid may be beneficial. There are a number of 
additional aids that may be beneficial including induction loops and vibration 
pads. It is often helpful to learn to lip read whilst hearing is still preserved, but 
it may be challenging to provide motivation for this while hearing is still 
acceptable. A week-long residential course is run by the Hearing Link 
Foundation, which is specifically aimed at people with NF2 and their families 
(http://www.hearinglink.org/nf2programmes). It offers practical support and 
training and is fully funded for individuals with NF2 in England. Details of 
hearing preservation surgery can be found in the management section. 
 
ii. Tinnitus 
 
Tinnitus may be defined as ‘the conscious experience of a sound that 
originates in the head of its owner’ (McFadden, 1982). In NF2, in the majority 
of cases, tinnitus is due to vestibular schwannoma. It may occur prior to 
measurable hearing loss and as such may be the presenting symptom of the 
 51 
 
disease. Tinnitus can itself cause and can also interfere in sound perception, 
amplifying any existing hearing loss.  
 
It is difficult to assess the actual prevalence of tinnitus in NF2 as in the 
majority of clinical series it is grouped in with hearing loss. However in a large 
genotype-phenotype study (Selvanathan et al., 2010), tinnitus was taken as 
an individual symptom, and occurred in 52.9% of those with nonsense or 
frameshift mutations and 52% of those with large deletions. The age of onset 
of tinnitus was significantly different (p=0.002) between those with 
nonsense/frameshift mutations (mean 22 years, 95% CI 19-24yrs) and large 
deletions (mean 30 years, 95% CI 25-35yrs). This was also the case for 
hearing loss (p=0.010). 
 
Tinnitus may also develop after treatment for vestibular schwannoma, and it 
is important that this issue is raised when consent is obtained. In a large 
surgical series of NF2 patients undergoing translabyrinthine surgery, 63% of 
patients had tinnitus pre-operatively. Of these, 61% noticed no change post-
operatively, it resolved in 17% and in 21% it worsened. 22% of patients 
developed new-onset tinnitus post-operatively (Moffat et al., 2013). There are 
few data specifically relating to tinnitus following radiosurgery for vestibular 
schwannoma. 6% of patients had ‘non-specific vestibular symptoms’ which 
included tinnitus post-treatment in one retrospective review of 96 NF2 
patients, but it is unclear if these were new symptoms following treatment 
(Rowe et al., 2003). 
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Management of tinnitus is symptomatic. Optimisation of hearing aids is often 
beneficial. A variety of devices, such as sound generators can help, 
particularly at night-time. Cognitive behavioural therapy has been effective in 
the general tinnitus population, and a systematic meta-analysis of the 
literature found ‘a significant improvement in the quality of life (decrease of 
global tinnitus severity) of the participants, thus suggesting that cognitive 
behavioural therapy has an effect on the qualitative aspects of tinnitus and 
contributes positively to the management of tinnitus (Martinez Devesa et al., 
2007). 
 
iii. Vertigo and balance problems 
 
The maintenance of balance is complex with sensory inputs from the 
vestibular system, eyes and muscles and joints via proprioception, integration 
in the brainstem and outputs to the eyes and joints, with further input from the 
cerebellum and cerebral cortex. It is therefore not surprising that balance 
problems are an issue for many in NF2. Vertigo or dizziness was the first 
symptom of NF2 in 8% in Evans’ clinical study and balance problems were 
present in all of those with ‘established vestibular schwannoma’ (Evans et al., 
1992a). 
 
True rotatory vertigo is the sensation of rotatory movement which can be 
extremely disabling to those affected. Vertigo in NF2 is most likely due to VS, 
but other coincidental common causes need to be ruled out, such as benign 
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paroxysmal positional vertigo.  Vertigo is generally diagnosed 
symptomatically, but clinical examination and formal vestibular testing may 
allow further characterisation and guide any rehabilitation.  
 
Management of balance disturbance in NF2 can be challenging. Symptoms 
of unilateral vestibular failure are generally improved by compensation by the 
contralateral side, which can be enhanced by specific movements and 
exercises; however this is complicated in NF2 by the likely presence of a 
contralateral VS. Mobility aids, such as a stick, may be helpful, and visual 
acuity should be optimised. 
 
iv. Facial palsy and paraesthesia 
 
Facial palsy may be measured using the House Brackmann score where 
grade I indicates normal facial function in all areas and grade VI relates to 
total paralysis (House and Brackmann, 1985). Facial palsy in NF2 may be as 
a result of compression of the facial nerve at the CPA by VS, by direct 
involvement in the nerve by schwannoma, due to mononeuropathy or, most 
commonly, as a result of treatment of VS by surgery or radiotherapy.  
 
Facial palsy is an uncommon presenting feature of NF2 in adults; however 
unilateral facial palsy was the presenting feature of NF2 in 20% of children in 
one study (Evans et al., 1999a). It is thought that in at least some of these 
cases the palsy was due to facial mononeuropathy.   
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The risk of facial palsy following surgery for VS can be reduced by careful 
timing of surgery. The likelihood of preserved facial nerve function decreases 
as the size of tumour increases, and this needs to be considered when 
decided a management plan (see section on Surgery in NF2). There may be 
a period of worsened palsy following surgery due to neuropraxia which will 
recover in time though not necessarily completely.  It is therefore important 
that facial palsy outcomes following surgery should be reported following a 
period of recovery, usually 6 months to one year. Physiotherapy and 
muscular stimulation may be used for rehabilitation during this period.  
 
The management of established facial palsy in NF2 can be divided into: 
management of eye symptoms; improvement of facial symmetry and facial 
reanimation. The cornea is at risk if eye closure is limited. Regular 
lubrication, ophthalmic review and occasionally tarsorrhaphy, eyelid weights 
or chains are required to prevent corneal ulceration. Facial symmetry may be 
improved by fillers, Botox and plastic surgical procedures, such as muscular 
slings, brow lifts and face lifts. The input of a specialist facial palsy 
multidisciplinary team is extremely useful. Facial reanimation may be 
attempted at the time of VS surgery if the facial nerve is divided, using a 
direct nerve graft to bridge the defect, or may be attempted as a second 
procedure using free muscle transfer or hypoglossal-facial nerve transfer. 
The presence of schwannoma on donor nerves needs to considered, but 
results are promising (Vakharia et al., 2012). 
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Facial paraesthesia may be due to compression of the trigeminal nerve by a 
VS or trigeminal schwannoma. Loss of corneal sensation is a good indicator 
of dysfunction, and, particularly when combined with incomplete eye closure 
does increase the risk of corneal damage. Trigeminal neuralgia may also 
occur.  
 
v. Brainstem compression 
 
Bilateral large VS may cause brainstem compression. Symptoms may 
include headache and visual disturbance and disk swelling may be noted on 
fundoscopy. Brainstem compression can become imminently life-threatening 
if obstructive hydrocephalus develops, which if unchecked leads to brain 
herniation and death.  Decompression with a ventricular shunt is often 
performed in these incidences, most-commonly followed by staged surgical 
de-bulking of the tumours. For large tumours (>3cm diameter) causing brain-
stem compression in the absence of hydrocephalus, surgical decompression 
is generally advocated as first line management (Blakeley et al., 2012). 
Radiosurgery is not recommended for large tumours (>3cm), particularly 
when causing brainstem compression, due to the potential for further 
compression by oedema at the treated site. 
 
vi. Diagnosis 
 
Imaging, preferably with gadolinium enhanced magnetic resonance, will lead 
to the detection of the majority of VS. Hearing may or may not be 
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compromised (see hearing section). Prediction of the size of the vestibular 
schwannoma by imaging may be by linear measurements or more 
increasingly by volumetric estimation (see imaging section). 
 
vii. VS growth 
 
A number of groups have studied vestibular schwannoma growth rate and 
patterns in people with NF2. In the four main longitudinal studies, 
discrepancies were found, with two studies revealing that VS growth rates 
decreased with increasing age, (Baser et al., 2002c, Mautner et al., 2002) 
one study revealing no change in growth rate with age (Slattery et al., 2004) 
and one revealing growth rate increased with age (Abaza et al., 1996). 
However reanalysis of the data from these studies combined with data from 
the UK NF2 Registry concluded that VS growth rates are highly variable but 
tend to decrease with increasing age  (Baser et al., 2005). Ito et al performed 
multivariate analysis on factors that may influence growth in 27 patients and 
found no significant factors (Ito et al., 2009).  
 
Dirks et al analysed growth patterns in NF2-associated intracranial tumours 
and found that the most frequent growth pattern was characterised by 
alternating periods of growth and quiescence – salutatory growth. 59.2% of 
intracranial tumours exhibited this pattern (46.7% of VS), 29.6% exhibited 
linear growth and 11.2% exhibited exponential growth (Dirks et al., 2012). 
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It does appear that treatment of a contralateral tumour may affect growth in 
some instances; Peyre et al found that when bilateral VS were threatening 
the brainstem, surgery on one side led to significant elevation in velocity of 
diametric expansion of the contralateral VS (Peyre et al., 2011). 
 
b. Non-vestibular cranial nerve schwannoma 
 
In the NF2 natural history study by Fisher (Fisher et al., 2007), 51% of 
patients (42/83) had at least one non-vestibular cranial nerve schwannoma 
(NVS). Of a total 64 NVS, 28% of patients had one, 19% had two and 3.6% 
had three NVS. The most common site was the trigeminal nerve (CN V) with 
72% (46/64) of NVS occurring at this site, followed by oculomotor (15.6%, 
10/64). There were few tumours on the remaining cranial nerves: 4.7% were 
vagal (3/64) and 1.5% (1/64) involved each of the trochlear; abducens; 
glossopharyngeal; accessory and hypoglossal nerves. There were no 
schwannomas affecting the optic or olfactory nerves in this series, and there 
are no reports of these in the literature. NVS do appear to be a marker for 
more severe disease, and are found to occur more frequently and at a 
younger age in those with nonsense/frameshift mutations compared to those 
with large deletions (Selvanathan et al., 2010). 
 
NVS are often asymptomatic, but may cause impairment of the affected 
nerve (e.g. loss of corneal reflex by trigeminal schwannoma, ‘down and out’ 
eye position by oculomotor schwannoma) or compression of other local 
structures. Lower cranial nerve schwannomas have the potential to cause 
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more significant symptoms, such as swallowing problems and aspiration, 
which can cause significant morbidity, and growth of lower cranial nerve 
schwannomas should be monitored to avoid these life-threatening 
complications (Fisher et al., 2007). 
 
NVS tend to be very slow-growing: in the natural history study, there were no 
significant changes in tumour volume from baseline to the first-year 
evaluation and from the first to second-year evaluation (Fisher et al., 2007). 
Four patients had a large NVS (>2cm3) and one of these increased in size 
between the first and fourth-year evaluation, the other three large tumours 
remained stable.  
 
c. Meningiomas in NF2 
 
Meningiomas are the second most common tumour in NF2 and form part of 
the diagnostic criteria. They most commonly develop intracranially, but are 
also found in the spine and have been rarely reported in the lungs (Walter et 
al., 2009). Intracranial meningiomas occur in between 45-58% of people with 
NF2 (Asthagiri et al., 2009) and are both a marker of more severe genotype 
(Selvanathan et al., 2010) and a predictor of mortality (Baser et al., 2002a). 
By 70 years of age, nearly 80% of patients with NF2 will have one or more 
meningiomas (Smith et al., 2011). Eight percent of people with NF2 present 
with a meningioma prior to developing vestibular schwannoma, and 20% of 
children who present with a meningioma will go on to be diagnosed with NF2 
(Evans et al., 2005). Meningiomas in NF2 do not appear to be more 
aggressive than sporadic meningiomas (Goutagny et al., 2012). 
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Meningiomas are best imaged with contrast-enhanced T1-weighted MRI, with 
T2 weighted-images used to demonstrate surrounding oedema or cysts. 
They enhance homogenously and typically have a dural tail. The presence of 
oedema indicates that the meningioma is likely to show more aggressive 
growth (Goutagny et al., 2012). 
 
i. Intracranial meningiomas 
 
Intracranial meningiomas are often multiple in NF2: the median number per 
patient is 3 and 28% of patients in one series had seven or more (Goutagny 
et al., 2013). Meningiomas are often asymptomatic and diagnosed on routine 
imaging, particularly those of the cerebral convexity. If they become large, 
they may lead to focal or generalised seizures. Intracranial meningiomas 
cause more serious neurological deficit when occurring in intracranial regions 
with bony margins, such as the optic canal or skull base, where they have the 
potential to cause cranial nerve defects at a relatively small size. Parafalcine 
meningiomas may encroach on the sagittal sinus, leading to chronic venous 
hypertension (Blakeley et al., 2012). 
 
The most common intracranial locations from one large study (Goutagny et 
al., 2012) are shown below: 
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Meningioma location Percentage of tumours 
Convexity and falx 71.8% 
Skull base 24.7% 
Lateral ventricles 2.8% 
 
Table 8 Location of meningiomas (Goutagny et al., 2012) 
 
Meningiomas of the optic nerve sheath (ONSM) are found more frequently in 
NF2 than the general population, and a review of eight clinical studies 
showed that 14 out of 356 patients with NF2 had ONSM (3.9%) (Bosch et al., 
2006b). In the early stages ONSM cause visual loss, optic atrophy and 
optociliary shunt vessels can be observed. At later stages intraorbital 
expansion may occur, leading to proptosis and strabismus. ONSM may be 
bilateral.   
 
The majority of intracranial meningiomas in NF2 patients are stable and can 
be managed by a watch-and-wait policy. In a study of 74 NF2 patients with 
287 meningiomas, 66% of tumours showed no or minimal growth, and only 
7.3% of tumours had a growth rate of 20% or more per year (Goutagny et al., 
2012). Only symptomatic or growing meningiomas require treatment. Surgery 
is currently the treatment of choice, and 45.9% of patients underwent surgical 
treatment for meningioma in the follow-up period (mean 110 months) in one 
study – although 12.5% were removed incidentally ‘en-route’ to removing 
another tumour (Goutagny et al., 2012). Radiosurgery has been used for 
meningioma in NF2 but there is no long-term follow-up data at present 
(Asthagiri et al., 2009). 
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ii. Spinal meningiomas 
 
See spinal tumour section. 
 
d. Spinal tumours 
 
Spinal tumours occur in between 63 and 90% of people with NF2 (Asthagiri 
et al., 2009). Spinal tumours are either intra-medullary - usually 
ependymoma, or extra-medullary – typically schwannoma or meningioma.  
Schwannomas seem to be the most prolific, accounting for 57.5% (177/308) 
of spinal tumours in one series, followed by intra-medullary (34.7%) and then 
meningioma (7.8%) (Patronas et al., 2001). The presence of a protein-
truncating mutation is significantly more likely to be associated with the 
presence of spinal tumours than any other mutation (Dow et al., 2005).  
 
Spinal tumours are normally identified following imaging of the spine. Whole 
spine MRI is performed as a baseline in all patients diagnosed with NF2 and 
also at regular intervals. Surgery for spinal tumours require careful 
consideration and a meticulous pre-operative evaluation, as symptoms 
attributed to the spinal tumour may in fact be due to neuropathy and patients 
may be no better or worse following surgery. 
 
i. Intra-medullary tumours 
 
The majority of intra-medullary tumours are histologically ependymoma, 
accounting for 75% of this tumour type (Asthagiri et al., 2009). 
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Ependymomas are found in 18-53% of people with NF2 but are frequently 
asymptomatic – only causing symptoms in less than 20% (Asthagiri et al., 
2009). Intra-medullary tumours appear to occur more commonly in those with 
nonsense and frameshift mutations (Patronas et al., 2001). They enhance 
uniformly with contrast MRI and may have multiple ‘seedlings’ along the 
brainstem and central canal of the spinal cord, usually in the cervical region. 
They may be associated with a syrinx. Other intra-medullary tumours have 
been reported in NF2, including astrocytomas and schwannomas  (Patronas 
et al., 2001). 
 
When symptomatic, intra-medullary tumours tend to cause back pain (56%), 
weakness (28%) and/or sensory disturbance (16%) (Asthagiri et al., 2009). 
The majority of those with intra-medullary tumours do not require 
intervention. In a follow-up study, only two patients out of eleven (18%) 
experienced any growth of their intramedullary tumour (mean follow-up 52 
months) and these patients were all managed conservatively (Dow et al., 
2005). Those who require treatment will generally undergo surgical excision 
of the tumour.  
 
ii. Extra-medullary tumours 
 
Extra-medullary tumours are usually meningiomas or schwannomas and can 
be present intra-durally or extra-durally.  Spinal schwannomas tend to arise 
from sensory rather than motor nerve roots. Extra-medullary tumours tend to 
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occur most commonly in the lower lumbar/cauda equina (69% of patients) 
and cervical regions (52%) (Dow 2005). 
 
Extra-medullary tumours are multiple in the majority of patients - 56% had 
multiple spinal tumours in the study by Mautner et al (Mautner et al., 1995). 
They may be divided into small (<5mm) and large (>5mm) tumours.  
 
Patients tend to have multiple small tumours which may or not be associated 
with solitary or few large tumours. Small tumours seem to be relatively stable, 
and in one series, there was no growth of any small extra-medullary tumours 
during the follow-up period (n=13, mean follow-up 53 months). Large extra-
medullary tumours by contrast seem to be more aggressive, with growth in 
36% of patients (Dow et al., 2005). Large tumours may require intervention if 
the lesion can be predictably pinpointed as to causing a reversible 
neurological deficit, the risk of complications is acceptable and the tumour is 
large and showing growth. In patients with large tumours, intervention rate is 
high, with surgical excision required in 57% of those with such tumours (Dow 
et al., 2005). 
 
e. Ophthalmologic Findings in NF2 
 
Ophthalmic pathology is a well-known feature of NF2 and appears in the 
diagnostic criteria. Abnormalities may be found incidentally on screening or 
may present with visual loss or cosmetic eye changes. Many ophthalmic 
changes may be asymptomatic.  Functional visual problems may result from 
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a primary NF2-specific eye pathology or may arise secondarily due to other 
NF2 pathology, such as disc changes due to raised intracranial pressure or 
corneal ulceration secondary to facial palsy. Patients with NF2 should 
undergo regular ophthalmological assessment as many lesions may only be 
detected on slit-lamp examination with pupillary dilatation by an experienced 
NF2 ophthalmologist. Dedicated MR imaging of the orbit may reveal 
previously undetected optic nerve sheath meningiomas. 
 
i. Incidence 
 
There are limited data available as to the incidence of ophthalmic pathology 
in NF2. Evans et al found that 38% of their 90 patients had lens opacities 
(Evans et al., 1992a). Bosch et al found NF2-specific ocular pathology in 
83% within their 30 patient cohort, and the incidence of NF2-specific and 
NF2-associated eye findings in their cohort are in the two tables below 
(Bosch et al., 2006a). However, these patients had all been referred for 
ophthalmological assessment so there may be some selection bias, with an 
over-estimation of incidence. 
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NF2-specific eye finding Incidence (n=30) 
Cataract 67% 
Epiretinal membranes 40% 
Combined pigment epithelial and 
retinal hamartoma (CPERH) 
3% 
Disk glioma 13% 
Optic nerve sheath meningioma 27% 
 
Table 9. NF2 specific eye findings (Bosch et al., 2006a). 
 
NF2-associated eye findings  Incidence (n=23) 
Disk oedema 30% 
Optic atrophy 17% 
Motility disorder 52% 
Pupil dysfunction 35% 
Lid dysfunction 43% 
Reduced corneal sensation 26% 
Exophthalmos 17% 
Keratopathy 22% 
 
Table 10. NF2-associated eye findings (Bosch et al., 2006a) 
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f. Peripheral nerve involvement in NF2  
 
Peripheral nerve involvement in NF2 may include distal symmetric 
sensorineural neuropathy, focal amyotrophy and mononeuropathy. It has 
been suggested that neuropathy be added to the diagnostic criteria for NF2 
to improve its sensitivity (Baser 2002). Peripheral neuropathy in NF2 may 
have been underestimated in the past: it was found in only 6% of patients in 
a large clinical study (Evans et al., 1992a). However a study in 2002 revealed 
the incidence may be as high as 66.7% on electrophysiological testing 
(Sperfeld et al., 2002). 
 
Children present with peripheral nerve involvement more commonly than 
adults and in one series at least 10% of children under 10 years old (n=3/30) 
presented with mononeuropathy: facial palsy in the absence of vestibular 
schwannoma or foot drop (Evans et al., 1999a). 
 
Symptomatic focal amyotrophy was first described as a presenting feature of 
NF2 in 2000 (Trivedi et al., 2000), however the ‘wasting of a muscle group 
with no obvious antecedent cause’ was recorded in 4% (n=6/150) in a large 
clinical study (Evans et al., 1992a). Mononeuropathy most commonly affects 
the facial nerve, causing permanent lower motor neurone palsy, often before 
the detection of a vestibular schwannoma (Evans et al., 2005). 
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Histology of peripheral nerves in patients with NF2 neuropathy has revealed 
loss of myelinated and unmyelinated fibres and abnormal Schwann cell 
proliferation, some with an onion bulb appearance (Asthagiri et al., 2009). A 
number of underlying mechanisms have been proposed as the cause of 
peripheral neuropathy in NF2, including: compression by multiple tumourlets 
along the length of an adjacent nerve; Schwann cell proliferation with 
entangled axons (schwannosis); Schwann cell dysfunction or local toxic 
effects by pathological cells (Asthagiri et al., 2009). Merlin isoform 2 has 
been found to have a specific role in maintaining axonal integrity and the 
reduction of axonal NF2 gene dosage may result in polyneuropathy (Schulz 
et al., 2013). 
 
g. Cutaneous manifestations of NF2 
 
Although cutaneous changes in NF2 are not as common or as prominent as 
in NF1, they are sometimes the first or presenting symptom. A number of 
cutaneous stigmata may be present in NF2, including café au lait (CAL) 
patches and skin tumours, including cutaneous plaque-like schwannomas, 
intra-dermal tumours and discrete subcutaneous peripheral nerve 
schwannomas. Skin tumours may be multiple (when present, average tumour 
number = 5.8) (Evans et al., 1992a) and appear to have a raised frequency in 
more severally affected people (Mautner et al., 1997). They usually occur 
above the waist (Ferner, 2007). Cutaneous lesions were the first clinical 
symptom of NF2 in 27.3% of patients in the series by Mautner et al (Mautner 
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et al., 1997). The prevalence of skin lesions in 5 major series of NF2 patients 
is summarised in the table below: 
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Table 11. Prevalence of cutaneous manifestations in NF2 
 
Series (S) 
Review (R) 
 
Kanter et 
al. (1980) 
(S) 
 
Evans et al. 
(1992a) (S) 
 
Parry et al. 
(1994) (S) 
 
Otsuka et al. 
(2003) (S) 
 
Mautner et al. 
(1997) (S) 
 
Asthagiri et 
al. (2009) 
(R) 
 
Number of 
patients 
 
73 
 
100 
 
63 
 
74 
 
88 
 
n/a 
 
Café-au-lait 
patches 
 
42% 
 
43% 
 
47% 
 
50% 
 
33% 
 
33-48% 
 
Skin tumour/s 
 
32% 
 
68% 
 
67% 
  
59% 
 
59-68% 
 
>10 skin 
tumours 
  
10% 
   
27.4% 
 
 
Cutaneous 
schwannoma 
  
48% 
   
41% 
 
41-48% 
 
Subcutaneous 
schwannoma 
  
43% 
  
70% 
 
48% 
 
43-48% 
 
Intra-dermal 
tumour 
  
27% 
   
8% 
 
Rare 
 
Neurofibroma/ 
mixed tumour 
     
5 NF, 2 mixed 
from 29  
 
Rare 
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h. Café au lait (CAL) patches  
 
Café au lait patches are areas of pigmentation of varying size and shape, 
although they characteristically have a smooth border. Their colour can vary 
from light to dark brown and they tend to have uniform pigmentation. 
Although multiple CALs are often present in NF1 (>6 is a diagnostic criterion) 
they tend to be less frequent in NF2. A review of clinical features in series of 
NF2 patients found that 33-48% of people with NF2 have CAL patches, and 
most only have one or two (Asthagiri et al., 2009). In a series of 48 patients, 
20 patients had CAL patches and of these 6 only had one patch (30%) and 
14 had multiple CAL (70%) with a mean of 2.6 patches. Two had six or more 
patches (10%) (Mautner et al., 1996). 
 
ii. Cutaneous schwannomas  
 
Cutaneous schwannomas were first described by Martuza in 1982 and are 
raised, well-circumscribed plaque-like lesions, often slightly hyperpigmented 
and typically smaller than 2cm (Martuza and Ojemann, 1982). They tend to 
have a roughened surface and hypertrichosis may occasionally be a feature 
(Mautner et al., 1997). Cutaneous schwannomas can occasionally cause 
discomfort and may be easily excised under local anaesthetic. Excision of 
cutaneous schwannoma and mutation analysis for the NF2 gene may be 
useful in the diagnosis of mosaic disease. 
 
The prevalence of cutaneous schwannomas has been found to be 
significantly greater in patients with more severe disease than in patients with 
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mild disease (Mautner et al., 1997). In their series, cutaneous schwannomas 
were found in 8% of mild patients and 55% of severe patients (p<0.001).  
  
iii. Subcutaneous schwannomas 
 
These fusiform or nodular swellings develop along peripheral nerves and on 
examination can be demonstrated to be deep to the skin, which moves easily 
over them.  They are often painful to pressure and may require excision for 
symptomatic control. Subcutaneous schwannomas may also be an indicator 
of disease severity, as they were found in 24% of patients with mild disease 
and 58% with severe disease (p=0.004) (Mautner et al., 1997). 
 
iv. Intradermal tumours 
 
These rare tumours are described as being epicutaneous and similar to NF1 
dermal lesions. They sometimes have violaceous colouring and histological 
analysis has demonstrated schwannoma infiltration (Mautner et al., 1997). 
 
v. Neurofibroma 
 
NF2 patients have also developed cutaneous neurofibromas and mixed 
tumours; Mautner et al found that of 29 skin tumours biopsied, 5 were 
neurofibromas and 2 mixed tumours  (Mautner et al., 1997). 
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vi. Genetic changes in NF2-related skin tumours 
 
Kluwe et al (2000) studied 40 NF2-related skin tumours and found NF2 
mutations in 5 (13%) and NF2 allelic loss in 18 (45%) of the tumours. In 17 
(43%) of tumours, alterations were found on both NF2 alleles. They conclude 
that loss of functional NF2 gene product is the critical event in the 
development of skin tumours (Kluwe et al., 2000). 
 
i. Seizures in NF2 
 
Seizures have been reported in association with NF2, but only within the 
context of large clinical studies. There has been no systematic assessment of 
seizure frequency in NF2.  In a genetic based study, 8% of adults with NF2 
were reported to have epilepsy (Evans et al., 1992b). There have been no 
studies regarding the aetiology of seizures in NF2, but a number of 
associated abnormalities may be responsible.  
 
Loss of NF2 gene function predisposes to tumour formation, predominantly 
the development of meningiomas (frequently multiple) and gliomas that are 
potentially epileptogenic (Evans et al., 1992b, Ferner, 2007, Trofatter et al., 
1993). Neuropathological studies have demonstrated a microdysgenesis 
including glial hamartomas that cluster in the grey matter of the cerebral 
cortex and the thalamus (Wiestler et al., 1989). 
 
Meningioangiomatosis is rare and usually sporadic but has been associated 
with NF2 in 16 out of 100 cases in the literature, only a minority of these 
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patients presented with seizures (Omeis et al., 2006). In NF2 the site is 
predominantly in the frontal cortex, but lesions can be multiple. 
Meningioangiomatosis involves the leptomeninges and underlying cortex with 
meningiovascular proliferation and leptomeningeal calcification (Omeis et al., 
2006, Wiestler et al., 1989). 
Intracranial calcifications unrelated to tumour were described in the choroid 
plexus, cerebral and cerebellar hemispheres in 7 out of 11 patients imaged 
with brain computerised tomography (Mayfrank et al., 1990) but the 
frequency in large NF2 populations, aetiology and relationship with epilepsy 
is uncertain.  
 
j. Vascular disease in NF2 
 
There have been anecdotal reports of vascular pathology in patients with 
NF2. A 36 year old man had an un-ruptured middle meningeal artery 
aneurysm which was successfully managed with embolization (Lesley et al., 
2004). Two strokes have occurred in children and young adults (Ryan et al., 
2005, Ng et al., 2009) and bilateral renal vascular disease and resulting 
hypertension has been reported in a 21 month-old child (Cordeiro et al., 
2006). 
 
k. NF2 in children 
 
At least 18% of people with NF2 present before the age of fifteen years, and 
10-18% of children presenting with a meningioma or schwannoma are likely 
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to develop NF2 so will require screening (Evans et al., 1999a). Children 
under ten years of age tend to present very differently than adults: hearing 
loss or tinnitus as a presenting symptom is uncommon (<20%) and 
presentations with facial mononeuropathy, seizures and visual loss occur 
more frequently than in adults (Evans et al., 1999a). People who present with 
symptoms of NF2 at a younger age are more likely to have positive mutation 
testing for NF2 and are likely to have a more severe genetic mutation and 
therefore phenotype (Selvanathan et al., 2010). 
 
The natural history of NF2 in very young children has been studied in three 
children who all developed bilateral VS in the first few months of life, and the 
authors postulate that this could be a congenital form (Ruggieri et al., 2013). 
All three children had bilateral VS as an incidental finding on MR imaging at 
the age of 4-5 months. They were asymptomatic for 10-14 years, then two 
had sudden and rapid progression (<12 months) at the age of 11 and 15 
years. The authors also found atypical skin plaques and evidence of cortical 
dysplasia within these children. 
 
l. NF2 in the elderly 
 
Although the majority of patients with NF2 are diagnosed in their twenties or 
thirties, occasionally patients may be diagnosed at a much older age. There 
has been a recent description of seven patients diagnosed at seventy years 
or older. Only four of the seven had bilateral VS. There was little tumour 
growth during a mean follow up of 96 months – 8 of the 11 VS showed no 
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growth and only one required treatment. All other tumours (including other 
schwannomas and meningiomas) remained stable. No mutation was found in 
the blood of any of the patients, suggesting mosaic disease (Goutagny et al., 
2013). The authors therefore advocated a watch-and-scan policy for people 
diagnosed with NF2 over the age of 70 years (Goutagny et al., 2013). 
 
1.8 Imaging in NF2 
 
The gold-standard method of imaging for NF2 patients is magnetic 
resonance imaging (MRI). Details of specific imaging techniques, screening 
and follow-up scans are discussed in other sections. There are specific 
factors relating to NF2 and imaging which are discussed below: 
 
a. Measuring tumour size and growth: volumetrics 
 
Tumour size was previously measured manually using standardised 
reference points. This method was often inaccurate, with errors introduced at 
many stages, and it was hard to accurately determine growth within a patient 
and between patients. Studies have shown that volumetric measurement of 
VS is more accurate than two-dimensional measurements (van de 
Langenberg et al., 2008). Linear measurement of VS on MRI underestimated 
volumetric growth by an average of 50% (Harris et al., 2008). 
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It is now possible to accurately obtain whole body tumour volumes measured 
with computerised volumetry and 3D segmentation of whole body MRI scans, 
reducing the time and resources required compared with manual 
measurement (Cai et al., 2009). It is likely that these methods will be used as 
end-points in studies of NF2 to allow accurate comparisons (Blakeley et al., 
2012). 
 
b. Coincidental findings on whole body MRI 
 
Whole body MRI may be used more commonly in the future, both for 
assessment of tumours and treatment outcomes. However there are issues 
related to coincidental findings: in one study of whole body MRI in NF1 and 
NF2 patients, 42% had one or more incidental findings, 6.5% of which were 
clinically significant, including avascular necrosis in 9.3% of NF2 patients 
(Jaremko et al., 2012). Patients should be aware of the potential of 
coincidental findings prior to undergoing MRI and there should be a protocol 
to be followed if they occur. 
 
c. Imaging with implants in situ 
 
With increasing use of cochlear implants (CI) and auditory brainstem 
implants (ABI) in NF2, there are concerns as to the impact on follow-up 
imaging. In vitro and in vivo testing of CI and ABI revealed image distortion 
around the device but no measurable adverse effects for the patient or 
device (Heller et al., 1996, Vincent et al., 2008). 
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Twelve patients with NF2 and implants (10 ABI, 2 CI) underwent 77 MRI 
scans, 43 of the head, 27 of the spine and 7 of other areas. The magnet was 
not removed, but following displacement of a magnet, a credit-card sized 
piece of plastic was bandaged tightly to the head over the long axis of the 
receiver stimulator (Donnelly et al., 2012). Two scans had to be abandoned 
due to pain, but local anaesthetic infiltration allowed their completion. In all 
cases, the implant continued to function normally. The view of the ipsilateral 
internal auditory meatus (IAM) was unimpaired in 67% of the head; the 
contralateral IAM was unimpaired in all cases. The authors felt that it was 
always possible to view a vestibular schwannoma, even when the view was 
impaired (Donnelly et al., 2012).  
 
1.9 Management of NF2 
 
Once a diagnosis of NF2 is made, all patients should be offered baseline 
screening, including: spinal and brain MRI; pure tone and speech 
audiometry; blood mutation testing and ophthalmological assessment. 
Depending on signs and symptoms, they may also undergo nerve conduction 
studies (NCS) electromyography (EMG) and/or electroencephalography 
(EEG). Most patients are then seen at least annually if they remain 
asymptomatic or have no clinical change. The standard investigations in a 
stable patient include: 
• Cranial MRI – annually (six monthly in adolescence – early twenties) 
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• MRI whole spine – every three years 
• Pure tone audiometry and speech audiometry – annually 
• Ophthalmological examination – annually for children and adults with 
abnormalities 
If there is any change in symptoms or neurological examination, more 
frequent assessment and imaging will be organised as appropriate.  
 
a. Specialist units for NF2 
 
Studies of mortality in NF2 have revealed a survival benefit when patients are 
managed within a specialised unit (Baser et al., 2002a). Since April 2010, 
NF2 care within England has been nationally commissioned and is provided 
in one of four specialist units (Guy’s and St Thomas’ in London, Oxford, 
Cambridge and Manchester) with radiosurgery offered in Sheffield. As 
relatively few patients undergo highly specialised surgery, such as ABI 
insertion, it is currently recommended that this only takes place in two units 
(Cambridge and Manchester). 
 
It is widely agreed that NF2 patients should be managed by a multi-
disciplinary team, and this is the overriding principle of the majority, if not all 
NF2 specialist units. The multi-disciplinary team usually includes the 
following professional members: neurologist; geneticist; neurosurgeon; 
otolaryngologist; ophthalmologist; pathologist; radiologist; audiologist and 
experienced nursing staff.  A psychiatrist and psychologist, paediatrician, 
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plastic surgeon, pain specialist and specialist physiotherapists may also be 
required for particular patients.  
 
b. Surgery for NF2 
 
The majority of patients with NF2 will undergo some form of surgical 
intervention during their lifespan. The timing of surgery, along with the 
procedure used and the surgical team involved is an extremely important 
aspect in the management of an individual with NF2. Developments in 
technology have allowed for surgical enhancement of hearing with cochlear 
and auditory brainstem implants and these are also discussed. Although VS 
often require some form of intervention, non-VS intracranial schwannoma 
rarely undergo excision, as their removal leads to loss of function of the 
affected nerve, which causes significant morbidity. Intracranial meningiomas 
and spinal tumours may be excised if they are causing reversible deficits. 
 
i. Surgery for vestibular schwannoma 
 
The decision to undertake surgery on VS in NF2 is very complex and 
indications still differ between individual patients and managing teams. 
Although the natural history of VS growth in NF2 is reasonably well 
described, its relation to hearing loss is much more variable and therefore 
cannot be used as an accurate predictor of future hearing ability. The 
‘triggers’ for surgical intervention may include intervening when the tumour is 
small in an attempt to preserve hearing; when the VS is clearly growing but 
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still less than 3cm in diameter, and risk of facial palsy is reduced; when 
hearing is lost in small but growing tumours or when there is evidence of 
significant brainstem compression. In short, there is a wide dichotomy of 
opinion that is regularly debated but rarely with a universally accepted 
conclusion. 
 
Early intervention may preserve hearing (see section below) but there are no 
predictors of when it may be successful and it may result in complications in 
a patient who would never have required surgery. Likewise, waiting until the 
tumour is large and causing brainstem compression often means that the 
tumour can only be de-bulked and has a high chance of recurrence. The 
decision of when to intervene must be tailored to each individual patient, 
taking into account patient preferences, the characteristics of that individual’s 
disease (including mutation type and natural history in the family) and the 
previous experience and expertise within the department. Surgery for VS in 
NF2 tends to follow trends over time, cycling between early and late 
intervention, total, near total and subtotal resection, translabyrinthine, 
retrosigmoid and middle fossa approaches.  It is likely to be normally 
distributed, with most departments generally falling into the middle of both 
extremes. 
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Surgical approach 
 
There are three methods of approaching a vestibular schwannoma in the 
cerebellopontine angle (CPA). These are the translabyrinthine, middle fossa 
and retrosigmoid approaches. The translabyrinthine approach involves a 
mastoid approach in which the labyrinth is removed.  In this way, the internal 
auditory canal is exposed together with the posterior fossa dura between the 
superior petrosal sinus and the jugular bulb. The middle ear structures and 
the cochlea are untouched. During the middle fossa approach, a small, 
temporal craniectomy is performed and the internal auditory meatus is 
approached from above. The retrosigmoid approach involves a craniectomy 
positioned behind the sigmoid sinus and below the transverse sinus thus 
accessing the posterior fossa immediately behind the temporal bone.  
Decompression by drainage of CSF and retraction of the cerebellum then 
provides excellent access to the CPA. 
 
The advantages and disadvantages of each approach are summarised in the 
table on the following page: 
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Approach Advantages Disadvantages 
Translabyrinthine No cerebellar retraction 
Any size tumour can be 
removed 
Early identification of facial 
nerve 
Proximal and distal access 
to the facial should a nerve 
graft be required. 
Destroys residual hearing 
Increased risk of CSF leak 
Middle fossa Possibility of hearing 
preservation 
 
Cramped access to CPA 
Temporal lobe retraction 
Limit to size of tumour that 
can be removed 
Risk to facial nerve 
Retrosigmoid Possible hearing 
preservation 
No limit to size of tumour 
Cerebellar retraction 
Incomplete view of fundus 
Immediate reconstruction 
of the facial nerve usually 
impossible.  
Increased risk of post-
craniectomy headache 
 
Table 12 Advantages and disadvantages of the surgical approaches to the 
cerebellopontine angle. From Scott-Brown’s Otorhinolaryngology Vol 3 (Gleeson, 
2008). 
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Facial palsy following VS surgery 
 
An extremely significant risk of VS surgery is facial palsy due to damage to, 
or division of, the facial nerve at the CPA. Facial palsy may be partial or 
complete (see Section 6 a iv) and may be temporary or permanent. Intra-
operative facial nerve monitoring allows for more accurate identification of the 
nerve and should improve outcomes (Blakeley et al., 2012). Even with facial 
nerve monitoring, facial nerve outcomes following vestibular schwannoma 
surgery in patients with NF2 are usually worse than in patients with solitary 
tumours.   
 
It is clear that preservation of facial nerve function is achieved more 
frequently with small tumours than larger tumours. Meta-analysis of surgical 
data is difficult due to the large number of variables and reproducibility of 
results, but it does appear that facial palsy rates are reduced when the 
tumour is less than 2.5cm in diameter (Blakeley et al., 2012). In a study of 
early proactive management of VS in NF2 (Brackmann et al., 2001), 92% 
patients with normal facial function pre-operatively continued to have 
normally facial function at long-term follow-up (n=38, 92.5% of tumours less 
than 2cm in diameter). In another large series, which included non-NF2 
patients, 100% of patients maintained facial function after surgery when the 
tumour was <2.5cm in diameter, compared to 83% when the tumour was 
greater than 2.5cm (Grey et al., 1996). However the use of non-NF2 data is 
misleading as the risk of facial palsy is much increased following VS surgery 
in NF2, possibly due to differing tumour biology and behaviour.     
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Hearing preservation surgery 
 
Timing of surgery for vestibular schwannoma in NF2 is still a contentious 
area, and opinion varies from unit to unit. An ideal surgical outcome would be 
entire removal of the tumour with complete preservation of hearing and facial 
nerve function, however good results from certain units may be hard to 
replicate and there is always the risk of morbidity, such as complete hearing 
loss and facial palsy, from an operation that may not even be required.  
 
Hearing preservation surgery is generally attempted with a tumour of less 
than 1.5cm in diameter and is undertaken by the middle fossa approach. 
Brackmann et al reported results from 40 procedures on 28 patients with 
NF2. Measurable hearing was preserved in 70%, 42.5% had hearing within 
15dB of their pre-operative pure tone average and 15% of their pre-operative 
speech discrimination score. 87.5% had normal facial nerve function after 
one year  (Brackmann et al., 2001). 
 
Cochlear implantation (CI) 
 
Cochlear implantation allows direct stimulation of auditory neurones within 
the cochlear by an electrode array. It can only be used where there is an 
intact cochlear nerve, and may be inserted at the time of vestibular 
schwannoma removal, or at a later date. Integrity of the cochlear nerve can 
be assessed pre-operatively using the technique of promontory stimulation, 
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and checked intra-operatively by recording the cochlear nerve action 
potential (CNAP) (Piccirillo et al., 2008). 
 
Functional hearing outcomes from a cochlear implant in a patient with NF2 
may be excellent, with 5/6 in one study able to use a telephone post-
implantation, with open-set speech understanding scores in the range of 90-
100% (Neff et al., 2007). This compares extremely favourably to the 3-7% 
open-set speech understanding in NF2 patients with an auditory brain stem 
implant. Long-term results in 5 patients with a mean follow-up period of 7.9 
years showed no deterioration in hearing over the follow-up period (Neff et 
al., 2007). However, other authors report less promising results, with only 2/4 
patients achieving open-set speech discrimination when a CI was used in 
NF2 patients with no hearing in the contralateral ear. All of these patients 
continued to use their implant every day thereby indicating the utility and 
importance of their implant (Lustig et al., 2006). 
 
Auditory brain stem implant (ABI) 
 
The auditory brain-stem implant allows auditory perception by bypassing the 
cochlear nerve and allowing direct stimulation of the cochlear nucleus, 
accessed via the lateral recess of the fourth ventricle. The first ABI was 
inserted at the House Ear Institute in 1979 and was a single channel device 
(Edgerton et al., 1982). Since then, technology has progressed rapidly, and 
current implants have a twelve electrode surface contact array.  
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An ABI may be inserted at the time of surgery for vestibular schwannoma, as 
an active device if all hearing is lost, or as a ‘sleeper’ device if hearing still 
persists, to be switched on at a later date when hearing is lost. ABI insertion 
may rarely be performed as a separate procedure, although placement is 
more difficult if performed at a second stage following vestibular 
schwannoma surgery, due to scarring and surgically-induced anatomical 
change. ABI cannot replicate results achieved with cochlear implantation, 
and although some users do get return to functionally significant hearing 
(Colleti et al., 2012), the majority find the ABI is a useful adjunct to lip-reading 
and can experience environmental background sound. A penetrating 
electrode has been used, as it was thought that design would improve 
contact with the cochlear nucleus itself and have an additional advantage in 
that the topographical representation of the frequency range within the 
cochlear nucleus is stacked from lateral to medial.  However, it was found 
that penetrating electrodes offered no advantage and, in fact, proved to be 
inferior in terms of speech recognition (Otto et al., 2008). 
 
Hearing outcomes with ABI in NF2 are significantly worse than those 
implanted in individuals without NF2.  It is postulated that this is due to 
selective damage to specific pathways for modulated sound in NF2, either by 
surgery and/or tumour (Colleti and Shannon, 2005).  Non-auditory stimulation 
by the ABI has also been experienced. This may be mild, such as vibro-
tactile sensations or twitching, and can be minimised by the switching off of 
responsible electrodes during device programming. More serious non-
auditory stimulation, such as twitching and pain, may result in non-use or 
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replacement of the implant. Non-use of the implant is not uncommonly 
reported as a result of poor results and/or non-auditory stimulation.  A recent 
prospective study showed that 3/20 NF2 patients were non-users of their ABI 
(Patel et al., 2012). 
ABI insertion can lead to difficulties in imaging using MRI, which is an issue 
in NF2 patients where regular assessment of tumours and screening for new 
tumours is required (see imaging section). It can cause difficulties in 
performing the scan and has necessitated magnet and even implant removal 
in the past or use of alternative imaging such as myelography (Ferner- 
personal communication 2013). It may also cause image distortion and 
difficulties in measuring tumour growth. These issues are particularly 
pertinent when a ‘sleeper’ device is inserted, as the drawbacks of the device 
are not balanced with benefits – after all, the implant may never be used. 
This needs to be carefully discussed with each patient and a joint decision 
made with the patient and their multi-disciplinary team.   
 
iii. Surgery for meningioma 
 
Many patients with NF2 have multiple meningiomas, and although less than 
a quarter of meninigiomas require surgical intervention during long term 
follow-up (23%), nearly half of patients with meningiomas required at least 
one surgical intervention for a meningioma (45.9%) (Goutagny et al., 2012). 
Indications for surgical excision of a meningioma in NF2 include symptoms 
such as seizures, intracranial hypertension or neurological deficit; significant 
growth on serial scanning; or for access to another tumour (Goutagny et al., 
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2012). Complications may include worsening neurological function or 
recurrence. 
iv. Spinal surgery 
 
Surgery for spinal tumours is generally only performed when it is highly likely 
that the lesion is causing a reversible deficit and the risk of complications is 
outweighed by the benefits. It is again important that decisions to intervene 
surgically are made in a multidisciplinary setting, and performed by spinal 
surgeons with experience of NF2.  
 
v. Other surgery for NF2 
 
Surgery for cutaneous and subcutaneous lesions may be required for 
diagnosis and genetic diagnosis or for functional reasons or pain relief. 
Surgical excision of peripheral nerve lesions is difficult and rarely indicated. It 
may not provide symptom relief and has the potential to cause serious 
complications, such as loss of power. It should therefore only be performed 
after thorough neurological examination, investigation and multi-disciplinary 
and specialist peripheral nerve input. 
 
c. Radiotherapy in NF2 
 
Although a well-accepted form of treatment for sporadic vestibular 
schwannoma and other intracranial tumours, there are concerns with regard 
to the use of radiotherapy in NF2 due to the risk of radiation-induced 
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malignancy. The form of radiation most commonly used in NF2 is stereotactic 
radiosurgery (SRS), either gamma-knife or linear accelerator (LINAC). This 
involves a single or limited dose delivered accurately to the tumour following 
a formal dose plan, where various iso-centres of radiation deliver sufficient 
radiation to the tumour while limiting the exposure to surrounding structures. 
It is generally recommended that only VS less than 3cm in diameter are 
considered for radio-surgical treatment (Blakeley et al., 2012).  The delivery 
of a therapeutic dose to larger tumours poses technical difficulties 
notwithstanding the risk of damaging adjacent structures.   Furthermore, any 
post irradiation swelling of the tumour could cause critical brainstem 
compression.  
 
A number of studies have assessed the effectiveness of radiotherapy in NF2 
tumours and associated complications. Rowe et al published a retrospective 
consecutive series of their treatment of 122 vestibular schwannomas in 92 
patients with NF2 (Rowe et al., 2008). They also provided extended follow-up 
data for 22 patients with 906 patient-years of follow-up. They predicted that 8 
years after radiosurgery for NF2 VS, 20% will have required further 
treatment, 50% will be well controlled and 30% will have had some 
progression but still be managed conservatively. Risk of facial palsy after 
treatment was 5%. Hearing assessment revealed that three years after 
treatment, 40% retained functional hearing, 40% had deterioration and 20% 
lost hearing in the treated ear (Rowe et al., 2008). 
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Mathieu et al treated 74 VS in 62 patients with NF2. They found actuarial 
control rates were 85% at 5 years and 81% at ten and fifteen years. Facial 
nerve palsy developed in 8%, trigeminal neuropathy in 4% and vestibular 
dysfunction in 4%. There were no cases of malignancy at time of publication 
(Mathieu et al., 2007). A small study of four NF2 patients treated with LINAC 
has also revealed promising results (Kuo et al., 2008). 
 
Care does need to be taken when selecting a treatment centre as local 
control and complications can vary massively – one centre reported the 
incidence of facial weakness in their cohort of 12 treated patients with NF2 
was 42% (Wentworth et al., 2009). In the UK, all radiotherapy for patients 
with NF2 is undertaken at one specialist centre. 
 
NF2 is a tumour-predisposition syndrome and there are concerns with regard 
to malignant transformation of existing tumours and the development of new 
malignancies. There have been more than 20 cases of malignancy in NF2 
patients who have undergone radiotherapy; however this includes those who 
have undergone external beam radiation therapy, which is thought to offer a 
higher risk of malignant transformation (Blakeley et al., 2012). In Rowe’s 
series of stereotactic radiosurgery for VS in NF2 there were only two cases of 
malignancy, one of which was pre-existing prior to treatment (Rowe et al., 
2008). 
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The increased risk of malignant transformation has to be tempered with the 
reduced life-span of patients with NF2. A growing vestibular schwannoma 
can lead to hearing loss, facial palsy, brain-stem compression and death; 
therefore it is often necessary to provide some form of treatment. Like 
radiotherapy, surgery also offers worse outcomes in patients with NF2 than in 
those with solitary vestibular schwannoma. With surgery there are the added 
risks of a general anaesthetic and complications that may develop in the 
recovery period, such as deep vein thrombosis and hospital-acquired 
infections. Surgery for vestibular schwannoma commonly leads to permanent 
post-operative changes, such as hearing loss, facial weakness and 
occasionally swallowing difficulties, and at higher rates than those found 
following radiosurgery. It is therefore appropriate to consider SRS as an 
appropriate treatment for VS < 3cm in NF2. 
 
SRS has been used as the primary treatment for sporadic intra-cranial 
meningioma, but there are no large series of its use in NF2-related 
meningiomas. Some authors have offered SRS to multiple tumour types in 
NF2 including meningioma, ependymoma and non-vestibular cranial nerve 
schwannoma (Wentworth et al., 2009), but patient numbers are very small 
and this treatment method is not currently recommended (Blakeley et al., 
2012). 
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d. Novel therapies for NF2 
 
Along with greater understanding of the molecular role of the NF2 gene 
product comes the potential of targeted drug therapy. In normal cells, the 
NF2 gene product Merlin (or Schwannomin) is a regulator of cell growth and 
cell-cell interactions. It also appears that Merlin may be a negative regulator 
of growth in other non-NF cancers (Blakeley et al., 2012). The following 
candidate drug targets have been identified: 
• Epidermal growth factor family 
• RAS-GTP pathway 
• mTOR 
• VEGF and PDGF 
• Heat shock proteins (inhibition) 
• DCAF1: ubiquitin ligase inhibitor 
A number of drugs that have already been approved for clinical use in other 
conditions may be appropriate for targeted therapy in NF2. Several phase II 
clinical trials are underway, with promising results.  
 
Bevacizumab is the most widely studied targeted therapy for NF2 to date. It 
is an IgG1 monoclonal antibody that binds biologically active vascular 
endothelial growth factor (VEGF). Bevacizumab has been used in over 30 
patients with NF2, and has shown both significant reduction in tumour 
volume (<20%) and improvement in hearing function in a number of these 
patients (Plotkin et al., 2009, Mautner et al., 2010b). Further clinical trials are 
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now underway in many centres. Tumour shrinkage has been sustained with 
continuous use in two patients, but regressed when the drug was 
discontinued, and the authors postulated that bevacizumab does not seem to 
directly target the tumour cells but may induce reversible shrinkage of VS by 
increasing vascular permeability of the tumour cells and reducing intra-
tumoural oedema (Mautner et al., 2010a). Bevacizumab does not appear to 
cause any persistent reduction in meningioma volume in NF2 (Nunes et al., 
2013). The toxicity profile of bevacizumab is relatively well known and it 
appears to be well-tolerated. There are some concerns regarding its negative 
effect on wound-healing – surgery is not advised while the drug is being used 
(Blakeley et al., 2012). 
 
Phase II studies are also underway for the following drugs: 
• Lapatinib  
• Sorafenib and nilotinib 
• PTC299 
 
 
 
 
 
 
 94 
 
1.10 Quality of life (QOL) in NF2 
 
a. Definition  
 
The World Health Organisation has defined health as ‘a state of complete 
physical, mental and social wellbeing, not merely the absence of disease’. 
The WHO quality of life group went on to define QOL as:  ‘an individual's 
perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, 
standards and concerns.’ They stated that: ‘it is a broad-ranging concept 
incorporating in a complex way the person's physical health, psychological 
state, level of independence, social relationships, personal beliefs and their 
relationship to salient features of the environment.’ They also comment that 
‘this definition reflects the view that QOL refers to a subjective evaluation 
which is embedded in a cultural, social, and environmental context. As such, 
QOL cannot be simply equated with the terms "health status", "life-style", "life 
satisfaction", "mental state", or "well-being". Rather, it is a multidimensional 
concept incorporating the individual's perception of these and other aspects 
of life’ (World Health Organisation, 1995). 
 
b. Health-related QOL 
 
Health-related QOL has gained increased interest since the 1970s, and is 
now seen as an important indicator of the success of patient management. 
There are many reasons why QOL measures may be beneficial in the health-
care setting. In the clinical environment they can aid medical decision making 
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and facilitate communication. They may act as a trigger for intervention and 
may be used as an additional marker of disease progress or treatment 
success. They may indicate factors that are of increased importance to 
patients and indicate concurrent problems such as anxiety and depression. 
They may ultimately improve symptom relief, care and rehabilitation. QOL 
has increasingly been used for political decision-making and financial 
‘rationing’ where resources are limited.  
 
Quantitative QOL measures or scores can also be used as a comparative 
marker between patients, treatment groups and units, and as such are an 
increasingly important end-point in audit and clinical trials of treatment with 
curative or palliative intent 
 
c. Methods of measuring QOL 
 
Quality of life is generally assessed by asking the patient their opinion. It can 
be assessed qualitatively by interviews which can vary from freeform to fully 
structured. QOL can also be quantitatively assessed using QOL instruments 
which may either be generic or disease or symptom specific. 
 
i. Generic Measures 
 
These instruments are intended for general use, irrespective of the patient’s 
condition or disease process, and are often applicable for the healthy 
population. The most commonly used is the Medical Outcomes Study 36-
Item Short Form (SF-36) (Ware et al., 1993). The SF-36 evaluates general 
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health status, its 36 questions address eight health concepts. There are two 
summary measures: physical health and mental health. Within physical 
health there are scales for physical functioning, role-physical, bodily pain and 
general health. Within mental health there are scales for vitality, social 
function, role-emotional and mental health. There is a general health 
transition question and a global question about health perception. Scoring of 
the SF-36 is complex, the questionnaire is not available freely for use and it 
does take some time to complete. 
 
The EuroQol (EQ-5D) (See Appendix B) is another generic measure, which 
is generally freely available and is much shorter and simpler to use than the 
SF-36 (Brooks, 1996). It assesses five dimensions: mobility; self-care; usual 
activities; pain/discomfort and anxiety/depression. It also incorporates a 
visual analogue scale (VAS) for ‘your own health state today’. 
 
ii. Disease Specific Measures 
 
Disease specific QOL measures are formulated for a particular medical 
condition or symptom. They tend to be more relevant to the particular patient 
group being assessed and can be shorter and less onerous to complete than 
generic measures. The method for construction and validation needs to be 
well structured and thorough in order to provide an alternative to generic 
measures. It has been advised that disease-specific scores should be used 
alongside the SF-36 (Brazier et al., 1992). Disease specific QOL measures 
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have been developed for a number of conditions, including lower-limb 
ischaemia (Morgan et al., 2001) and pressure ulcers (Gorecki et al., 2013).  
 
d. Quality of life in NF2 
 
There have to date been few published studies regarding QOL in NF2. Patel 
et al. undertook semi-structured interviews with six people with NF2 (Patel et 
al., 2011). They reported the negative impact of NF2 on daily activities, 
including work, and social isolation. They noted that patients expressed a 
range of negative emotional reactions in response to their diagnosis and the 
impact of the disease and that there was frustration at the limited awareness 
of NF2 among health professionals and within their local community. 
 
Neary et al investigated QOL in 62 patients with NF2 (71% response rate) 
(Neary et al., 2010b). They posted out a questionnaire with 32 components 
and found that the greatest perceived problem was deafness, leading to 
communication problems with social contacts, close partners, family and 
friends. There appeared to be a relationship between general mood changes 
and hearing difficulties, social communication problems, balance difficulties 
and mobility problems. They found that self-confidence was only significantly 
related to social communication problems.   
 
Neary et al also assessed QOL in 62 patients with NF2 (71% response rate) 
using the SF-36 (Neary et al., 2010a). They found that subjects with NF2 
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scored less than the standardised norm in both physical and mental 
component scores. They found that there were significant correlations 
between several components of the SF-36 and the following components 
from their questionnaire: perception of difficulty communicating with their 
significant other; social communication; balance; hearing difficulties and 
mood change.  
 
1.11 Conclusion 
 
NF2 is a rare genetic condition that has a variety of clinical manifestations 
affecting the brain, spine, eyes and skin. Disease severity is variable, both in 
the number and type of manifestation, and the impact that they may have on 
an individual’s health and quality of life. It is therefore difficult to estimate the 
impact of the disease based purely on genotype, phenotype, imaging or 
clinical examination. Quality of life is fast becoming an invaluable asset in the 
holistic assessment of the patient. Generic tools to assess health-related 
QOL are already in wide use; however they can be time-consuming for the 
user, complex to analyse for the clinician and are not specific to the disease 
itself, particularly in the case of NF2. There have been a small number of 
studies investigating QOL in NF2, which confirm the variable and significant 
impact the condition can have on QOL. With the greater emphasis on 
evidence-based medicine and the identification of novel therapeutic targets, 
there is a clear need to measure QOL in NF2 patients, not only as a part of 
general clinical assessment, but also as an outcome measure in clinical 
trials.  
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2 Retrospective case note review of NF2 
patients: interesting trends and novel 
findings 
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2.3 Summary 
 
A comprehensive retrospective case note review of NF2 patients managed in 
the GSST NF2 clinic between 1998 and 2008 was performed and 61 
patients’ notes were reviewed. The data were analysed and four areas were 
selected for further study: cause of death; surgical intervention; hypertension 
and epilepsy. The retrospective case note review showed interesting trends 
in the management and outcome over a time of change in NF2 management. 
It emphasised the need for specialised care for this complex group, and over 
the course of this project, it has become policy in the UK. It revealed novel 
findings of a higher rate of hypertension in this NF2 patient cohort and of 
cortical dysplasia as a potential cause of epilepsy in NF2. 
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2.4  Aims 
 
To describe interesting trends and novel clinical manifestations of NF2 
identified within the patient cohort. 
 
2.5  Methods 
 
a. Study Approval 
 
Approval was obtained for the retrospective case note review and the 
hypertension study by the GSTT Audit Department. 
 
b. Target population and exclusions 
 
All patients with a diagnosis of NF2 who had attended the GSTT NF2 clinic 
between 1997 and 2008 were identified using: 
1. Database of NF2 patients managed within the department 
2. Skull base database of all patients managed at GSTT and King’s College 
Hospital since 1994 (MJG) 
2. Review of case notes of NF2 patients in the Neurofibromatosis Unit 
All patients with a diagnosis of NF2 were included in the case note review. 
Exclusions included patients whose clinical notes could not be traced. 
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c. Data collection 
 
Case notes of twenty patients with NF2 in the target group were reviewed 
and used to develop potential fields for a database which were refined 
following discussion with the multidisciplinary team. The database was 
anonymised in line with Trust confidentiality guidance, each patient was 
identified on the database by a number, and identifiable patient details were 
kept on a central password protected computer.   
The database was developed using a simple Microsoft Excel spread sheet 
and was divided into the following sections: 
• Demographics (including age, gender, ethnicity, occupation and 
handedness) 
• Route of referral to the service 
• Clinical features (including presenting symptom, age at presentation, 
clinical features of NF2, other medical history) 
• Clinical findings (including neurological examination, cutaneous and 
ophthalmological findings and blood pressure) 
• Investigations (including scan results, tumours and genotype) 
• Treatment (including surgery, radiotherapy, medication and clinical 
trial inclusion) 
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d. Data input 
 
The data were retrieved by retrospective analysis of clinical case notes, and 
were inputted by the author (RH). Accuracy was confirmed by random 
validation of 10 fields in ten separate patients by an independent observer 
(SH).   
 
e. Data analysis 
 
The data were reviewed and the following areas were selected for further 
study: 
 
i. Cause of death 
 
Patients who had died whilst under the care of the Department were 
identified and cause of death was reviewed. This topic was selected as there 
was relatively little published data providing information on cause of death in 
NF2. 
 
ii. Surgical intervention 
 
The type, timing and number of surgical interventions in the cohort were 
analysed, and comparisons were made between those undertaken by 
specialist and non-specialist surgeons. This area was selected as being 
particularly topical, as at the time of study, NF2 services in the UK were 
being reorganised. 
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iii. Hypertension study 
 
Following data input, it was noted that there may be an increased incidence 
of hypertension (BP > 140/90 mmHg) in NF2 patient compared to the general 
population, and the hypertension study was developed. Patients who had 
had their blood pressure measured within the GSTT NF2 outpatient clinic 
were identified from the database and were matched for age, ethnicity and 
gender, with controls using consecutive patient records from the general 
neurology clinic. Patients receiving anti-hypertensive medication and those 
who had died during the study period were excluded. The same 
measurement method, clinic setting and sphygmomanometer (Omron M6, 
automated) were used in all cases.  
 
iv. Epilepsy study 
 
Patients who had a history of seizures were identified from the database and 
clinical, histological and radiological characteristics were reviewed.  Imaging 
of patients with seizures was case-matched and compared to NF2 patients 
with similar clinical and demographic characteristics who did not experience 
seizures. A retrospective case note review was performed. Inclusion criteria 
were those patients with a confirmed clinical diagnosis of NF2, attending the 
NF2 clinic between 1997 and 2008. Patients who had a history of seizures 
were identified and clinical, histological and radiological characteristics were 
reviewed with SC and BI. Differences between the total number and site of 
meningiomas were compared and tested for significance using a student t-
test. 
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2.4  Results 
a. Patient Demographics 
Patients attending NF2 service at GSTT 1997-2008  
Total number of patients eligible for inclusion with available notes = 61/88 
Number of patients with unavailable case notes = 27/88 
45 generalised NF2 (73.8%), 16 mosaic NF2 (26.2%). 
32 males, 29 females  
Mean age:  
• at date of analysis = 40.0yrs (4 – 81yrs) 
• at first symptom = 23.4yrs (1-50yrs) 
•  
b. Cause of death 
6/61 patients died during follow-up (9.8%), one with mosaic NF2 and five with 
generalised NF2. The mean age at death was 43.7yrs, mean age at 
symptom onset was 19.5yrs and mean survival was 24.2 years. 
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Patient Gender Age at first 
symptom 
Age at 
death 
Cause of death 
1 M 21 28 Haemorrhage following 
excision of VS 
2 F 7 44 LRTI, secondary to radiation-
associated encephalopathy 
3 M 20 76 Myocardial infarction 
4 M 44 76 LRTI (2° to COPD) 
5 F 14 17 Malignant osteosarcoma 
6 F 11 21 Cerebro-vascular accident 
(non-tumour related) 
 
Table 13 Cause of death in NF2 cohort (1997-2008) 
 
d. Surgical interventions 
i. Demographics 
Complete surgical data was available for 57/61 patients. 
A total of 43 out of 57 patients had surgery relating to their NF2 at some time 
in their lifetime (75.4%) 
• 30 out of 41 with generalised NF2 (73.2%) 
• 13 out of 16 mosaic NF2 (81.3%)  
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ii. Timing of surgery 
Age at first procedure: 
• Mean age = 24.5yrs (range 1-63yrs) 
o Generalised NF2 = 26.1yrs  
o Mosaic NF2= 31.5yrs 
Time from first symptom to surgery 
• Mean = 5.9yrs 
17 out of 43 patients had surgery before diagnosis (39.5%) 
• Generalised = 8/30 (26.7%) 
• Mosaic NF2 = 9/13 (69.2%) 
32 out of 43 patients had surgery before specialist clinic referral (74.4%) 
 
iii. Type of procedures 
Of those patients that had surgery (n=43): 
• Average number of procedures = 3 (range 1-8) 
o Generalised NF2 = 3.4 
o Mosaic NF2 = 2.3 
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Table 14 Surgical procedures performed on NF2 cohort 
 
iv. Location of surgery 
62/130 procedures were performed by specialist NF2 surgeons in a major 
centre (47.3%). Specialist NF2 surgeons were defined as those practising 
within a centre offering multi-disciplinary NF2 care (such as Guy’s and St 
Thomas’, Manchester, Oxford or Cambridge) or those who offered specialist 
services to or worked alongside a specialist unit (such as specialist facial 
nerve surgery offered by a specialist plastic surgery unit). 
Procedure Type Number of 
procedures 
Number of 
patients 
Resection of vestibular schwannoma 34 25 
Procedures for facial palsy 17 10 
Shunt procedures (primary or revision) 17 11 
Spinal surgery 16 12 
Other intra-cranial resection 15 14 
Resection of schwannoma involving 
major plexuses 
12 4 
Resection of sub/cutaneous 
schwannoma 
8 5 
Ophthalmology 4 3 
Hearing rehabilitation 3 3 
Other 4 4 
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Procedure Type Number performed 
by specialist NF2 
surgeons 
Number performed 
by other surgeons 
Resection of vestibular 
schwannoma 
22 (4 outside our 
unit) 
12 
Procedures for facial palsy 14 3 
Shunt procedures (primary or 
revision) 
7 10 
Spinal surgery 5 11 
Other intra-cranial resection 4 11 
Resection of schwannoma 
involving major plexuses 
0 12 
Resection of sub/cutaneous 
schwannoma 
7 1 
Ophthalmology 0 4 
Hearing rehabilitation 3 0 
Other 2 2 
 
Table 15 NF2 specialist versus non-specialist surgeon 
 
v. Morbidity and mortality 
One death in 130 procedures: post-op VS resection haemorrhage (our unit) 
Documented complications: 
• Facial nerve palsy = 18/34 (8/18 in our unit) 
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• Shunt infection/blockage = 8 
• Swallowing problems (requiring NG/PEG feeding) = 3 
• CSF leak = 2 
• Spinal instability = 2 
• Wound infection = 2  
• Lower respiratory tract infection = 1 
• Hydrocephalus = 1 
• Arm weakness = 1 
• Globe puncture (eye) = 1 
 
vi. Impact of multi-disciplinary clinic 
Multi-disciplinary clinic commenced 2000 
• Patients seen in clinic prior to 2000 = 19 
Total number of procedures: 
• Pre-2000, 53 procedures performed 
o Of these 15 were in our unit – 28.3% of total 
• Post-2000, 77 procedures performed 
o Of these 34 were in our unit – 44.2% of total 
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Figure 5 Number of patients undergoing vestibular schwannoma excision by 
specialist (NF2) and non-specialist (other) surgeons by year, compared to number of 
patients managed within the NF2 specialist clinic 
 
VS surgery and facial palsy: 
• Pre-2000, 12 out of 17 had palsy – 70.6%  
o 5 of 8 operated in our unit had post-op palsy – 62.5% 
• Post-2000, 6 out of 17 palsy – 35.3%  
o 3 of 10 operated in our unit had post-op palsy – 30% 
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d. Hypertension 
i. Demographics 
Fifty patients within the NF2 database were eligible for this study. Age range 
at time of BP measurement was 1-81 years with a mean of 39.52 years, 
there were 27 males and 23 females. 
 
It was possible to match 45 of these individuals for age (within two years), 
ethnicity and gender with patients who had attended the general neurology 
outpatients within the last month (for whom case notes were readily 
available).  
 
ii. Blood pressure (BP) measurements 
 
Mean systolic BP 
• NF2 group, mean = 137mmHg (95% CI 133-143mmHg) 
• Control group, mean = 128mmHg (95% CI 123-132mmHg) 
• Paired t-test – means significantly different p=0.003 (2-tailed) 
 
Mean diastolic BP 
• NF2 group, mean = 84 mmHg (95% CI 81–88 mmHg)  
• Control group, mean = 77 mmHg (95% CI 73–80 mmHg) 
• Paired t-test - means significantly different p=0.003 (2-tailed) 
  
The mean diastolic and systolic BP of patients with NF2 was therefore 
significantly higher than the matched control group (p=0.003) 
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Twenty-one NF2 patients (42%) were hypertensive according to the British 
Hypertension Society Guidelines (systolic > 140 mmHg or diastolic > 90 
mmHg), compared with 22% within the general neurology group (p = 0.033 
by Fisher’s exact test). 
 
There was no significant correlation between systolic or diastolic BP in either 
group dependent on gender, however both systolic and diastolic BP 
correlated positively with age over both groups: 
   ageyrs BPsyst BPdiast 
ageyrs 
 
Pearson 
Correlation 
1.000 .438** .232* 
Sig. (2-tailed)  .000 .024 
N 95 95 95 
BPsyst 
 
Pearson 
Correlation 
.438** 1.000 .704** 
Sig. (2-tailed) .000  .000 
N 95 95 95 
BPdiast 
 
Pearson 
Correlation 
.232* .704** 1.000 
Sig. (2-tailed) .024 .000  
N 95 95 95 
 
Table 16 Correlations between age and BP in both groups (**correlation is 
significant at the 0.01 level (2-tailed) *correlation is significant at the 0.05 level (2-
tailed)). 
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e. Epilepsy 
Sixty-one patients within the database had full clinical information available to 
confirm or deny a history of seizures. Six had a confirmed history of seizures 
(9.8%). Mean age of this group was 37.8 yrs, with a range of 27-52 years. 5 
were male and 1 female. Seizure was the first presentation symptom of NF2 
in two patients. All six patients had cranial meningiomas, compared to 22 
patients in the cohort who had cranial meningiomas without seizures (40%).  
 
The number and site of meningiomas within the group with epilepsy and 
meningiomas were compared to those in the group without epilepsy but with 
meningiomas. The mean number of meningiomas in the total cohort was 2.6, 
mean in the epilepsy group was 2.5 and in the non-epilepsy group was 2.6 
(no significant difference, p=0.874). In the epilepsy group 43.75% of 
meningiomas were on the right (n=7), 37.5% were on the left (n=6) and 
18.75% (n=3) were in the midline, compared to 35.4% on the right (n=18), 
45% on the left (n=23) and 19.6% in the midline (n=10) in the non-epilepsy 
group. The position of the meningiomas within the cranial cavity appeared to 
be distributed in a similarly in both the epilepsy and non-epilepsy groups. 
(See table 24). 
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Site of meningioma Epilepsy Group Non-epilepsy group 
Sphenoid wing 14.3% (2) 16.7% (9) 
Posterior fossa 14.3% (2) 13.0% (7) 
Anterior 21.4% (3) 26% (14) 
Superior 36.4% (4) 31.5% (17) 
Parietal 21.4% (3) 23.0% (7) 
  
 Table 17 Site of meningiomas in epilepsy and non-epilepsy groups 
 
Imaging of five affected patients was reviewed (SC). In all cases, cortical 
lesions were discovered. In four of the five, these were likely to be secondary 
to surgery or radiotherapy, but in one case three lesions were present with no 
obvious underlying cause and appeared dysplastic in nature. (Figure 7)  
 
 
Figure 6 Areas of high signal intensity (arrowed) thought to indicate cortical 
dysgenesis. 
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One patient underwent a right temporal lobectomy for intractable epilepsy 
and the histology was reviewed (by BI). The specimen revealed evidence of 
glial microhamartomas and also meningioangiomatosis with associated 
neurofibrillary tangles and granulovacuolar degeneration in the surrounding 
cortex. (Fig 7 and 8) 
 
 
Figure 7 Meningioangiomatosis.  
(A-B) The surgical site is surrounded by numerous hyalinised blood vessels which 
are densely packed and invade the surrounding cortex. (C) Distant cortical areas 
also show blood vessel proliferation, highlighted by CD34 immunorectivity (D), 
where the cortex also shows disturbance of the neuronal network. (E-F) Scattered 
neurofibrillary tangles are visible even by H&E and confirmed by tau 
immunohistochemistry.   
A 
F E 
D C 
B 
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Figure 8 Glial microharmartomas.  
(A) Cortical lamination is disturbed by glial microhamartomas, underlying white 
matter is thinned. (B) Glial microhamartomas consist of small clusters of round, 
small to large nuclei, with perinuclear halo formation. (C) Occasional large bizarre 
nuclei with irregular contour. (D) Glial microhamartoma in deep white matter. (E) 
Strongly positive with S100, few positive with GFAP (F-G) bcl-2. (H) 
Microhamartomas containing small round cells showed cytoplasmic paranuclear dot-
like positivity. 
 
 
H G 
F E 
A B 
D C 
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2.5 Discussion 
a. Cause of death 
 
This retrospective descriptive study investigated deaths that had happened 
within the GSTT NF2 cohort. The mortality rate in our group was 9.8%, lower 
than the 20% in the UK NF2 registry study (Baser et al., 2002a),  however in 
the UK study only 29.6% of cases had been managed in a specialist centre. 
No patients died directly ‘due to tumour burden’: two died secondary to 
elective treatment (similar to UK registry study findings); three died of 
conditions apparently unrelated to their NF2 and one died due to 
osteosarcoma.  
The individual who developed radiation-related encephalopathy had 
undergone post-operative radiotherapy (most likely fractionated) in 1973 to 
residual meningioma in the right middle fossa, and then underwent 
stereotactic radiosurgery to the same area in 2007. An MRI scan in 2008 
revealed ‘radiation necrosis’. She became wheelchair and then bed-bound, 
eventually succumbing to a lower respiratory chest infection.  
Osteosarcoma has not previously been reported in NF2, but the NF2 gene 
product merlin has been implicated in osteosarcoma in mice (McClatchey et 
al., 1998) so this may warrant further investigation.  
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b. Surgical interventions 
 
This retrospective descriptive study described surgical interventions within 
the GSTT NF2 cohort. In our cohort 75% of patients had a surgical procedure 
and of these 39.5% had surgery before diagnosis and 74% had surgery 
before specialist clinic referral.  
There is now a clear consensus that all patients with a diagnosis of NF2 
should be managed within a specialist clinic, and all surgery should be 
performed in a specialist unit.  
Before the nationally commissioned NF2 service, our specialist unit 
performed more VS surgery than non-specialists in our patients, but less 
spinal, plexus and intra-cranial surgery. This may well reflect the fact that in 
most cases, a watch and wait policy is followed within the specialist unit, 
particularly with spinal and plexus surgery as neurological outcomes appear 
to be worse in NF2-related tumours than those sporadic ones.  
There has been a reduced rate of facial nerve palsy after 2000, and this may 
reflect a local drive to more sub-total resection of VS, based on surgeon 
experience. 
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c. Hypertension 
 
This study was a retrospective cohort study, with the exposure being NF2, 
and the outcome being hypertension. It is the first to show a significant 
difference in BP between NF2 individuals and a matched control group and is 
important for the management of patients with NF2, and in the differential 
diagnosis of secondary hypertension. There are however anecdotal reports 
of hypertension and vasculopathy in NF2.  
 
This was a retrospective study and there is potential for bias. There may be 
misclassification, with overestimation of BP due to inaccuracy of 
measurement or recording BP. In this case the bias would be non-differential, 
with both groups affected, and so shouldn’t influence the comparison. If the 
misclassification was associated with ‘white coat hypertension’, where 
patients attending the NF2 clinic were more anxious than those attending the 
general neurology clinic, the bias would be non-differential and could have 
magnified the true difference. There may be selection bias, as both the cases 
and controls were only included if they had attended their appointment and 
their BP had been measured and recorded. This will have excluded those 
who did not attend, those who did not need to attend, and those who may 
have refused measurement. This may mean that the study is not 
representative of the general NF2 population.  
 
Numbers included in the study are small, due to the fact that NF2 is a rare 
disease. The power of this study is therefore low, but may be improved if 
more patients could be included, such as in a national or multi-national study. 
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The method of measurement of BP – a one-off measurement – is not 
adequate to diagnose persistent hypertension, and a further study, for 
example using 24 hour ambulatory BP measurement would be more 
appropriate to detect clinically important hypertension. 
 
However, despite its limitations, we do recommend that BP is continued to be 
measured routinely in all NF2 patients, with initiation of appropriate treatment 
if required, as this is a minimally invasive measurement, which is currently 
already routinely undertaken in this department. Bevacizumab is being 
evaluated in NF2 to reduce vestibular schwannomas’ growth (Plotkin 2009, 
Mautner 2010) and it may promote severe hypertension (Monsuez 2010): our 
study highlights the need for caution. There may be an underlying 
vasculopathy in NF2 patients, similar to NF1, and this requires further 
elucidation. 
 
 
 
 
 
 
 
 
 123 
 
e. Epilepsy 
 
This was a descriptive study of the prevalence of epilepsy in our NF2 
patients. There are no published studies on the types of epilepsy in NF2.  
Our NF2 patients with epilepsy had varying severity of NF2 and a mixture of 
seizure types but complex partial seizure with secondary generalisation was 
predominant.  Seizures were the presenting manifestation of severe NF2 in 
two of our patients aged 7 years and 19 years, but the age range of first 
seizure was from 7-52 years.  A diagnosis of NF2 may therefore fall into the 
differential diagnosis for seizures in children and young adults. 
 
The six patients with seizures all had meningiomas, but there was no 
difference in the site or number of meningiomas between patients with 
epilepsy and the 22 NF2 individuals without seizures.  We detected imaging 
evidence of non-tumour related cortical changes in the majority of our 
patients with epilepsy, and evidence of cortical dysplasia in one. Histology of 
one patient also identified glial microhamartomas in a known area of 
epileptogenicity. This may indicate that an underlying non-tumour related 
dysplasia may lead to epilepsy in patients with NF2.  
 
Dysplastic foci have previously been reported in patients with NF2 (Wiestler 
et al., 1989). Wiestler et al. observed immature neuroectodermal cells within 
the cerebral cortex and basal ganglia in the brains of all six deceased NF2 
patients who underwent autopsy. On the basis of cytological and 
immunoreactive findings they designated these foci as glial micro-
hamartomas, as was the case in our patient. These may therefore form the 
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epileptogenic foci in patients with NF2, with or without cranial meningiomas. 
Pre-operative investigation with EEG and MR imaging is essential to ensure 
the focus for seizure is a meningioma and not a dysplastic focus when 
surgical removal is planned to reduce seizures.  
 
2.6  Conclusion 
 
The retrospective case note review showed interesting trends in the 
management and outcome over a time of change in NF2 management. It 
emphasised the need for specialised care for this complex group, and over 
the course of this project, it has become policy in the UK. It revealed novel 
findings of a higher rate of hypertension in this NF2 patient cohort and of 
cortical dysplasia as a potential cause of epilepsy in NF2. 
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3 Quality of life in NF2 
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3.1  Summary 
 
The aim of this part of the project was to describe the impact of NF2 on QOL, 
using both qualitative and quantitative methods, and to use this knowledge to 
develop a disease-specific quality of life measure for NF2. Although generic 
QOL measures exist, they were not particularly well suited for use in the NF2 
population.  This is largely due to the time they take to complete and the 
complexity of use and analysis for staff and patients.  Furthermore, generic 
scores cannot differentiate between the multiple disease manifestations that 
may lead to the impact on domains of QOL. It was therefore beneficial to 
develop a new QOL tool. 
The methodological approach both to the analysis of the qualitative and 
quantitative data and questionnaire development was robust and structured. 
Although NF2 is a rare condition, patient numbers were well within 
acceptable numbers for this type of project in other, more common groups, 
and questionnaire response rates were high. 
Analysis of the NFTI-QOL showed it had good internal validity, with 
consistency across the questions, and strong correlation with physician-rated 
severity, SF-36 and EuroQOL. It also appeared to be testing what it was 
designed to test as scores were significantly different to the control groups. 
The NFTI-QOL was acceptable to patients, staff and relatives and has since 
been adopted into routine clinical assessment in the National NF2 units. It 
appears to be reliable and was validated against two widely used generic 
measures. It is thought that the NFTI-QOL should be applicable for use 
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between clinics within the UK and also overseas, but this will become clearer 
following future testing.  
Potential sources of error include random error, due to differences in an 
individual’s understanding and interpretation of a question, and systematic 
error, however the rigorous methodology employed should have minimised 
this source of error. 
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3.2  Aims  
 
a. To assess the impact of NF2 on quality of life using qualitative and 
quantitative measures. 
b. To develop and validate a disease-specific score to measure 
quality of life in NF2 for use as an assessment tool in clinical 
practice and as an outcome-measure for treatment. 
 
3.3  Methods 
 
a. Study approval 
 
Ethical approval was obtained for the patient interviews and completion of 
questionnaires from the South East London 5 Research and Ethics 
Committee (REC reference 08/H0810/68) and by the Guy’s and St Thomas’s 
Research and Development Committee, London (Ref RJ109/N107). Potential 
participants were provided with an invitation letter and study information 
sheet and all gave written consent. Principles of patient confidentiality were 
followed, data was anonymised where appropriate and secure methods of 
data storage were followed. 
 
b. Target population, sub-groups and exclusions 
 
The target population was defined as all adults (16yrs or older) who fulfilled 
the diagnostic criteria for NF2 and attend the National Specialised 
Commissioning Team (NSCT) NF2 service at Guy’s and St. Thomas’ NHS 
Foundation Trust (GSTT).  Exclusion criteria included: patients under 16yrs; 
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patients who could not give informed consent; patients for whom there was 
no up-to-date contact information. A total of 65 eligible patients were 
identified within the target group. 
The whole cohort of 65 eligible patients were included in the field testing 
section of the study, however sub-groups were also formed from within this 
group to take part in additional parts of the study:  
• All patients were invited to attend an NF2 information day. 
During this day, the attendees were invited to attend a focus 
group, along with their friends and relatives, and a total of thirty-
two people attended. 
•  The first twenty patients to attend the GSTT NF2 clinic on 
commencement of the study were asked to take part, and all 
agreed. All twenty were asked to complete a pilot questionnaire 
– forming the questionnaire pilot group.  
• The first fifteen from the above group were also asked to take 
part in an interview, forming the interview group. 
 
c. Control groups 
 
Control groups were individuals who did not have NF2 – and were used to 
assess the construct validity of the NFTI-QOL. For control group 1, it was 
decided to compare the NF2 cohort to individuals that had some clinical 
problems similar to NF2, but not all. It was therefore decided to use those 
with sporadic unilateral VS as they may have had unilateral hearing loss, 
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tinnitus, facial paralysis and vertigo, but not the visual or bilateral symptoms 
of NF2. Thirty patients who consecutively attended the GSTT Skull Base 
clinic with a sporadic vestibular schwannoma (SVS - non-NF2) were asked to 
take part and all agreed. 
For control group 2, it was decided to compare the NF2 cohort to well 
individuals from the ‘general population’; therefore thirty individuals were 
recruited from staff working within the Neurology and Ear, Nose and Throat 
(ENT) departments at GSTT. All agreed to take part. 
 
d. Qualitative methods of assessing QOL 
 
A focus group session and fifteen in-depth patient interviews used to obtain 
qualitative data on the impact of QOL in those with NF2. The focus group 
session took place on 15th January 2010 at Guy’s Hospital, London. All 
patients attending the NSCT GSTT NF2 clinic were invited to attend an NF2 
Open Day, along with their friends and families. All attending were invited to 
attend the focus group session, and all thirty-two people at the day attended. 
Participants were divided into four groups and discussed the impact of NF2 
on their lives, with a moderator from the GSTT NF2 clinical team. There was 
then a discussion amongst the larger group which was transcribed. 
The interviews were all conducted by RH in the Neurofibromatosis Unit. They 
underwent in-depth semi-structured interviews based on a schedule of main 
questioning areas which was produced following literature review of previous 
 132 
 
QOL work in NF2 and discussion with experienced multi-disciplinary team 
members and an expert NF2 patient. 
The schedule included questions exploring:  
• initial presentation and diagnosis of NF2 
• Emotional and psychological impact 
• Physical impact 
• Relationships 
• Coping strategies. 
 
The interview schedule was used as a guide; however the interviewees were 
allowed to direct the interview in their own chosen direction. All interviews 
were allowed to continue until they came to a natural end.   
The interviews were recorded with written consent and then manually 
transcribed verbatim. Examples are included within appendix A, where they 
do not include patient identifiable data, and where the contributor gave 
explicit consent for verbatim inclusion. The accuracy of the transcripts was 
checked against the original recordings by SH. 
The interviews were then analysed and the data described using Framework 
analysis. Framework analysis is a strategy to analyse qualitative data and 
involves the development of thematic framework which is used to classify 
and organise the data (Ritchie and Lewis, 2003). Data from the interviews 
were categorised into five main themes, with eighteen sub-themes and 
illustrative examples are given for each. 
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e. Development of the disease specific QOL questionnaire (NFTI-QOL)  
 
The NF Two Impact on QOL (NFTI-QOL) questionnaire was developed using 
the following sequential stages to ensure robust construction.  
 
f. Assessment of disease severity within the patient cohort 
 
It was initially necessary to develop a method to assess current disease 
severity in order to allow assessment of the sensitivity of the new 
questionnaire. All 65 patients within the target population were eligible for 
inclusion in this part of the study. 
Three clinicians (RH, RF and GL) independently gave a severity score to 
each eligible individual with 1 indicating mild disease, 2 moderate disease 
and 3 severe disease. Severity was assessed based on current patient 
wellbeing rather than potential for future disease progress, and was based on 
personal knowledge of the patient and review of current clinical case notes 
and imaging. The inter-observer scores were analysed. In an attempt to 
further understand the reasoning behind the decisions the clinicians made 
with regard to the severity score, correlation between the clinician severity 
score and a number of disease factors was undertaken. The severity scores 
were then discussed amongst the clinicians and where there were differing 
score, consensus was reached. A question within the pilot questionnaire 
asked patients to assess their disease severity, using the same scoring 
system (Q17) and the patient-rated severity score was compared to the 
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physician-rated score. The physician-rated scores were used for analysis of 
the field-test. 
 
ii. Developing a conceptual framework (Item generation) 
A comprehensive list of symptoms, social and emotional difficulties related to 
NF2 was produced using the following: 1. literature review (Medline 1966 – 
2011, search terms: NF2); 2. the focus group session with 32 NF2 patients 
and relatives; 3. the fifteen in-depth semi-structured interviews with NF2 
patients. A potential list of items to include was produced following review of 
these approaches, and this list was consolidated and rationalised following 
discussion by a multi-disciplinary panel of NF2 specialists. This consisted of 
three clinicians (RH, RF, GL) an NF2 specialist nurse (MVB) and a 
psychologist (JG).  
 
ii. Developing the pre-test (pilot) questionnaire 
The pilot questionnaire was developed from the item list to assess the impact 
of NF2 on QOL in all main areas of interest. It was further refined after review 
by members of the multi-disciplinary team and two ‘expert’ NF2 patients for 
ease of completion and acceptability. The 31-point pilot questionnaire was 
administered to 20 patients with NF2, along with the EuroQOL. 
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iii. Item reduction 
The pilot questionnaire underwent factor analysis, to reduce it to 7 items. 
Statistical advice and support was given by JG. An extra item related to 
vision deemed to be clinically important (Q4) was added during testing to 
produce the final 8 item NFTI-QOL.  This was again sense checked by the 
NF2 ‘expert patient’ to ensure ease of completion and acceptability prior to 
field-testing. 
 
iv. Field-testing  
A questionnaire pack containing the final 8-item NFTI-QOL, a covering letter, 
information sheet, stamped addressed envelope and two generic QOL 
questionnaires, the SF-36 and EuroQOL were posted to each eligible patient. 
Patients were given 4 weeks to respond. Non-responders were reminded 
once by telephone after four weeks. A second pack containing the original 
material and a reminder letter was mailed if patients could not be reached by 
telephone or had lost their packs. The questionnaires were posted to each of 
the eligible 65 patients with NF2. 
 
vi. Evaluation of NFTI-QOL 
Methodological advice was provided by JG. The sensitivity of the NFTI-QOL 
was assessed by correlating NFTI-QOL score to the physician-rated disease 
severity score (Pearson correlation). Concurrent validity was assessed by 
correlating NFTI-QOL with SF-36 and EuroQOL. Construct validity was 
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confirmed by administrating the NFTI-QOL to control groups 1 and 2: patients 
with SVS (non-NF2) and the general population. Internal reliability across the 
NFTI-QOL was also assessed. 
 
3.4  Results 
 
a. Focus group session 
 
All thirty-two people attending the NF2 information day took part in the focus 
group session. Individuals in attendance were divided into four groups, with a 
NF2 team member moderating each group. Each group was asked to share 
and discuss the impact of NF2 on their lives. There was an opportunity for 
free discussion, with individuals sharing their own experiences for around 
twenty minutes, observed by the group moderator. The findings of each 
group were then shared and discussed by the group as a whole and this part 
of the session was transcribed by a professional transcriber. (See appendix 
A) 
Common themes that were raided included the impact of NF2 on physical 
activities, with balance impairment again being raised as an important issue. 
There was discussion on the impact of visible impairment on the general 
public’s perception of people with NF2. Many examples were given of when 
people with NF2 had been mistaken as being drunk or otherwise incapable, 
which led to distress and potential harm, such as being denied access to 
public transport at night. There was also discussion of the role of loved ones 
as carers, and particularly of children as carers for parents with NF2.There 
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was discussion surrounding negative impact on work – having to change jobs 
or take time off for appointments. Many patients could no longer work. 
 
b. Semi-structured Interviews 
 
i. Patient demographics 
Fifteen patients were recruited consecutively following their attendance at the 
NSCT GSTT NF2 clinic. Demographics were as follows: 
• Nine males, six females 
• Mean age = 42 years (range 18-74 years) 
• Mean age at diagnosis = 33 years (range 11-72 years) 
• Five patients had familial NF2, 10 sporadic 
• Six patients were in employment, two were students and seven were 
not in employment 
All interviews took place in a quiet environment in a clinic room within the 
Neurofibromatosis Unit at GSTT. Interviews were of a mean duration of 70 
minutes (range 45 – 90 minutes). Interviews were either oral with 
communication aids as required or written/typed when patients were deaf 
and could not lip-read or could not speak. The interviews were transcribed 
verbatim by RH and samples of transcription were checked for accuracy by 
SH. For examples of transcription, see Appendix A. 
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c. Framework analysis 
 
Each interview recording and transcription was analysed over time by RH. 
With repeated reviews, it became possible to categorise all data in the 
following themes:  and sub-themes 
Theme Sub-theme Theme discussed in 
interview 
(total patient number and 
patient IDs) 
 
Emotional 
(E) 
E1. Response to 
diagnosis 
15  (P1-15) 
E2. Feelings/mood 10 (P1,2,5- 8, 11-14) 
E3. Personality change 6 (P1,2, 5-8) 
E4. Role of ‘fate’ 2 (P1,P8) 
E5. Coping strategies 8 (P1,2,8,9,11-13,15) 
E6. Positive impact 7 (P1,2,6-8,11,13) 
 
Physical 
(P) 
Ph1. Hearing 11 (P1,2,5,6, 8-13,15) 
Ph2. Balance 5 (P1,5, P10,11,15) 
Ph3. Facial palsy 5 (P1,5-7,11) 
Ph4. Pain 2 (P7,8,11) 
Ph5. Impact on activities 
of daily living 
12 (P1,2,5-13,15) 
 
Ph6. Impact on work 8 (P1,6-9,11-13) 
 
Relationships 
(R) 
R1. Partner 5 (P2,5,6,10,11) 
R2. Friends, family and 
colleagues 
7 (P1,2,5,6,11,13,14) 
 
R3. Children 8 (P1,2,5-8,13,14) 
R4. NF2 in the family 5 (P5,6,9,13,14) 
 
Knowledge of 
NF2 
(K) 
K1. Personal 5 (P1,8,9,14,15) 
K2. Healthcare 
professionals 
5 (P2,5,9,11,13) 
K3. General population 3 (P5,11,13) 
The future (F)  15 (P1-15) 
 
Table 18 Framework analysis of fifteen patient interviews 
 
The following examples for each theme and sub-theme are given direct from 
interview transcription and are identified by patient number (P1-15). 
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i. Emotional impact of NF2 
The emotional response to having NF2 was varied amongst patients, with 
some denying any emotional impact and others describing prolonged periods 
of emotional turmoil. On a number of occasions there was a consistent tone 
through the whole interview, for example a general strategy of positive 
thought (P1), cynicism (P2) or negativity (P5). The following sub-themes 
emerged during interview analysis:  
 
E1. Emotional response to diagnosis 
Diagnosis with NF2 appeared to elicit a strong emotional response in the 
majority of interviewees. In most it was negative: 
“when I first found out I had to be sedated” (P4) 
“I was in a state of shock. I made a will. It was like being told I had cancer.” 
(P3) 
In some cases there were more initial positive feelings: 
“it will sound stupid, but I was like quite excited… it was new and exciting and 
stuff” (P1) 
“it was good to finally find out that there was something wrong with me” (P13) 
Other reactions included: 
“I went crazy, before I had £20k in the bank, now I’m £20k in debt” (P8) 
“I just thought it was an inconvenience to be honest” (P10) 
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E2. Feelings/mood 
It was clear that a number of individuals had a low mood and were likely to 
be suffering from features of depression: 
“I’m never really happy” (P3) 
“my children say ‘you’re a right moaner’” (P4) 
“I do get down, not like before” (P7) 
“there’s nothing to look forward to” (P14) 
NF2 clearly has had a negative impact on confidence and has triggered a 
sense of vulnerability in a number of those interviewed, where the word 
‘vulnerable’ was introduced with no prompting: 
“I feel too vulnerable to fight.” (P7)  
“I feel really vulnerable” (P3) 
“the vulnerability makes you closer” (P1) 
Three patients raised the subject of suicide, although all denied current 
ideation. 
 
E3. Personality change  
Some individuals thought that their general personality had ‘changed’ since 
diagnosis, some for the worse and some for the better: 
“I’ve become a harder person” (P4) 
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“I’m more cynical” (P2) 
Others thought that they hadn’t undergone any change 
“there’s been no change in my mood” (P1) 
“I think my personality has just changed with age, I don’t think I’d be any 
different if I didn’t have NF2” (P6) 
 
E4. Role of ‘fate’ 
Two individuals believed that they were ‘fated’ to develop NF2 and they had 
always known that they would develop a disease: 
“it sounds weird, but I always expected to get something” and 
“I’m not religious or anything, but I think I was meant to get the whole NF2 
thing” (P1) 
“When I was a teenager I just knew that I wouldn’t live long and there would 
be something wrong with me. So when I found out about the NF2 it was just 
a confirmation, I wasn’t really surprised.” (P8) 
  
E5. Coping strategies 
When asked about their methods of coping with the NF2 diagnosis, eight 
interviewees discussed specific mechanisms of coping. These varied from 
taking a positive attitude to not thinking about the future.  
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“when I was in rehab after my spinal op I saw so many people worse off than 
me, I feel lucky that I got off so lightly” (P8) 
“I don’t really think about the future, I shut it out” (P8) 
 
E6. Positive impacts 
Four individuals could see a positive emotional impact of NF2: 
“I feel that I’m a nicer person. I think that I have better empathy” (P6) 
 “The NF2 pushes me to do things… I don’t want any regrets in life” (P8) 
“ I’ve saved money… I’ve got nothing to spend it on now, I can’t go away” 
(P3) 
“I can use my position to help others with NF2” (P14)  
 
ii. Physical impact of NF2 
NF2 had a varied impact on the physical status of the interviewees, due to 
the variety symptoms and their severity. Some interviewees reported little 
effect on the day-to-day functioning but many reported debilitating problems. 
Although hearing was the most common physical issue, the more ‘visible’ 
disabilities, such as balance disturbance and facial palsy appeared to elicit 
more negative reactions in patients than hearing loss when suffered in 
combination:  
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“I can cope with my hearing loss, the worst thing is my balance and face – it 
stops me going out and having a social life” (P4) 
“I am worried about my hearing but not as worried as about my face and 
balance as then people can see that there’s something wrong with you.” (P7) 
 
Ph1. Hearing 
Both the loss of hearing and the idea of hearing loss were issues that many 
felt strongly about. The fact that hearing loss was unpredictable and unlikely 
to follow a set pattern did lead to uncertainty and distress. Hearing loss led to 
a sense of isolation in many and also impacted on communication with 
friends and family, strangers and health professionals. The sadness at the 
loss of music and nature sounds was particularly prevalent. 
“When I lost my hearing it became really difficult… I feel like I’m missing out” 
(P5) 
“I can’t listen to music anymore. I can hear it but it’s just sounds, it’s not the 
same” (P15) 
“If I was in the garden I wouldn’t be able to hear the birds singing” (P9) 
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Ph2. Balance 
For those who had a balance problem, it appeared to cause significant 
morbidity, significantly impacting on daily activities, work and even 
relationships. It was a common occurrence that the individual was mistakenly 
identified as being drunk with the social stigma attached to this.  
“I can’t stand to look in the mirror, I hate my face” (P14) 
“it’s the balance that’s the problem. That’s what stops me doing things. I can’t 
walk the dog, go shopping, cycle with my kids” (P5) 
“If I fall over people think that I’m just a drunk” (P5) 
“the worst thing is the balance problem, it’s a constant reminder that I have 
NF2” (P3) 
 
Ph3. Facial palsy  
Again, for those who had a facial palsy, it caused significant problems, with a 
visible ‘deformity’ leading to lack of confidence and social isolation. It also 
caused functional problems – with one individual refusing to eat in public. 
Facial palsy was also raised as an issue by those who didn’t have it but knew 
of someone who had. 
“I used to work in Next childrenswear and I did get a lot of stares from the 
children” (P1) 
“shouting or talking really fast are hard to do without it sounding weird” (P1) 
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“the worst thing would be to have a paralysed face like my mum” (P7) 
 
Ph4. Pain 
Pain was a significant issue for three of the interviewees, and did significantly 
impact on quality of life. It mainly consisted of headaches, with some bodily 
pain, particularly in the mornings. 
“I find it hard to get going in the morning because my joints hurt, but once I 
take my headache pills and have some tea, it seems to help.” (P7) 
 
Ph5. Activities of daily living 
NF2 has had a negative impact on the physical activities of most 
interviewees. It has physically prevented them from taking part in a range of 
social, travel and day to day activities. Some feared further loss, such as 
having to use a wheelchair and not being able to manage their day to day 
care. Although one interviewee felt his general health had improved as he 
was taking better care of himself, others felt that their general health had 
deteriorated.  
“I used to love travelling but now I can’t” (P2) 
“I used to see myself as a young fit man. Now I can’t physically do the things 
I used to.” (P3)  
“Now I’m not so fit, because I get stressed, I need to smoke, need something 
to distract me” (P7) 
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Ph6. Work 
Although some individuals were still managing to work, all had had to make 
some changes and adaptations to allow them to do so. NF2 had led to a 
change in choice of career for a number of the younger interviewees. 
“It’s stopped me from going in the army and that’s all I ever wanted to do” 
(P7) 
“I’ve had to change the amount of time I spend in the classroom now, I do 
more paperwork” (P12) 
 
iii. Impact on relationships 
R1. Partner 
Although some interviewees reported either no impact of the NF2 on their 
relationship, or improvement in the relationship, others reported relationship 
breakdown and distress. Some actively avoided relationships as they didn’t 
want to put a new partner through their suffering. The difficulties of meeting a 
new partner was discussed, two interviewees had successfully met new 
partners over the internet in specialised chat rooms. There were some issues 
of guilt over meeting a new partner with a pre-existing NF2 diagnosis. 
“Poor X, he has to put up with a wreck of a wife” (P5) 
“I was in a relationship for six years and had to end it because she wanted 
children” (P2) 
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“My fiancée is the only good thing that’s come from NF2, I would never have 
met her if not and she’s saved my life.” (P11) 
“my wife is young and I’m worried that she doesn’t realise how bad it could 
get” (P6) 
 
R2. Friends and family 
Many interviewees felt that they had worse relationships with friends and 
family following the development of NF2 but it was generally felt that the 
relationships they now had were stronger, and they had found their ‘true 
friends’.  
“it improves relationships… one to one personally with family and friends is 
more close” (P1) 
“Lots of so-called friends disappeared… the few friends that I’ve got left are 
really good friends.” (P2) 
There were some more subtle issues raised with regard to improved 
relationships – and the feeling that family may gain some benefit from the 
fact that the individual is unwell so they can take care of them: 
“I’m not saying that she liked it… she just liked to care for me again, because 
I’m the youngest” (P1) 
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R3. Children 
The impact of NF2 both on children and future children was obviously an 
issue. Those with children were worried about the impact of their condition on 
the child’s upbringing and were concerned that they were missing out. There 
were some children who were acting as carers for their parent.  
“my daughter does a lot for me, she’s not had much of a childhood” (P5) 
“I just wish I could cycle along with my daughter with our hair in the breeze” 
(P13) 
For those who did not have children, many had given serious thought to 
whether they would have children due to the risk of passing on NF2. Some 
were aware of the potential for pre-implantation diagnosis and thought that 
this was a positive development. 
 
R4. NF2 in the family 
The discussion of NF2 in patients with familial NF2 revealed both the impact 
of growing up with an unwell parent, and the fear of passing on the condition 
to their child. 
“I felt so guilty, like I’d killed my son… I do blame myself, if I’d known I had 
NF2 I would never have had children” (P4) 
“I don’t think my daughter has the condition… if she did have it, it’s just bad 
luck, you can’t do anything about it” 
“my father never had a facial palsy so I wasn’t expecting it” (P5) 
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iv. Knowledge of NF2 
K1. Personal 
Interviewees with familial NF2 generally had a good knowledge of the 
condition prior to their diagnosis, although some expressed surprise that their 
symptoms differed from those of their parents and fear that their condition 
might be as severe as their siblings. 
All of the patients with sporadic disease had never heard of NF2 prior to their 
diagnosis and there was general consensus that an internet search was not a 
good idea. 
“I put NF2 in Google and thought ‘oh my god!’ I wasn’t happy when I read 
that” (P9) 
“You can’t help typing it into Google and there’s a lot of crap on the internet. 
There’s been some nights when I’ve spent hours looking through case 
studies” (P1) 
Information given at diagnosis varied. A number of interviewees and their 
families had attended the LINK NF2 course and were highly positive as to the 
information they were given. Opinions on NF2 patient groups varied, with 
some highly engaged and others completely uninterested. 
 
K2. Health professionals 
All interviewees were very satisfied with the quality of care they had received 
at the GSTT NF2 clinic and the knowledge of the clinicians. There was a 
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divide with regard to their pre-referral care – some interviewees felt very 
strongly that their local doctors did not have a good knowledge or 
understanding of NF2 and they couldn’t trust them with their care.  
“I was seeing an ENT surgeon but they said it was a waste of time seeing me 
regularly” (P3) 
“My ophthalmology appointments were terrible, they talk to my wife and not 
me, they treated me like I was stupid.” (P6) 
 
K3. General population 
A key feature was the general disappointment in the lack of knowledge of 
NF2 in the general population, particularly compared to other life-threatening 
conditions: 
“People with cancer can get treatment and support, MacMillan nurses. 
People with NF2 get no help, no one knows what it is, there’s no treatment.” 
(P4) 
 
v. The future 
All interviewees discussed their future hopes and plans. They had three 
different responses: those who were hopeful and optimistic about the future; 
those who were scared and had negative feelings about the future and those 
who didn’t want to think about it at all. 
“I think positive and look forward… a new chapter” (P9) 
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“I just don’t think about it. I try to take one day at a time” (P5) 
“I do worry about the future and how much worse it’s going to get. I worry 
about who will look after me.” (P4) 
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c. Physician-rated severity score 
 
All sixty-five patients within the eligible population had their disease severity 
rated. Correlation between judges was significant (p<0.001) – see table 
below. Concordance between the three judges was rated ‘fair’ (Pearson’s 
correlation/Spearman’s correlation coefficient).  
 Judge 1 Judge 2 Judge 3 Severity 
Judge 1 Pearson Correlation 1 0.441 0.801 0.842 
  Sig. (2-tailed)   0.001 0.000 0.000 
  N 65 65 65 65 
Judge 2 Pearson Correlation 0.441 1 0.570 0.539 
  Sig. (2-tailed) 0.001   .000 .000 
  N 65 65 65 65 
Judge 3 Pearson Correlation 0.801 0.570 1 0.862 
  Sig. (2-tailed) 0.000 0.000   0.000 
  N 65 65 65 65 
Severity Pearson Correlation 0.842 0.539 0.862 1 
  Sig. (2-tailed) 0.000 0.000 0.000   
  N 65 65 65 65 
 
Table 19 Correlation between judges on severity score (statistical support from JG) 
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Following the consensus meeting, the patient group had the following 
severity scorings: 
 
Figure 9 Eligible patient group consensus severity score 
 
Correlations between physician-rated severity score and clinical 
variables 
In order to further understand why the clinicians may have chosen their 
particular severity rating for each patient, the correlation between the severity 
score and 37 clinical variables was assessed, including: 
• Age: at first symptom; at diagnosis and at first operation 
• Gender 
• Neurological signs: facial palsy; cranial nerve palsy; upper motor 
neurone signs; lower motor neurone signs; sensory signs; ataxia. 
• Cutaneous manifestations 
• Ophthalmological signs 
• Seizures 
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• Positive family history for NF2 
• Previous surgical intervention 
• Emergency hospital admission 
• Hearing loss 
• Tumour load: VS; cranial schwannoma (non-VS); cranial meningioma; 
spinal schwannoma; spinal meningioma; ependymoma 
• Genotype 
• Peripheral neuropathy 
 
Statistical analysis was performed using Spearman’s Rank Correlation 
(significance 2-tailed) and the following items were found to strongly correlate 
with the severity score: 
• Facial nerve palsy (0.701 p<0.000) 
• Cranial nerve palsy (0.491 p<0.000) 
• Upper motor neurone signs (0.410 p=0.003) 
• Ataxia (0.488 p<0.000) 
• Previous surgical procedures (0.586 p<0.000) 
• Emergency admissions (0.428 p=0.002) 
• Ependymoma (0.529 p<0.000) 
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d. Developing the NF2-specific quality of life questionnaire 
 
i. Patient demographics 
Pilot questionnaire group (n=20): 
11 females, 9 males 
Age range 17-82 (mean = 45 years) 
Physician rated disease severity: 
Mild: 6 (30%) 
Moderate: 4 (20%) 
Severe: 10 (50%) 
 
Field testing group (final NFTI-QOL) (n=65): 
Responders (n=50) 
32 females, 18 males 
Age range 16-82 years (mean = 44 years) 
Physician rated disease severity: 
 Mild = 9 (18%) 
Moderate = 22 (44%) 
Severe = 19 (38%) 
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Non-responders (n=15) 
8 females, 7 males 
Age range 19 – 67 (mean = 40 years) 
Physician rated disease severity: 
 Mild = 5 (33%) 
Moderate = 8 (53%) 
Severe = 2 (13%) 
 
Control group 1 - SVS (n=30) 
16 males, 14 females 
Age range 28-80 years (mean = 56.5 years) 
 
Control group 2 – healthy (n=30) 
18 males, 12 females 
Age range 17 – 65 years (mean – 41.6 years) 
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ii. Item generation 
Following the literature review, in-depth interviews and focus group session, 
a list of relevant items was produced (see appendix). It consisted of a total of 
149 items, with six common symptoms. They were divided into the following 
sub-groups:  
Positives (n = 10) 
Negatives (n = 101) 
Worries and concerns (n = 14) 
Coping strategies (n = 24) 
The common NF2 symptoms identified were: balance problems; hearing loss; 
facial palsy and headaches/pain. Problems with eating and drinking and 
vision were apparent in the literature review but did not appear important in 
the interview and focus group. 
 
iii. Developing the pilot questionnaire 
The pilot questionnaire consisted of 31 questions (see appendix B). Q1-16 
were NF2 specific and were developed from the item list. Q17 was a patient 
disease severity rating (mild, moderate or severe) and Q18-31 were 
reproduced from the Hospital Anxiety and Depression Score (HADS). The 
pilot was produced by RH then reviewed by a clinical nurse specialist (MVB) 
and psychologist (JG) for appropriateness and acceptability. It was also 
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reviewed by two NF2 ‘expert’ patients and after minor changes was tested by 
the pilot group. 
 
iv. Pilot testing results 
The pilot questionnaire was completed by all twenty members of the pilot 
group. Data was missing from Q1 (not answered by 3/20), Q5 (not answered 
by 4/20) and Q9 (not answered by 3/20). The pilot group also completed the 
EuroQOL questionnaire on the same occasion (see introduction and 
appendix B for further details of EuroQOL). 
The results from the pilot questionnaire were correlated to physician-rated 
disease severity, age, gender and EuroQOL. Support in this analysis was 
provided by JG. 
 
 
 
 
 
 
 
 
 
 159 
 
The pilot questions were divided into the following sub-groups for analysis:  
Grou
p 
name  
Pilot questionnaire 
questions included 
Description of group 
NFTI-
TOT 
 
Q2+Q3+Q4+Q6+Q7+Q8
+Q10+Q11+Q12+Q13+Q
14+Q15+Q16 
NFTI-QOL pilot questions excluding Q1, 
5 and 9 due to missing data and anxiety 
and depression questions. 
ANX 
 
Q18+Q20+Q22+Q24+Q2
6+Q28+Q30 
NFTI-QOL pilot questions: HADS, 
anxiety questions 
DEP 
 
Q19+Q21+Q23+Q25+Q2
7+Q29+Q31 
NFTI-QOL pilot questions: HADS, 
depression questions 
PAT-
SEV 
 
Q17 Patient-rated severity 
EUR
O1-5 
 
E1+E2+E3+E4+E5 Euro-QOL questions excluding visual 
analogue score 
EUR
OVA
S 
 
E6 Euro-QOL visual analogue score 
 
Table 20 Pilot questionnaire sub-groups 
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The sub-group correlations were analysed using Pearson Correlation. 
There were no correlations between any of the pilot questionnaire sub-
groups and age or gender. 
The following strong correlations were found: 
 
Physician-rated severity score. 
Correlated strongly (Pearson correlation, 2-tailed significance) with: 
• NFTI-TOT (0.563, p=0.015) 
• EURO-VAS (-0.604, p=0.008) 
• PAT-SEV (0.724, p=0.001) 
There was no correlation between physician-rated severity score and the 
non-VAS questions from Euro-QOL (EURO1-5). 
 
NFTI-TOT 
NFTI-TOT correlated strongly with: 
• EURO1-5 (0.708, p<0.000)  
• EURO-VAS (-0.460, p=0.041)  
• ANX (0.623, p=0.008)  
• DEP (0.870, p<0.000) 
• PAT-SEV (0.579, p=0.007) 
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Anxiety and Depression 
 
Anxiety questions (ANX) correlated strongly with: 
• DEP (0.684, p=0.002) 
• NFTI-TOT (0.623, p=0.008) 
• EURO1-5 (0.666, p=0.003) 
• EURO-VAS (-0.615, p=0.009) 
 
Depression questions (DEP) correlated strongly with: 
• ANX (0.684, p=0.002) 
• NFTI-TOT (0.870, p<0.000) 
• EURO1-5 (0.806, p<0.000) 
• EURO-VAS (-0.493, p=0.032) 
 
 
d. Item reduction 
Factor analysis was performed using the sub-groups NFTI-TOT and ANX 
and DEP. It showed clustering around the following areas: 
Balance and dizziness 
Hearing 
Facial weakness 
Travel and mobility 
Life: outlook/role 
Anxiety and depression 
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As there was strong correlation between the HADS anxiety and depression 
scores and EURO-QOL. It was therefore decided that a version of the 
EURO-QOL question 5 would be used to assess anxiety and depression in 
the NFTI-QOL (see figure 10). 
 
 Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed             
 Figure 10 EURO-QOL question 5 
 
 
The shortened NFTI-QOL psychometric was produced by developing 
questions that would envelop the areas of clustering. All questions had four 
possible answers, scoring 0-3. Where there was no impact on QOL, a score 
of 0 was given, increasing to 3 for a large impact on QOL.  
The NFTI-QOL initially consisted of seven questions, but an eighth question 
regarding visual problems was added (Q4) during the period of field testing 
as it was felt after reflection that although it wasn’t a prominent feature in the 
pre-test group, visual problems were important in a minority of the wider NF2 
population, particularly where visual impairment compounds hearing loss. 
Although speech and swallowing problems may be symptoms of NF2, they 
were not raised as issues impacting on QOL in our interviews or focus group, 
so were not included. 
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The format of the shortened NFTI-QOL was designed to allow it all to fit onto 
one A4 sheet. Scoring labels were added to each question part to allow for 
easier results input. No loading was thought necessary as the clustering and 
correlations around each area were not grossly different. The final version is 
in Appendix B. 
 
e. Field testing  
 
The questionnaire pack consisting of the NFTI questionnaire, Euro-QOL and 
the SF-36 was sent out to the 65 eligible participants. Fifty completed packs 
were returned (77% response rate). The additional question on vision (Q4) 
was added during field testing (see above) so was completed by 37 
participants. All parts of the NFTI-QOL were fully completed by all 
respondents.  
Each question was scored from 0-3, 0 indicating no or minimal impact on 
QOL and 3 indicating significant impact. The minimum total possible score 
from the NFTI-QOL was 0 (no or minimal impact on QOL) and the maximum 
total possible score was 24 (very large impact on QOL). The range of scores 
in the responder group who had completed the revised questionnaire 
including question 4 varied from 0-20, with a mean score of 9.4 (n=37, SD 
5.57). The mean of the NFTI-QOL score without Q4 was 8.3 (n=50, max 
score=21, SD 4.80). Results from the NFTI-QOL field test are as follows: 
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Question Subject Number of individuals scoring: Total 
0 1 2 3 
1 Balance 8 9 24 9 50 
2 Hearing 8 3 31 8 50 
3 Facial weakness 27 10 10 3 50 
4 Vision 15 7 15 0 37 
5 Mobility 19 21 8 2 50 
6 Role/outlook 9 19 16 9 50 
7 Pain 26 12 11 1 50 
8 Anxiety/depression 21 15 9 5 50 
 
Table 21 NFTI-QOL field test results 
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The following graph (figure 11) shows the percentage of responders who felt 
that the following symptoms caused difficulty with or stopped them from 
performing their usual activities (scored 2 or 3): 
 
Figure 11  Proportion of responders who felt the symptom caused difficulty with or 
stopped their daily activities. 
 
Other findings included: 
• 20% were unable to walk without help 
• 24% had moderate or severe pain 
• 28% reported moderate or severe anxiety or depression 
• 50% felt that NF2 had a moderate or large negative effect on their role 
or outlook on life. 
The total NFTI-QOL score showed good sensitivity by strongly correlating 
with physician-rated disease severity (Pearson correlation=0.576, p<0.000). 
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f. Validation 
 
i. NFTI-QOL versus SF-36 
The SF-36 consists of eight scaled scores which are the weighted sums of 
the questions in their section, and are directly transformed to a 0-100 scale. 
UK population norms from Jenkinson et al. (1999)  Results are as follows: 
SF-36 domain UK population 
norm   
NF2 test 
group mean  
Correlation with total 
NFTI-QOL score 
Physical 
functioning 
score 
 87.99 
(SD 19.65) 
57.4 
(SD 32.9) 
-0.715 
p<0.000 
Role physical 
score 
87.17 
(SD 22.01) 
51.5 
(SD 45.3) 
-0.510 
p=0.001 
Role emotional 
score 
85.75 
(SD 21.18) 
59.3 
(SD 45.8) 
-0.564 
p<0.000 
Social 
functioning 
score 
82.77 
(SD 23.24) 
64.7 
(SD 33.3) 
-0.798 
p<0.000 
Mental health 
score 
71.92 
(SD 18.15) 
61.84 
(SD 26.7) 
-0.688 
p<0.000 
Energy/vitality 
score 
58.04 
(SD 19.60) 
49.2 
(SD 27.5) 
-0.773 
p<0.000 
Pain score 78.80 
(SD 23.01) 
67.3 
(SD 29.0) 
-0.656 
p<0.000 
General health 
perception 
score 
71.06 
(SD 20.43) 
48.7 
(SD 31.1) 
-0.651 
p<0.000 
 
Table 22 SF-36 results, correlations with NFTI-QOL (Pearson correlation sig 2-
tailed, SD=standard deviation) and UK population norms   
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The total NFTI-QOL score correlated strongly with all eight scores of the SF-
36 in the target population group. Although standard deviation around the 
NF2 means are large due to the relatively small number (n=50), it does 
appear that the NF2 means may lie outside the population norms in all 
domains. 
There was strong correlation (p<0.01) between the physician-rated severity 
score and all SF-36 domain scores apart from role physical score and role 
emotional score. 
There was no correlation between any of the SF-36 domain scores and age, 
gender or gene mutation type. 
 
ii. NFTI-QOL versus EuroQoL 
Both parts of the EuroQol (Q1-5 and visual analogue score) correlated 
strongly with each other (Pearson correlation = -0.660, p<0.000). 
Physician-rated severity score also correlated with the EuroQol Q1-5 (0.343 
p=0.015) and more strongly with the EuroQol VAS (-0.554 p<0.000).  
The NFTI-QOL total score also correlated strongly to the sum of questions 1-
5 of the EuroQoL (Pearson correlation=0.707, p<0.000) and the EuroQol 
visual analogue score (Pearson correlation=-0.584, p<0.000). 
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iii. Field group versus control groups 
The mean NFTI-QOL total score was calculated for the following groups: 
• NF2 group:  
o n=37 
o mean=9.4 
o SD=5.56 
• Solitary vestibular schwannoma group: 
o n=30 
o mean=5.5 
o SD=3.79 
• Normal population: 
o n=30 
o mean=0.4 
o SD=1.07 
The NFTI-QOL total score was significantly different between the NF2 group 
and the solitary vestibular schwannoma group (independent t-test, p<0.000) 
and also between the NF2 group and the normal population group 
(independent t-test, p<0.000). 
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Item Mean score ‡ANOVA 
between 
groups 
NF2 SVS Healthy 
controls 
n=50 n=30 n=30 
Q1. Hearing 1.68 1.13 0.13 <0.001 
Q2. Dizziness 
and balance 
1.78 1.43 0.00 <0.001 
Q3. Facial palsy 0.78 0.20 0.00 <0.001 
Q4. Sight† 1.0 0.37 0.03 <0.001 
Q5. Mobility and 
walking 
0.86 0.40 0.00 <0.001 
Q6. Role and 
outlook on life 
1.5 0.83 0.07 <0.001 
Q7. Pain 0.74 0.60 0.03 <0.001 
Q8. Anxiety and 
depression 
0.96 0.47 0.17 <0.001 
Total score 
[95% CI] 
9.41 [7.55-
11.26] 
5.50 
[4.09-
6.91] 
0.43 [0.03-
0.83] 
<0.001 
 
Table 23 Comparison of NFTI-QOL scores between NF2 patients, solitary vestibular 
schwannoma (SVS) patients, and healthy controls. (†n=37 for Q4, ‡ Kruskal Wallis 
non-parametric ANOVA) 
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iv. Reliability and item loadings 
The NFTI-QOL showed good internal reliability (Cronbach’s alpha = 0.87).  
Loadings of each item on the whole scale NFTI-QOL are shown below: 
Item Pearson 
Correlation 
Significance (2 tailed) 
Q1. Hearing 0.817 <0.001 
Q2. Dizziness and 
balance 
0.668 <0.001 
Q3. Facial palsy 0.772 <0.001 
Q4. Sight 0.662 <0.001 
Q5. Mobility and 
walking 
0.720 <0.001 
Q6. Role and outlook 
on life 
0.853 <0.001 
Q7. Pain 0.605 <0.001 
Q8. Anxiety and 
depression 
0.706 <0.001 
 
Table 24 Individual item loadings on the whole scale 
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g. Post-field testing adaptations 
 
An optional blank A4 sheet was added to the back of the NFTI-QOL to allow 
for expansion of answers if felt necessary. 
The NFTI-QOL was also altered for use in the US (by RH and AB. See 
appendix B) and is awaiting validation. 
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3.5  Discussion 
 
The aims of this section were to assess the impact of NF2 on quality of life 
and to develop and validate a disease-specific score to measure QOL in 
NF2.The impact on quality of life from NF2 has been comprehensively 
evaluated within this study, in both qualitative and quantitative ways. It is 
clear that NF2 is a variable disease, both in terms of clinical manifestations 
and impact on activities and outlook. However, there are common themes 
that surfaced in the qualitative methods which informed the structure of the 
quantitative methods. 
 
a. Focus group session and interviews 
 
The initial part of this study consisted of qualitative research, a focus group 
session and fifteen interviews. The focus group was undertaken to obtain a 
sense of the impact of the condition, with free and unguided ‘conversation’ in 
an informal atmosphere. There was no recording of the smaller group 
breakouts, although the larger group discussion was transcribed. Although 
this may have led to some omissions, it was felt to be more important to allow 
free speech with no concerns from the participants that they were ‘saying the 
wrong thing’.  
 
In contrast, the in-depth interviews were recorded. This had the obvious 
benefit of capturing the detail of the discussion but potentially limited 
responses or frank discussion. Steps were taken to ensure that participants 
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felt able to fully express their feelings and opinions. The interviewer (RH) was 
not a regular member of the treating team and the individual was reassured 
that his/her comments would not be shared without specific consent. The 
interviews were undertaken in a private room, with no interruptions.  
 
The interviews were semi-structured, in order to introduce certain themes 
and offer cues if conversations faltered, but were generally a conversation 
between an individual who had undergone a certain life event and an 
engaged listener. The interviews were allowed to flow in directions mainly 
dictated by the interviewee. The main themes that were discussed in the 
interviews were the emotional impact of diagnosis, the physical impact of the 
disease, impact on relationships, knowledge of NF2, by both the individual, 
family and healthcare workers and the future. 
 
There is no consensus as to how many interviews are ‘enough’ in qualitative 
research. (Baker and Edwards, 2012) The sample size of fifteen patient 
interviews was selected following guidance for best practice, taking in to 
account the small size of the NF2 population, the level of information 
saturation that would be likely to occur and the limited time of the 
investigator. There may have been selection bias, as although patients were 
asked to take part sequentially, they were selected from those attending the 
NF2 clinic. This excluded those who did not attend their hospital 
appointment, either through choice or circumstance. The selection window 
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was relatively small, so those who attended frequently had a greater ‘chance’ 
if being selected than those who attended less frequently. 
 
Quality of life in NF2 has been assessed previously by Patel (Patel et al., 
2011) who undertook six semi-structured interviews with people with NF2 
and their findings were borne out by this study; however the positive impact 
of NF2 on life was new to this study, such as the individual who said “I feel 
that I’m a nicer person. I think that I have better empathy” (See Results 
p108).  A positive response to life from NF2 was reported by four of the 
fifteen interviewees. The belief that NF2 diagnosis can be positive may 
already be a coping mechanism within the NF2 population and it could also 
potentially be utilised to provide psychological support to NF2 patients.  
 
It was also clear from the interview process that a number of patients were 
exhibiting symptoms of depression. These patients were referred, with their 
permission, to the psychiatric team. Following the interview process, a 
specialised psychiatrist was introduced into the multi-disciplinary clinic and 
both medication and counselling therapy were offered where appropriate. 
This is a very important finding, as these symptoms had not arisen or been 
discussed in the usual multi-disciplinary clinic setting, where patients are 
seen and assessed by a number of health professionals.    
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b. Physician severity scoring 
 
Physician severity scoring was undertaken as it was necessary to develop a 
method to assess current disease severity in order to allow assessment of 
the sensitivity of the new questionnaire. This could not be based on genotype 
or imaging findings as in NF2 these don’t tend to be representative of the 
individuals clinical condition. During the scoring it became clear that the 
decisions were made on a ‘gut-instinct’ by the clinician with knowledge of the 
patient, taking into account the holistic wellness of the patient and their 
interaction with their environment. In order to try and better understand this, 
the score was correlated against a number of clinical factors. 
 
The factors that correlated were those that may cause a functional disability 
to the patient – such as facial and other cranial nerve palsies, upper motor 
neurone weakness and ataxia. It could be that these more ‘visual’ disabilities 
were what stayed with the clinician as they recalled the patient in their mind 
for severity scoring. It is also interesting that the clinician score correlated 
strongly with the patient’s rating of their own disease severity. It may be that 
these findings could be used in future work to develop a disease scoring 
system. 
 
c. Assessment of QOL using generic measures 
 
This is the first study to assess the QOL in NF2 using both the EuroQOL 
(EQ-5D) and SF-36 generic scores. Our patients scored significantly worse 
than the population norms in all domains of each score, confirming the 
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negative impact on many aspects of QOL by NF2. The SF-36 scores were 
comparable to those found by Neary in Manchester (Neary et al., 2010a) and 
this may reflect the fact that both units are National Specialised Centres for 
NF2 in England and include patients with similar disease severity. 
 
The NF2 patients commented in their feedback that the SF-36 was too long, 
took too much time to complete, and was too complex. It was particularly 
troublesome for patients who have fatigue or who have visual problems, as 
found in NF2. Both EuroQOL and SF-36 assess QOL using general physical, 
emotional and vitality domains, but provide no differentiation as to the cause 
of the disability, such as hearing, balance or vision. This may lead to blunting 
of the instrument, for example, a change in balance that is worsening QOL 
may not be ‘visible’ in the generic questionnaires, due the presence of 
additional symptoms. 
 
d. The NFTI-QOL 
 
In this study a disease-specific questionnaire was developed to measure 
QOL in NF2, as an assessment tool in clinical practice and in clinical trials. It 
is quick and simple to complete, and took our patients around 3-5 minutes to 
complete. Difficulties may arise for patients who are both deaf and unable to 
read the questionnaire, but this could be overcome by using other 
communication tools, such as tactile signing. In our field-testing, all parts of 
each question were completed, implying high acceptability. This is in 
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comparison to the pilot questionnaire and also the SF36 and EuroQOL, 
which had missing questions when completed by the same group.  
 
We chose to make the NFTI-QOL a self-report questionnaire rather than 
interview based questionnaire. It may be that the NFTI-QOL could be 
adapted as a tool for carers to complete in those more seriously affected if 
necessary, although this would require further validation. 
 
The construction of the questionnaire followed a structured pathway in order 
to ensure maximum reliability and validity. The response rate of 77% to our 
postal questionnaires was high and should limit bias: there was no significant 
difference in age, gender or disease-severity in our non-responders. Potential 
sources of error in the NFTI-QOL may be due to systematic error in the 
completion of questions – for example by the respondent ticking all of the first 
boxes, or all of the last boxes, however the short length of the questionnaire 
and the lack of repetition in all of the questions should mitigate this. There is 
the possibility of the ‘halo effect’ where a negative response for one question 
leads to a falsely negative response for all, but there was no evidence of this 
in our field testing group. There is the potential for confusion with regard to 
the pain question, as it asks for pain symptoms over a different time frame (1 
week) compared to one day for the other questions, but this was not raised 
as an issue by any of our responders. 
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The total NFTI-QOL score is higher in people with higher morbidity. 
Comparison with the control groups indicated that the healthy population 
scored significantly lower in all domains of the NFTI-QOL, confirming 
construct validity. Furthermore, patients with SVS scored highly on hearing, 
balance and pain, but scored lower on the other domains than NF2 patients 
and had a significantly lower total score.  
 
Balance and dizziness problems had the largest negative impact on QOL in 
our patients.  The symptoms were reported by 84% and it was disruptive to 
usual activities in 78% of individuals.  Hearing problems were found in 84% 
and were disruptive in 66% of patients; visual problems were present in 60% 
and were disruptive in 41% of individuals; facial palsy was present in 46% 
and disruptive in 26% of patients. During the interview studies and focus 
group session NF2 manifestations that were obvious to the general public, 
such as balance disturbance and facial weakness, caused significant 
distress. Some patients had been ejected from public places as they were 
perceived erroneously to be under the influence of alcohol. We have 
developed an NF2 information card for use by our patients in public settings 
to try and increase public understanding and awareness. 
 
The method of developing the NFTI-QOL included the use of a much longer 
questionnaire which then underwent factor analysis to determine 
representative questions, and it was seen that there was clustering around 
seven topics which were converted to the final NFTI-QOL questions. The 
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issues of sight, speech and swallowing did not appear to impact significantly 
on QOL in our focus group or interview patients, and therefore it was decided 
initially not to include them in the questionnaire. 
 
The decision was made to encompass anxiety and depression questions into 
one question based on the EURO-QOL anxiety and depression question. 
The EURO-QOL is a well-respected and fully validated quality of life score. In 
our pilot study we found that the total of the numerous HADS anxiety and 
depression questions correlated strongly to the single EURO-QOL question. 
Although this may have led to some blunting of NFTI-QOL as a tool for the 
diagnosis of anxiety and depression, it is meant to be a screening tool, not a 
diagnostic tool, and the principle behind its development was to make a short 
questionnaire that is easy and quick to complete. This was discussed with 
our NF2 expert patient who felt that it was an acceptable question, as did the 
rest of the multi-disciplinary team. It may however lead to the 
underestimation of anxiety and depression in individuals who either lack 
insight into mental health issues or who do not wish to disclose their 
symptoms in this form. 
  
As mentioned in the methods, the decision was made to add a sight question 
mid-testing. This was thought necessary to provide a more comprehensive 
assessment of QOL in NF2 as sight problems may occur in isolation from 
other symptoms. Sight was found to have a moderate to severe impact on 
QOL in 30% of those tested in the field-test. In contrast, in our cohort, speech 
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and swallowing problems occurred predominantly as a complication of VS or 
surgery for VS and manifested along with other tested symptoms.   
 
Following discussion at a national meeting, a blank page was added at the 
end of the questionnaire for in depth comment that may be used by 
investigators. A further 30 NF2 patients have since used the additional page 
and their comments amplify their questionnaire answers rather than adding 
new information 
 
Since its development, the NFTI-QOL has been used in other units in the UK 
and internationally and has been further tested in 288 patients in a 
longitudinal study, demonstrating its ability to detect changes over time. 
(Ferner et al., 2014)  
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3.6  Conclusion 
 
The impact of NF2 on QOL has been analysed in this section of the thesis, 
and a new disease-specific QOL questionnaire has been developed, tested 
and validated. It has proven useful for everyday clinical assessment, and as 
an outcome measure for clinical care – it is now being used as an outcome 
measure in the national NF2 centres and in England and the USA to monitor 
response to novel therapy.  
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Transcription of focus group session 
 
Date: 15.1.10 
Venue: Guys Hospital 
Subject: NF2 - Information Day 
 
RH 
 
Great to see you all here.  Quality of Life is hard to define, can be different for 
all. I will shorten this to QOL. 
 
[see screen] World Health Organisation [see screen] not sure if we all have 
that quality of life. 
One person having a certain tumour, it may not bother them but for a tap 
dancer in the audience it may affect them.  it depends how it will affect you. 
We want to help you improve your quality of life.  We are looking not just at 
how big the tumour is but how it affects you. 
Now, can we divide into groups to talk to each other and suggest ways NF2 
can affect your quality of life. 
 
[see screen]  Now, spend some time talking to the people around you, about 
how NF2 has affected you.   
 
 
 
Group discussions 
 
 
If you are all ready, we will go around the room feel free to say whatever you 
like.   
 
Comments 
 
Main issues that affect her are balance weakness in leg, can't go for long 
walks and horse riding and walking the dark, quite difficult for her.   
 
What things has it stopped you doing? 
 
Walking down steps so if I want to go clubbing with mates, I have to go 
somewhere without too many steps, ensure I don't drop things, like in 
Tesco’s.  I need to hold my balance, I have my new son and picking him up 
and keeping my balance, very difficult.  I used to go horse riding and just 
general stuff, I need friends with me most of the time.  I can't always bend 
down to the pushchair.  
 
How do people respond to you? 
 
Everyone is very good. I am more conscious, in public places, I can get off 
the train but I am ok and then suddenly lose my balance. When drinking with 
my friends people think I am drunk.  
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After the operation, I didn't know where to put myself in the family group.  I 
am sitting not in a good place.  My family didn't realise that everything 
changes, they don't always remember. it has changed. 
 
Has your role in the family changed? 
  
Yes, because I can't hear them. They can be in another part of the house 
and I can't hear them.  I have problem with coordination with my eye and my 
limbs.  I see things on the floor but I still step on them I can't avoid it.   
 
Hello. It has ruined my life. I can't do anything. I don't go out on my own.  My 
little girl, 11, she is my carer:  she does lots of things - the oven.  I have a 
good family, lost most of my friends, they can't be bothered.  People don't 
realise what it is like, but I have to get on with it. 
 
Have you changed things that you do to make it easier, what did you do 
before that is different now? 
 
Can't go to the funfair.  Can't take them out but they get the hump if she can't 
go on a ride.  The daughter does it all, the son is autistic and people on the 
outside world don't care about her. 
 
 
When you say you have centres set up but you have to travel miles to get 
there.  Worthing is useless - the physio departments don't do anything. 
 
  
RF - Just recruited 2 other nurses so that should improve.   
 
I am Paul's mum. He is recovering from a brain operation.  He is still in 
hospital and says hello to all. 
His balance and communication is bad but he is on computer and made 
great friends since having NF2.  They are outside the family, nothing to do 
with NF2, it is through a Church.  They are there 24/7 for him.  He is the only 
one in the family with the problem but he still great.  We get on with our lives 
and think positive.   
 
Hello. Families with NF2, when I was younger I could do everything but I look 
fit, but sometimes I feel why is this happening, but I am living with it.  My 
vision is going.   
 
 
I used to do sport, I lost all my friends, I enjoy music and dancing and clubs. 
But, if I go there, I may fall down.  People may think I fall over intentionally.  If 
you look fine then people think you are not sick.  But I am sick.  In a club, you 
don't know where you are stepping.  Sometimes I don't find my hand. My 
brain knows I have hands and a leg! 
 
Do people agree, if you can't see something you think everything is fine.  
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Anyone have problems with members of the public? 
 
I have experienced that in work.   
 
People do stare and I did have problems with that.  You do get over that.  
You say to friends and they are happy to look at me and it doesn't matter to 
them.  You get used to a lot of things, things are always hard but be 
adaptable.  I was a violinist when I lost my hearing so I sold it and went 
travelling to Australia.  it is friends that you really need, they are so important.  
If you are without friends, there are ways of contacting people. Through our 
charity you can contact people. We can help you with that. 
 
He is 7, he is usually happy and has good quality of life and we are grateful 
to that.  It is inspiring listening to others and it is good to hear from Andrew.  
His balance is not always great and suffers weakness in legs. For us, it is the 
emotional side.  You try to live in the moment there is that at the back of our 
minds, that hangs over us, what the future holds for him.  When he has the 
scan, there will be a sleepless night. 
 
The balance issues and people misinterpreting you, we used to do things 
with people with Huntingdon’s disease.  We gave them a credit size card for 
their wallet that says they have the disease and that they are not drunk.  In 
NF2 people can be accosted by police, we could develop that.  Would that be 
helpful?   
 
I am a Speech therapist - I am Sue.  We find people that have had strokes 
with language problems, the Stroke Assoc has produced the same sort of 
thing.  Asking people to take their time.   
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Interview Transcriptions 
 
Interviewer = I, Participant = P 
 
 
Interview 1 
 
I – I have 4 or 5 headings for this interview, if you want to talk about anything 
else, just let me know.  
 
P- Yes 
 
I – If we can just start with when you were diagnosed with NF2, can you tell 
me a little bit about that? 
 
P – Ok, it was when I was 16, year 11, I had an i-pod and I always assumed 
the right earphone was broken. I couldn’t hear from it. One day I was in the 
playground with one of my mates and he was like “can I listen to your i-pod” 
and I said “yep, but watch out, the right earphone is broken.” He listened and 
said “no it isn’t” and I was like “oh”.  I thought that was strange. And then I 
developed a little lump here [points to face] and another little lump here 
[points to face] and I was concerned. My mum said that they were just fatty 
lumps. 
 
I – Did you tell your mum about your hearing loss as well? 
 
P – Yes and I sort of connected them, I thought it was strange. We had a 
biopsy taken from that lump and he said it was a schwannoma. And he said 
“I reckon we should do an MRI scan” 
 
I – And what did you think then? 
 
P – I was like, it will sound stupid, but I was like quite excited, I’d never had 
anything wrong with me, I was fit and healthy and it was like, oh wow. I was 
missing lots of school which was quite nice. It was new and quite exciting and 
stuff. Anyway, I had the scan and I was about to play football. He rang us up, 
I could still hear in my left ear so I could speak to him, and he said, “the 
results are back”. I was like, “I’m going to play football, can we re-arrange the 
time” and he goes “well I think you should come in”, hinting at something, and 
I was like, “ok”. That’s when we found out obviously on the right side, like a 
big tangerine, 4cm and I was like ‘whoah”. And he said you know, “an 
operation to remove it”. He said in 6 months or more you’d probably collapse 
or something like that you know. And I was like “Oh”. It was really strange, it 
was just weird, because I couldn’t have imagined all the events.” 
 
I – It’s quite a lot to cope with at that age 
 
P – I wasn’t scared, because I was 16, I didn’t know that much. I’d never had 
an operation and so it was like “bring it on”. I was naive you know. 
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I – how upset were you when you first found out? 
 
P – It was sort of like typical me, it sounds weird, but I always expected to get 
something. I could sort of feel that something wasn’t write. The few months 
leading up to the operation, I was a bit, I developed shingles and was 
sleeping a lot. My mum noticed that and I was, like in the playground or in a 
film and stuff, I wasn’t my usual chirpy self.  So I was sort of expecting it but 
you obviously couldn’t predict that.  
 
I – Were you surprised when you found out? 
 
P – I obviously missed loads of school, I didn’t realise the severity. It was like, 
just do it and move on. I didn’t realise the severity. It wasn’t a question of not 
having the operation, I had to have it. So it like, yeah, I’ve got to do it. 
 
I – So as the decision had been made, it was quite easy to face the next 
obstacle? 
 
P – I didn’t realise about NF2. I just thought, brain tumour, get it removed. I 
was in the last year of GCSEs and I knew I’d come back for my exams, 
exams in July, operation in February, it was quite a while. The school were 
alright about it, they said if you’re too unwell you don’t have to do them but 
you can still get into the sixth form because they knew I was a good student. I 
didn’t really think about it that much, it was kind of like exciting because it 
was new. 
 
I – Did you tell many of your friends? 
 
P – Yes I did actually. They couldn’t really believe it. When I said I had a 
brain tumour they were like “shit, you’ve got a brain tumour”. It wasn’t a joke. 
In school everyone heard about it and the last week leading up to the 
operation if I walked into a class I got a standing ovation. It was really nice. I 
got quite a few hugs. 
 
I – Did that help or were you embarrassed by all the attention? 
 
P – None of us had ever faced a situation like this. None of my mates had 
anything wrong so they were sort of like joking about it, the usual banter, like 
‘in hospital look out for the nurses’. We were 16, we weren’t prepared for it. 
 
I – Is joking something that you use to get through things? 
 
P – Yes, I think that it takes off the pressure. It doesn’t make it seem like 
such a big deal.  
 
I – How long do you think it took before they made your diagnosis? Did it take 
a long time or was it quite quick? 
 
P - Quite quickly. I’d always had, for as long as I can remember,  a dull pain 
right there [points] where the tumour was and I always assumed, because I 
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always slept on my right side because there was a picture on my left wall that 
I was scared of, so I always slept facing away from it. I just assumed that the 
little pain was because I was sleeping on that side. The actual scan was in 
November time and the operation was in February, it was quite urgent. The 
hearing, that first went in the new term, I noticed it from October time. That’s 
why no-one, me, my mates, we just couldn’t, we weren’t sure what to do with 
it as it happened so quickly. 
I – What about your family? How do you think they coped with it all? 
 
P – I think [pause] my mum was like, because I was the youngest son, the 
youngest in the family, she was like, I’m not saying she liked it, I don’t mean 
that. She just liked to care for me again, because I’m the youngest and stuff. I 
think they’re alright about it. 
 
I – has your relationship changed with your mum and dad? 
 
P – I think that its got better. Because my mum and dad are divorced. I saw 
my dad loads anyway. They got divorced when I was 8 yrs old and they’ve 
both got married again. Dad’s got kids actually. I mean, definitely my mum. 
Because we’ve been through a lot, going to hospital and on the train, one-to-
one time you know. With the deafness, it makes it one-to-one talking and I 
have to concentrate on what the person is saying and they do the same and 
speak slowly. The vulnerability makes you closer. I’d say we became closer 
because we spent more quality time together. It made me realise how much 
they cared, because they were upset and stuff. 
 
I – do you think its changed your life? Are you the same person you were 
before you found out? 
 
P – it has changed me a lot. I used to be, like, sit in the middle of the table 
and dictate the talk. But now, I can’t do that. It’s rare if I’m sitting in a group, 
for me to follow along. I’ve got to make the topic of conversation. If its just a 
random topic, I won’t get it. And it has made me more, not like shy and 
withdrawn, but more like, not as outgoing. If somebody comes to talk to me, 
that’s fine. It happened so quickly – you change a lot from 16 to 20, so who’s 
to say I wouldn’t have become like this anyway? I’ve kept the same friends, 
so in that respect I haven’t really changed much because if I had changed I 
would have had different friends. My character is still pretty much the same. I 
think I’m handling it ok. 
 
I – What about your relationships with your siblings? 
 
P – We always got on really well, but now because they have to talk slower 
and speak to me one-on-one it shows how much you need each other. It 
made me realise that I needed them. Because they’re older than me, they’ve 
always been really protective. So they probably feel even more protective, 
because there’s something wrong with me. They probably feel more superior, 
which is good, they can look after me. 
 
I- So do you think that they may like it in some way? 
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P – Yes, it’s strange. Its just because it happened so quickly. I’m not religious 
or anything, but I think I was meant to get the whole NF2 thing. Because it 
hasn’t really changed me. I don’t know what I would be like without it, things 
might not be a lot different, you know. 
 
I – Does it make you angry? 
 
P – No, it’s annoying. I just see it as if it was meant to happen. I’m still the 
same person. When I was ten, I’d say to myself, I want to pass my driving 
test first time – I did that last year. I want to go to a good university in a big 
city – Leicester is a big city. I’m on track you know. My goals haven’t 
changed. 
 
I – Is there anything you can’t do, physically. 
 
P – The balance is a problem. We went to Ibiza with my mates last summer 
and there was a beach with lots of rocks. They were all climbing them but I 
just knew I couldn’t so that restricted me. 
 
I – how did that make you feel 
 
P – I never felt that I was missing out or anything. I can’t do that, so I’ll go 
and do something else, something better. On a train, standing up, that’s 
tough. I always make sure I have something to hold on to. Sport, I’ve had to 
change. I still play football, that’s a really big passion, I’ve noticed that I’m not 
the same player that I was. I do a lot of gym work now or running. It’s a solo 
thing. I run a lot outside, I hate treadmill running. I like the whole scenery 
thing and being outside. I run maximum four miles. I keep a decent pace. 
 
I – what do you think about when running? 
 
P – I think about my life, but not really about NF2. I have a nice life at the 
moment, I have a lot to look forward to. Its not like I’m alone, I’m lucky in that 
respect. I wouldn’t run with a friend, because I’d have to look at them the 
whole time. I do like being on my own sometimes. Like in the gym, I prefer it 
on my own – me time. I’d have been like that anyway. NF2 is part of me. I 
really don’t think my life have changed that much. I only know of 3 guys with 
NF2. It sounds really insensitive, but they’re my motivation of what not to 
become. It sounds bad, but they all work part-time, they’re not that well-
educated and they don’t have a lot of friends. I sort of feel like I’m a new 
hope. I look at them and I think… 
 
I – How did you meet them? 
 
P- At LINK. I met two guys at that and one was one of their friends. When I 
tell my mum this, she says I shouldn’t think like that, but its true, they’re not 
an inspiration, they’re an anti-inspiration. 
 
I – What do you think the difference is between you and them? 
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P – They’ve got no aspiration. I understand that they have difficulties dealing 
with their condition, but I think we’re on a level playing field. I think that some 
people jump the hurdle and carry on. Those guys have got NF2 and let it 
beat them. Sometimes when I’m at University reading and I’m tired, I think if I 
go to have a sleep, I’ve let NF2 beat me. When I was at LINK the person said 
that there would be an NF2 person joining us in the middle of the week and I 
was looking forward to it. It was the opposite and it made me think that 
maybe I should be inspirational to other people. The guys I’ve meant wouldn’t 
be inspirational to me. If there was some new guy, a little kid with NF2, I’d 
hope that I could give them hope. That’s one way NF2 has changed me. Like 
the Paralympics. Pre-NF2 I dismissed it but now I appreciate that it’s really 
inspirational. I want to get this operation out of the way, but then… I’d like to 
give inspiration to other people and show them there’s more to life than NF2.  
 
I – Do you think about NF2 a lot, or does it not normally come up in everyday 
life? 
 
P – Obviously now I’m thinking about it a lot because of my operation. I’ve 
always been one to think ahead. Even now I plan ahead. I asked the other 
NF2 bloke “what are you’re hope” and he said “don’t really have any” “what 
are your fears?” “Don’t really have any.” That’s the complete opposite ethos 
to me. I do think about it a lot but I think of ways around it. I like to think about 
every scenario. Like the operation – I’ve always known it’s a possibility so I 
what to think about it. I work out difference outcomes and work out how I’ll 
deal with it. You do always think about it. It doesn’t mean a bad thought – its 
like a normal person, if they’re sitting by the sea, they’ll always have in the 
back of their mind ‘maybe I’m going to drown’.  Subconsciously its always 
with you, but its not like you’re sitting on a bus thinking ‘I hate NF2’. Its not 
always a big deal. 
 
I – What do you think about work in the future? 
 
P – I had to change my career aspirations. Now I want to be a management 
accountant. When I had my first operation, my stepdad is a chartered 
surveyor, and I said to him ‘what about being an accountant?’ And he said 
that accountants were really boring, so I dismissed it. I wanted a career like 
law or economics and business. I got some advice from a man from LINK 
and he said that accountancy would suit a deaf person. As I was weighing it 
up I thought it was secure, good money. I think a job does define you and 
helps with your ego. It would be nice to help people that are deaf and with 
NF2. A lot of guys who have illness are the executive directors of charities. 
My mum always says ‘it’s going to be a struggle for you to work fulltime’. I 
use that as a motivational factor to prove her wrong. At university fatigue 
hasn’t been an issue, I was always up-to-date with my work and if I can do 
that, then well not. 
 
I – Do you think your family are pleased that you went to university? 
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P – My dad, definitely. He’s quite successful in retail, so he’s like 
‘achievement, achievement’. My mum, its because I’m the youngest and she 
does worry. But they’re paying for my accommodation, so I guess they must 
be glad. 
 
I – Do you think your mum is protective of you? 
 
P – She was always like that, because I’m the youngest. Yesterday I had to 
text her to tell her where I was. I went travelling to Europe last summer. I still 
let her know and text her, I know she’s worrying and its not a big deal to just 
text her and relieve her worries. 
 
I – Does it ever annoy you? 
 
P – Not really. It would annoy me if she wasn’t a loving mum. Its nice. I’ve got 
a car, so I get a lot of freedom from that. She doesn’t restrict what I do. My 
oldest two brothers: the oldest one was in jail, his friends aren’t good people 
and he got involved in drugs. Then my second oldest brother has always 
been quite single minded and doesn’t listen to anyone. I think its nice that 
mum has me who she can worry about and see as a more normal youngest 
child that she can worry about and ‘baby’. She’s never said that I can’t do 
something. Deep down she must know that I’ve been through a lot.  
 
I – Do you ever get moody, do you have a temper? 
 
P – I am really mellow. My dad used to get really angry, when we were in the 
car he used to get road rage and stuff. My brothers have a bit of a temper. 
I’ve just always been really chilled out. I take everything in my stride. I can 
confidently say that NF2 has nothing to do with how laid back I am. If 
anything, its made me realise that life is too short to stay angry all the time.  
 
I – Can you see any positive things that having NF2 has done for you and 
your family? 
 
P – It improves relationships. It is a good thing. I can’t think what my life 
would be like without it. I could have got in with the wrong crowd, my 
personality might have changed. The good stuff; one to one personally with 
family and friends is more close. 
 
I – Do you have any other ways of coping with NF2/ 
 
P – I just plan, that’s the best strategy. If you plan things, you can hope for 
the best and expect the worst.  
 
I – Have you done any research into NF2? 
 
P – Yes, you can’t help typing it into google and there’s a lot of crap on the 
internet. There’s been some nights when I’ve spent hours looking through 
case studies, looking for inspiration I suppose.  I remember when I first got 
diagnosed. The doctor said to my mum, ‘don’t look on the internet because 
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you’ll read a lot of bad stuff.’ And that same day she went home and looked it 
up and I remember seeing the stuff she’d printed off and I read it and was like 
‘shit’. They made it hit home that it was a bit more serious than I thought. I 
just accepted it. It is depressing when you see other guys working part-time, 
like I’m scared that’s what I’ll become but it acts as motivation. 
 
I – Do you see that as a failure on their part? 
 
P – I can’t judge success or failure, but it’s the same as those guys who work 
9-5 in a factory. You’ve got to think of lots of factors in their life. But a young 
bloke – if it were me I would definitely see that as a failure. Going to a good 
university was a real confidence booster. There are lots of universities that 
aren’t very good, but because Leicester is an established university. It makes 
me feel better. 
 
I – would you like to have a family in the future, is it something you’ve thought 
about? 
 
P – What like marriage and stuff? My dad and his new wife have got two 
young children and I get on well with them so it would be nice. I’m not one of 
those guys who wants to settle down when I’m 20. My stepdad married my 
mum when he was 36. They don’t have any kids and I’d regret that if I didn’t 
have any kids. I do think that I’d like a family life, it’s the ingredients of a 
happy life. They’re the risk of passing it on, but they can test.  
 
I – would you not want a child with NF2? 
 
P - If there was a developing fetus and they could say that its going to have 
NF2 then I would terminate it.  
 
I – Some people with a genetic condition would want a child with that 
condition, what do you think? 
 
P – Strange! I wouldn’t want to impose NF2 on them.  
 
I – Which of the problems: balance and hearing has the worst effect on your 
life? 
 
P – the hearing. If I’m not looking at someone its really hard. The balance 
can be improved, handrails and things. The hearing is worse. After the 
operation, not hearing the music again will be bad. In Ibiza you see all these 
people loving the music and you think about that. Losing a sense is like 
losing a part of you and it is really annoying, but you just have to deal with it.  
 
I – How do you think you’re going to cope with it. 
 
P – Well my hearing is pretty crap now but it will be different having no 
hearing, this implant, who knows what it will sound like. This is the most 
challenging chapter. You do worry what it will be like with no hearing. One 
saving grace is that it has got worse slowly. The good thing about it being 
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gradual is that I’ve had time to deal with it, my friends have had time to 
adjust, my family have had time to adjust. The fact that its been gradual over 
four years, its helped. 
 
I – what do you think will be the worst thing about losing your hearing? 
 
P – probably in group situations. Its just so hard to participate. If someone 
says something and you don’t hear them, you lose what they’ve said. Text 
messaging and the internet helps. If mobile phones didn’t exist, I might lose 
contact with my friends. I think its more than a coincidence that I’ve lost my 
hearing yet texting and the internet is really popular. Its funny how it works 
out. Losing the hearing is the whole package – there’s not just element I’d 
miss, its all of it. Its like when you put toast in a toaster, you know you have 
to remember it because you won’t hear it pop up.  
 
I – Has your facial paralysis made much of a difference? 
 
P – I walked into school as normal and told everyone the facts. It’s a 
secondary school with 2000 pupils and word got around. I just said what the 
story was. I think – I’ve had a life saving operation and though its annoying, 
facial paralysis is not a bad end product from a life saving operation.  
 
I – Does it bother you when you meet people for the first time. 
 
I – There’ve been numerous occasions, like when I got on a bus, the driver 
said ‘have you had a stroke?’ and at the bank, this cashier kept asking me 
questions. That makes you feel vulnerable. I think that’s why I go to the gym 
a lot, not to look meaner but to make myself less vulnerable. I used to work in 
Next childrenswear and I did get a lot of stares from the children, it is 
annoying. 
 
P – Has it stopped you from doing anything? 
 
I – Drinking through a straw or blowing up balloons! I hate eating in public, 
but quite a lot of people do. Its like moving your mouth. Photograph were an 
issue, but now I do a funny pose to attract attention. Shouting or talking really 
fast are hard to do without it sounding weird.  
 
P – When you meet new people, does anyone ever ask about it? 
 
I – I don’t really explain it. I don’t get asked much, I don’t look too vulnerable, 
because I’m pretty normal, its not a big issue. When someone says – what’s 
wrong with your face, I can’t be bothered to explain it, I just walk away, I 
won’t take time to explain my reasons. I don’t get a lot of hassle. Maybe a 
new person, like a friend of a friend, their initial look might be a bit longer, like 
in fresher’s week meeting lots of people, it was weird but it was fine. I settled 
in really well.  
 
P – Does having to go to lots of hospitals annoy you. 
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I – After the first operation, any hospital when I walk down the corridor I see 
people in bed and feel sorry for them. But I do like it, meeting doctors and 
people, they’re nice people and good company. When I was at school I could 
take time off and that was good! On my gap year I was working and had to 
take time off and that was fine. I do worry about my dad having to take time 
off in this financial climate. Me personally, I don’t have lots of commitments at 
University so I can just get the train. At the moment its not a problem. 
 
P – what about the scans, do you get nervous. 
 
I – yes, its not the scan that’s the hard part, it’s the results! When I got the 
results before the University and I needed an operation, I was expecting it. I 
knew it because I’d had bad dreams and my balance was worse. Before then 
I always expected good news, I’ve always been the kind of person who liked 
getting a test back because I’d normally done quite well, so my normal 
reaction was to look forward to the results. But from now on, any scan I won’t 
look forward to it. 
 
P – What about the eye checks and those screening tests 
 
I – Yes I’ve had that and it was fine.  
 
P – would you rather have regular checks or would you rather just go if you 
had a problem? 
 
I – what like ignorance is bliss? No, a test can go both ways and it may be 
good news. My dad is 50 now and I tell him to go to the GP to get checked 
but he’d rather not know. Its only a test, I don’t exactly like them but its 
important to benchmark your progress. 
 
P – have you joined any NF support groups? 
 
I – I did look on the internet for a forum but couldn’t find any groups. 
 
P – did your experience at LINK put you off? 
 
I – I’m going back to LINK in July and it would be good to talk to others about 
it. In the future I’d be interested. 
  
P - is there anything we could do to improve our clinic? 
 
Even though patients have severe hearing loss, some doctors talk really 
quietly and don’t move their mouths enough so I can’t understand. I don’t 
know if its an ego thing? It may be that some doctors think they’re the 
important one and patients should listen to me.  
 
END 
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Interview 2 
 
I - Can I just ask about when you were first diagnosed? 
 
P - It was when I was teaching in 1993, we were learning to Morris dance 
and I found that I couldn’t lift my feet up which was really strange, I hadn’t 
noticed that before. By Christmas that year, my legs felt heavy and cold and I 
couldn’t run, I started to fall over. 
 
I - What did this make you think? 
 
P - I was really scared, I thought I must have multiple sclerosis or motor 
neurone disease, I was terrified. 
 
I - So what happened next? 
 
P - Well I was living in xx at the time and I went to the hospital there. They 
transferred me to xx Hospital and I had lots of tests and an MRI scan. I had 
lots of medical students examining me and practising on me and that really 
upset me as I didn’t know what was wrong with me. At the time I couldn’t 
walk. I was then told that it was due to a spinal tumour – a spinal 
schwannoma and it was removed. 
 
I - When was the diagnosis of NF2 made? 
 
P - After my scans they realised what was going on. I’d never heard of it 
before, and I was initially pleased that it was that rather than MS or MND. I 
was seen by a geneticist and that really upset me, they said that ‘most 
people with NF2 wouldn’t have children’ which was devastating. I was cross 
that doctors kept calling it a disease. 
 
I - What about the NF2 clinic? 
 
P - The first thing I felt when I walked in to the clinic was a massive sense of 
relief, that someone knew what was going on and could help me.  
 
I - How did you find out more about NF2? 
 
P - I joined the NF association and found it extremely helpful, I got most 
information on NF2 from there. I didn’t look on the internet, I’m not sure why 
really. 
 
I - How has NF2 changed your life? 
 
P - Well initially I always wanted three children, but now I’ll stick with two, I 
couldn’t risk having another with NF2 
 
I - What do you think about pre-conception testing? 
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P - I totally disagree with it. I would never have it. It’s like it completely 
devalues mine and Harriet’s lives – we wouldn’t be here if it had been used. 
Actually the thought of it makes me really angry. 
 
I - How do you cope with NF2 
 
P- Prayer helps a great deal. I’m part of a prayer group with my church and it 
helps to know that God loves me unconditionally. People at church don’t 
really know what NF2 is, but they pray for me whenever I have an 
appointment or a scan. It really helps to have a community supporting you. 
 
I - How else has your life changed since your diagnosis? 
 
P - I feel that the diagnosis has been strengthening, it has changed my 
personality, I’m more confident than I was before. It has also helped me to 
succeed in my job – I just have to get on with it now. The children at school 
are very good – I have no problems with them. I’ve explained about my 
hearing aid. My brother had hearing difficulties and I had a very good 
experience with him so that has helped me. 
 
I - How has it changed you physically? 
 
P -I can’t run in a straight line, and I can’t cycle. I wanted to do the Race for 
Life but I couldn’t. Sometimes this makes me feel sorry for myself but my 
friends, family and prayer pull me out of it. 
 
I - What kind of a person are you? 
 
P - I see myself as a happy, bubbly person. I try to see the positive in 
everything and to have a positive attitude. 
 
I - Do you have thoughts about the future? 
 
P - I know that I’ll have a restricted lifespan, so I’m keen to take all the 
opportunities I’m given. I do think about my own death. I worry that my 
children will not be as close to their cousins and extended family than I was 
as we seem to be growing apart. I try not to dwell on it. 
 
I - How has your diagnosis affected your family? 
 
P - I don’t think that it has changed my husband. The worst time was when 
Harry was diagnosed. I knew that there was something wrong when she 
couldn’t breast feed. During the pregnancy, I didn’t really think about NF2, I 
was too busy worrying about other things. As I hadn’t been affected until I 
was much older, I thought that it wouldn’t give her any trouble. I thought that 
she wouldn’t be affected until she was in her thirties and by that time 
technology would have advanced so much that she wouldn’t really be 
affected. When she was born I was told that she was blind and I felt guilty 
that she had inherited NF2. Then I realised that she did have some vision 
and she was diagnosed with retinal hamartomas.  
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I - Do you have concerns about your daughter’s future? 
 
P - I do worry that she won’t be able to drive – we live in a village, I worry that 
she’ll rebel against the NF2 as a teenager. At the moment she is fantastic. 
Her sister really looks out for her and we just treat them the same.  
 
I - Does the management of your condition bother you – appointments and 
scans? 
 
P - Most of the year, I completely forget that I have NF2. It’s when I have 
appointments and scans that I get reminded. I start worrying in the weeks 
running up to my appointments, particularly that things will have got worse 
and that I’ll need an operation.  
 
I - Do you have any suggestions on how we could improve our clinic? 
 
P - Try to de-hospitalise the waiting room – books, coffee, magazines. 
 
I - How do you find the number of people in the clinic? 
 
P - I find it reassuring and I like it that the whole team is there – and that they 
are all experts.  
 
I - Are you able to hear everyone well, do you feel happy asking questions? 
 
P - No problems there at all. 
 
I - What do you think about the NF association weekends/meetings 
 
P - The weekends are too far away and last too long. You have to think about 
NF2 for the whole weekend. You’re forced to socialise with people you have 
nothing in common with apart from the worst thing in your life – NF2. You’re 
making false links with people with whom your only link in the condition – not 
something to celebrate! 
When Harriet was first born, I wasn’t interested, all of the NFA leaflets when 
straight in the bin. Now I am keen on meeting other mums with children with 
NF2. 
 
I - What hopes do you have about the future? 
 
P - I do have big hopes about further non-surgical treatment – drug treatment 
and gene therapy. 
 
END 
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Interview 3 
 
I – Can you tell me what happened when you first found out that you had 
NF2? 
 
P – I was first told I had NF2 in 1993. In 1992 I had an epileptic fit, but 
nobody thought anything of it. I had another one and a scan was organised 
for me. I had no idea what NF2 was when I was first told. When they found 
out it was NF2 they transferred me to Southampton and the neurosurgeon 
there wanted to operate on me. I saw an NFA newsletter and got in touch 
with Dr Ferner. 
 
I – Did you understand what NF2 was? 
 
P – Nobody described it and no-one looking after me seemed to know what it 
was. This made me really frightened, but things have changed a lot since 
then, I’m not frightened anymore. 
 
 I – What impact did the diagnosis have on you? 
 
P – Not much to start with, I could still play hockey, I could still here, things 
hadn’t really changed. Then in 1996 I had another seizure and I had to have 
an operation to remove the tumour, I couldn’t play hockey anymore after that. 
It was really hard even to walk. I tried to carry on working but then in 2000 I 
was having problems walking. I couldn’t work. I’d wake up in the morning with 
no idea how I might feel so I couldn’t keep working. 
 
I – How did your friends and family cope with everything? 
 
P – Well, after my first operation, I got about 70 get well cards, and after my 
third and fourth I only got about 12. Lots of so-called friends disappeared. 
That really upset me, I realised how shallow people were. The few friends 
that I’ve got left are really good friends. My dad couldn’t cope with the fact 
that his little baby was ill. He goes to great lengths to tell people to behave to 
help me, e.g. so I can lip read. It really bothers him and makes me really sad 
but he can’t change.  
 
I – Has having NF2 changed you as a person? 
 
P – I think so, I’m more cynical, I try not to bother about pathetic things. It 
really annoys me when people complain – I think ‘if only that was my worst 
problem’. I do sometimes think about ending it all, but I don’t think I ever 
would. It would be selfish and upset my family too much. I do feel that I’ve got 
things to live for. I play olf with a friend still. I have a friend in the US with NF2 
and she’s really helpful, we email each other. 
 
I –What about your relationships? 
 
P – I was in a relationship for six years and had to end it because she wanted 
children. I had to break up with her and found it really hard, I do still. She’s 
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now got three children. I have met one other girl and I would be keen to meet 
up again and perhaps start a relationship. 
 
I – What about having children? 
 
P – I do really want to be a dad, but couldn’t live with myself if they had NF2. 
I’ve decided that I’m not going to have children. 
 
I – How else has having NF2 affected you? 
 
P – I think that I’ve come to terms with having NF2, but I don’t like it! The life I 
had before and the life that I have now are very different. I used to love 
travelling but now I can’t. I can’t be alone because of my epilepsy. I was 
really independent before, I travelled on my own, I find it really hard to be 
reliant on other people. I’m a private person – I don’t want to burden anyone 
else. I talk to my dog about things and also to my friend Geoff. No-one else 
knows.  
 
I – How do you cope with things? 
 
P – I don’t know, I just do! What else can you do? I can’t do anything about it, 
worrying about it won’t change anything. You just have to hope. I keep things 
to myself, I think it would be unfair to tell my parents, it must be awful to see 
your child being unwell.  
 
I – What do you find hardest to deal with? 
 
P – how debilitating NF2 is. If it was just one thing, fits, paralysis, being deaf 
then I could cope. Because its all of them, it just wears you down. I try not to 
worry about the future, ignorance is bliss.  
 
I - Can you think of anything good that’s come from having NF2? 
 
P – Meeting Dr Ferner, Mel and other people with NF2. I used to have an 
NFA advisor when it was bigger but don’t anymore, now I have a counsellor.  
 
I – Would you like to be more involved in events for people with NF2/ 
 
P – I would like to come to meetings, particularly in the evenings, but lots of 
people won’t – there’s such a big range of illness severity – people who 
aren’t badly affected might think – that could be me! I used to be the 
youngest at NFA events now I’m the oldest, everyone else has died. 
 
I – How do you find dealing with hearing loss? 
 
P – I miss listening to music every day. I can hear a tune in my head, I try to 
remember different songs and play them in my head. I do have days when 
that gets me down. I don’t know how I pick myself up out of it. The biggest 
thing that I miss is the sound of the sea. Sounds like that you take for 
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granted. Birdsong. It takes a lot of getting used to. Going to football matches 
and they’re silent. 
 
I – how have you found the management of your NF2? 
 
P – I feel in control of it, as much as I want to. I really like Guy’s. My local 
hospital was a disaster. I don’t mind seeing so many doctors in the clinic – 
and have no problems with communication and understanding what is going 
on. I don’t think that it’s a good idea having a whole day in the clinic, I find 
that really tiring. 
 
END 
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PILOT - The Guy’s NF2 Impact – Quality of Life Score (NFTI-QOL) 
 
It would be helpful to know some basic information about you: 
 
Current age: (years)______ Sex:        Male   /   Female (please circle) 
 
For the following questions, please circle the most appropriate answer for how you feel at 
this time.  
 
Questions about work include paid and voluntary jobs and also housework. If you are 
retired or unemployed, please circle N/A (not appropriate). 
 
Q1. Have balance/ dizziness problems caused you difficulty at work? 
(e.g. stopped you performing your usual job, made you change what you wanted to do for a job) 
YES 3    NO 0   N/A 
                  
Q2. Have balance/ dizziness problems caused difficulties in your social life?  
(e.g. going out, planning holidays, etc) 
  YES 3      NO 0 
                   
Q3. Have balance/ dizziness problems caused difficulties in your family life? 
(e.g. playing with your children, caring for others, doing housework, relationships) 
  YES 3      NO 0  
          
Q4. Have balance/ dizziness problems restricted your ability to travel?    
(e.g. cannot ride bike, travel by car, plane, public transport) 
   YES 3      NO 0 
 
Q5.  Have hearing problems caused you difficulty at work? 
(e.g. answering the telephone, talking in a crowded room) 
  YES 3    NO 0   N/A 
                  
Q6. Have hearing problems caused difficulties in your social life?  
(e.g. talking to friends, listening to music, meeting new people)  
  YES 3    NO 0 
                   
Q7. Have hearing problems caused difficulties in your family life?  
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(e.g. conversations with family, keeping in touch)  
  YES 3      NO 0 
Q8. Have hearing problems restricted your ability to travel?    
(e.g. cannot ride bike, travel by car, plane, public transport) 
   YES 3      NO 0 
 
Q9. Have problems with your appearance (e.g. facial weakness) caused you difficulty at work? 
  YES 3    NO 0    N/A 
                  
Q10. Have problems with your appearance (e.g. facial weakness) caused difficulties in your 
social life? (e.g. meeting new people, going to the pub, going shopping) 
  YES 3       NO 0 
                  
Q11. Have problems with your appearance (e.g. facial weakness) caused difficulties in your 
family life? 
  YES 3      NO 0 
          
Q12. Have problems with your appearance (e.g. facial weakness) restricted your ability to 
travel?   
(e.g. cannot ride bike, travel by car, plane, public transport) 
   YES 3      NO 0 
 
Q13. Has your medical condition changed your role in life? 
(e.g. unable to care for family, be the breadwinner) 
YES 3    NO 0 
 
Q14.  Has your medical condition prevented you from achieving what you wanted to do in life? 
(e.g. job aspirations, education, sports, family) 
YES 3      NO 0 
 
Q15. Does your medical condition make you feel vulnerable? 
(e.g. unsafe, loss of confidence, weak) 
  YES 3      NO 0 
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Q16. Do you worry about the possibility of passing your medical condition on to your children? 
YES 3      NO 0 
 
Q17. How severe would YOU say your medical condition is? 
   
MILD 1   MODERATE 2   SEVERE 3 
  
For the next section, circle the answer that best describes how you have been feeling 
during the LAST WEEK. You do not have to think too much to answer.  
 
Q18. I feel tense or ‘wound up’: 
     Most of the time    
     A lot of the time 
     From time to time (occasionally) 
     Not at all  
 
Q19. I still enjoy the things I used to enjoy: 
     Definitely as much 
     Not quite as much 
     Only a little 
     Hardly at all 
 
Q20. I get a sort of frightened feeling as if something awful is about to happen: 
     Very definitely and quite badly 
     Yes, but not too badly 
     A little, but it doesn’t worry me 
     Not at all 
 
Q21. I can laugh and see the funny side of things: 
     As much as I always could 
     Not quite so much now 
     Definitely not so much now 
     Not at all 
 
Q22. Worrying thoughts go through my head: 
     A great deal of the time 
     A lot of the time 
     From time to time, but not often 
     Only occasionally 
 
Q23. I feel cheerful: 
     Not at all 
     Not often 
     Sometimes 
     Most of the time 
 
Q24. I can sit at ease and feel relaxed: 
     Definitely 
     Usually 
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     Not often 
     Not at all 
 
Q25. I feel as if I am slowed down: 
     Nearly all the time 
     Very often 
     Sometimes 
     Not at all 
 
 
Q26. I get a sort of frightened feeling like “butterflies” in the stomach: 
     Not at all 
     Occasionally 
     Quite often 
     Very often 
 
Q27. I have lost interest in my appearance: 
     Definitely 
     I don’t take as much care as I should 
     I may not take quite as much care 
     I take just as much 
 
Q28. I feel restless as if I have to be on the move: 
     Very much indeed 
     Quite a lot 
     Not very much 
     Not at all 
 
Q29. I look forward with enjoyment to things: 
     As much as I ever did 
     Rather less than I used to 
     Definitely less than I used to 
     Hardly at all 
 
Q30. I get sudden feelings of panic: 
     Very often indeed 
     Quite often 
     Not very often 
     Not at all 
 
Q31. I can enjoy a good book or radio/TV program: 
     Often 
     Sometimes 
     Not often 
     Very seldom 
     
 
This concludes the NFTI-QOL. Many thanks for your time.  
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NFTI-QOL 
 
(Neurofibromatosis 2 impact on quality of 
life) 
 
English version for the UK 
 
 
 
 
 
 
 
INSTRUCTIONS FOR COMPLETING THE NFTI-QOL 
Please complete the following information: 
     Age: ______ years 
Gender: Male □⁯   Female □⁯      (please tick) 
                                                                                                        1                                    2 
 
 
For each of the questions on the next page, please tick the one box that  
describes how you feel today 
Usual activities include: work; housework; study; sport; social; family or 
leisure activities 
 
 
                                                                                           Patient ID/Label:                  
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If you have any further comments regarding the impact of NF2 on your quality 
of life, please write them here: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You have now completed the NFTI-QOL. Thank you for your input. 
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